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Abstract 
 
Globally, cancer is the second leading cause of death. Chemotherapy is commonly used 
in the treatment of cancer. However, in clinic, a wide variety of cancers display 
resistance to chemotherapy leading to the failure of cancer therapy. This phenomenon 
is called multidrug resistance (MDR). MDR could occur via various mechanisms. An 
important mechanism is related to overexpression of drug efflux transporters, especially 
ATP-binding cassette (ABC) transporters. In the whole ABC transporter family, P-
glycoprotein (ABCB1/P-gp), multidrug resistance associated protein 1 (ABCC1/MRP1) 
and breast cancer resistance protein (ABCG2/BCRP) are mostly reported to confer 
MDR. They efflux diverse structurally unrelated anticancer drugs outside of cells and 
reduce cytotoxic effects. To overcome multidrug resistance, a possible strategy is to 
develop potent inhibitors which target efflux transporters and inhibit the transportation 
process.  
In this study, we adopted the essential features which were depicted before and 
synthesized various phthalazine, quinazoline and pyrimidine derivatives as ABCG2 
inhibitors. Hoechst 33342 and pheophorbide A assays were carried out by my colleague 
to investigate their inhibitory potency. In project 1 and 2, several compounds with 
phthalazine or quinazoline scaffold displayed moderate inhibitory activities against 
ABCG2. But, generally, they were less potent than corresponding 4-anilino-2-
phenylquinazoline derivatives. In project 3 and 4, 2-phenylpyrimidine derivatives were 
synthesized and biologically evaluated. In comparison to Ko143 which is a very potent 
ABCG2 inhibitor, compound 61, 62, 71, 72, 81 and 82 showed comparable or even 
higher inhibitory efficacy. The structure activity relationship was discussed in the 
following chapters. Owing to the excellent potency of these substances, further in vitro 
and in vivo studies such as intrinsic cytotoxicity are on the way. 
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1. Introduction 
 
1.1 Multidrug resistance (MDR) and chemotherapy 
 
One of the leading causes of mortality in the world is cancer. Except surgery, 
chemotherapy is commonly used in treatment of a variety of cancers. Drug sensitive 
malignant cells are killed, but some cells are tolerant and resistant to anticancer drugs. 
After a period of time, tumor begins to grow again resulting in failure of chemotherapy. 
This phenomenon is called multidrug resistance (MDR).1 
MDR in cancer could occur via various mechanisms including activation of detoxifying 
systems, blocked drug uptake, drug efflux, activation of DNA repair mechanisms etc.2 
An important mechanism is related to drug efflux transporters, especially ATP-binding 
cassette (ABC) transporters which are able to efflux many structurally diverse 
anticancer drugs.3 P-glycoprotein (P-gp, ABCB1), breast cancer resistance protein 
(BCRP, ABCG2) and multidrug resistance-associated protein 1 (MRP1, ABCC1) are 
the extensively studied members associated with MDR in the ABC transporter family.4  
 
1.2 ATP-binding cassette transport proteins 
 
1.2.1 Introduction of ABC transporter family 
 
ATP-binding cassette (ABC) proteins play various roles in biological processes, such 
as importing nutrients into the cell,5 detoxification6 and secretion of substrates.7 Most 
of them are members of complexes which mediate transportation of compounds across 
membranes. Based on the direction of transportation, ABC transporters are separated 
into importers and exporters. Both importers and exporters typically contain two 
transmembrane domains (TMDs) and two nucleotide-binding domains (NBDs).8 TMDs 
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of different ABC members are phylogenetically diverse to facilitate transportation of 
various structurally unrelated substrates.9 NBD is the engine and provides the power of 
transport via hydrolysis of ATP. The sequences of NBDs are highly conserved to 
facilitate ATP binding process.10 One TMD and one NBD are fused as half transporter 
which is not functional. To be biologically active, these half transporters have to 
dimerize to full transporters.11 The examples of ABC half transporters are ABCG2, 
Sav1866 from Staphylococcus aureus and MsbA from Escherichia coli.12 
48 ABC genes exist in human genome and they were divided into seven subfamilies: 
ABCA to ABCG.13 The members of this diverse family exert different effects in various 
biological processes.  
The ABCA subfamily contains 12 full transporters and is related to some genetic 
diseases. For example, mutation of ABCA1 protein results in recessive Tangier’s 
disease. Stargardt disease, retinitis pigmentosa and age-related macular degeneration 
are related with ABCA4 mutation.14  
The ABCB subfamily contains 4 full transporters and 7 half-transporters. Mutations of 
ABCB genes are associated with different diseases, such as diabetes type 2 and lethal 
neonatal syndrome. The member ABCB1 is also called P-glycoprotein (P-gp) or 
multidrug resistance protein 1 (MDR1) which is the most extensively studied protein 
involved in multi-drug resistance.14, 15  
The ABCC subfamily contains 13 genes. ABCC7 is also called cystic fibrosis 
transmembrane conductance regulator (CFTR). Mutations of the CFTR gene result in 
cystic fibrosis which means dysregulation of epithelial fluid transport in the lung, 
pancreas and other organs derived from chloride ion channel dysfunction. Sulfonylurea 
receptor (SUR) coded by ABCC8 gene is a protein involved in insulin secretion, 
neuronal function and muscle function. Mutations in SUR may lead to neonatal diabetes 
mellitus. ABCC1, which is also called multidrug resistance-associated protein 1 
(MRP1), is another well-studied protein involved in multi-drug resistance.16  
ABCD subfamily contains 4 genes coding half-transporters. Mutation of ABCD1 gene 
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is known to cause Adrenoleukodystrophy (ALD) which is characterized by 
neurodegeneration and adrenal deficiency. The functions of other members are not clear 
now.17 
The ABCE subfamily has only one member ABCE1 which is an organic anion-binding 
protein. It has only ATP-binding domain and lacks TMD precluding its function as a 
transporter. But, it was found to promote interferon activity in the processes of certain 
virus infections.14, 18 
Similar to ABCE1, the ABCF subfamily has 3 members which only have NBD but no 
TMD. Therefore, they are not able to transport compounds inside or outside of cells, 
but are believed to play a role in inflammation processes.14 
The ABCG subfamily contains 5 genes which code six “reversed” half transporters. 
Opposite to the orientation of all other ABC genes, NBD of these six transporters is on 
the N terminus and TMD at the C terminus. Mutations of ABCG genes are associated 
with sterol accumulation disorders and atherosclerosis. ABCG1 plays a role in 
cholesterol efflux in macrophages. ABCG3 might be involved in the transport of 
hydrophobic compounds or specific peptides from lymphocytes. ABCG5 and ABCG8 
seem to block intestinal absorption and increase biliary excretion of sterols. Most 
notably, ABCG2 whose normal function is not clear can export diverse anticancer drugs 
outside of cells leading to multidrug resistance.19 Detailed information about it is 
provided in section 1.2.5.  
 
1.2.2 Structure and mechanism of ABC transporters 
 
Since the first discovery of an ABC transporter in mid-1970, many researchers have 
devoted much effort to obtain the crystal structures of ABC transporters and elucidate 
the molecular mechanism of their transport activities.20 Before 2006, studies of 
structural biology of ABC proteins were focused on NBDs. NBD structures of 
TAP1/2,21 CFTR,22 MRP123 and the hemolysin transporter HlyB24 were studied and 
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published. The knowledge derived from analyzing these structures is very essential to 
understand how the “engine” works. As a result, the ATP switch model was proposed.25 
The model revealed that NBD has two critical conformations: closed dimer when two 
ATPs binding and open dimer after ATP hydrolysis. Transforming NBD conformation 
from open to closed dimer leads to conformational changes in TMD and final release 
of substrate. Later, two complete structures of MsbA (lipd A flippase) were reported. 
But the interpretations were wrong in the beginning and have been rectified now.26 In 
2006, Sav1866 from Staphylococcus aureus — the first full-length high-resolution 
structure of ABC exporters — was published.27 It was the first time to reveal the 
structural organization of TMDs. NBDs and TMDs are connected via coupling helices 
which are responsible for mechanically transmitting the movement of NBD fueled by 
ATP hydrolysis to TMDs. In 2009, the mouse P-gp structure was solved.28 It was the 
first time to reveal the structure of a full transporter from eukaryotic origin with four 
domains sharing one polypeptide chain. But the structure was not accurate and major 
correction was applied later.29 In 2013, the structure of ABCB10 was solved, extending 
the structural interpretation to an ABC protein of human origin.30 Recently, the structure 
of ABCG2 was also reported.31 
Although the development of structural studies on ABC transporters is obvious, the 
detailed molecular mechanism of transportation is still not fully understood.  
In Figure 1, a generally accepted mechanistic proposal of exportation is described — 
the alternating access model.32 State 1 is the resting state of ABC transporter. TMDs are 
in an inward-facing orientation, while NBDs are in an open conformation with low 
binding affinity for ATP. Substrates could bind at binding pocket of TMD from not only 
cytoplasm but also lipid bilayer. Especially some hydrophobic compounds are able to 
be recruited directly from membrane. Some studies suggested that the binding site on 
the same transporter which is accessed by diverse substrates might be not unique, there 
might exist multiple sites. The initiate point of transport cycle is the interaction of 
substrate and high-affinity binding site on TMD. It induces a conformational change of 
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NBDs enhancing the affinity for ATP. The interaction of NBDs and ATP converts 
transporter to a closed conformation (state 2). Such a state has been observed in some 
crystal structures. Closing NBDs leads to conformational changes of TMDs, so TMD 
is converted to an outward-facing conformation reducing the affinity of substrates to 
TMD, and the substrates are finally released toward periplasm (state 3). From state 1 to 
state 3, the surface of cavity surrounding substrates must change. When ATP is 
hydrolyzed, the produced energy drives NBDs apart. The movement of NBDs is 
transmitted to TMDs via coupling helices, so the conformation of TMD is converted 
from outward-facing to inward-facing and the transporter is restored to state 1. It is still 
unclear whether two ATPs are hydrolyzed simultaneously or consecutively and which 
step in the cycle provides power stroke, or how many ATPs are consumed in one cycle? 
Many questions still remain to be answered.33  
 
Figure 1: The generally accepted alternating access mechanism of exportation for ABC 
transporters.34 Glowed blue double line: boundary of membrane bilayer; blue rectangle: TMD; 
orange oval: coupling helices; green concentric circle: NBD; yellow hexagon: substrate; purple 
circle: ATP; red triangle: ADP; number denotes state. 
 
Except the alternating access model, other models or mechanisms such as outward-only 
mechanism35 and Constant-Contact-Model36 were also proposed. Due to the diversity 
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and complexity of ABC transporter members and substrates, one single conserved 
mechanism is probably not able to explain the movements of every exporter in ABC 
transporter family. The same transporter might also use different mechanisms for 
transporting different substrates.34 
 
1.2.3 ABCB1 / P-glycoprotein (P-gp) 
 
In 1976, Juliano and Ling discovered that the sensitivity to some cytotoxic anticancer 
drugs was reduced in rodent cells.37 The “culprit” was called as “permeability 
glycoprotein”, named P-glycoprotein. P-gp (ABCB1/MDR1) is the first discovered and 
most widely investigated transporter of the ABC protein family. Several thousand 
compounds have been reported to bind to it and to be excluded out of cells.38 It is widely 
expressed and distributed on the Golgi membrane, intracellular canaliculi and plasma 
membrane of different tissues, including colon, intestine, liver, adrenal gland, kidney, 
lung, muscle, pancreas, stomach, placenta and endothelial cells at blood-testis barrier, 
blood-brain, blood-placenta barriers.39, 40 The ways it disposes xenobiotics (such as 
anticancer drugs) and metabolites include biliary excretion in liver, urinary excretion in 
kidney and absorption barrier of oral bioavailability.41 As consequence, the 
accumulation of anticancer drugs in various tissue cells is limited leading to multidrug 
resistance. 
 
1.2.3.1 Structure and mechanism 
 
P-gp is a 170 kDa glycosylated membrane protein. Like many other members of the 
ABC transporter family, the P-gp protein is composed of two halves. Each contains a 
transmembrane domain (TMD) which consists of six hydrophobic transmembrane 
helics and a nucleotide binding domain (NBD) which is located on the inner part of 
membrane and binds ATP to facilitate transport (Figure 2).42  
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Figure 2: Topology model of ABCB1 (P-gp) 
 
Since the discovery of the ABCB1 gene, many mutations and polymorphisms have been 
detected, but only a few variants were found to be crucial for protein expression and 
function of transportation. Genetic variations of ABCB1 gene in the form of single 
nucleotide polymorphisms (SNP) have shown impact on disease susceptibility and drug 
response. For example, mutation in the Walker B domain resulted in blockage of 
efflux.43 Mutation in TMD led to altered affinity for substrate.44 The 3435 C>T 
polymorphism is perhaps one of the best-studied silent mutations. But the correlation 
of this polymorphism with decreased/increased expression of P-gp and drug response 
is still under debate.45 
Before the structure of P-gp was obtained, many different biochemical and biophysical 
strategies including mutagenesis, photo-affinity labelling and fluorescence 
measurements were employed to reveal the mechanism of translocation process. The 
collective data led to generation of a hypothesis called “substrate-induced fit” model.46 
According to the model, drugs bind at a common large domain in the cavity of P-gp. 
But distinct types of drugs may bind with different residues. There is evidence to 
support two different drugs occupying distinct regions in the binding pocket.47 Both 
halves of polypeptide participate in drug binding. However, in order to elucidate drug 
binding process in more detail, structural data are needed. The first structure of P-gp 
purified from CHB30 cells was obtained in 1997 using electron microscopy-single-
particle analysis (EM-SPA).48 However, EM-SPA technique was not able to give a high 
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resolution for this size protein (resolution: 25 Å). Therefore, except for the general 
dimensions of protein, not much valuable information was displayed. Over the next 
years, the same group spent much efforts on improving the resolution with electron 
microscopy. 2D structural data was updated three times and the resolution was 
improved to 8 Å.49-51 In these reports, multiple conformations were presented and it was 
provided that the major conformational movements were driven by NBDs and the 
central pore existed. These were essential evidence for elucidating the translocation 
mechanism. In 2009, the first X-ray crystal structure of mouse P-gp was obtained with 
resolution of 3.8-4.4 Å.28 But, in 2014, this structure had been corrected.29 An 
interesting feature reported in the paper was that the physical separation of NBDs 
reached 30 Å. It is under debate whether this configuration belongs to real empty P-gp 
or is just an artefact of crystallization. Another paper has also reported three crystal 
structures of mouse P-gp.42 The different separation distances of NBDs in three 
structures proved the flexibility of conformation of P-gp. Although all of these 
structural data have provided us with a wealthy of information to understand the 
function of this transporter, the detailed understanding of how P-gp is able to bind such 
a large variety of compounds remains unsolved.  
 
Figure 3: P-glycoprotein co-crystallized with BDE-100 (PDB ID: 4XWK)52 
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There are two models (Figure 4) that were postulated to explain the action of P-gp: 
Hydrophobic vacuum cleaner model and Flippase model.53 As the substrates of P-gp 
are relatively hydrophobic, these models both accept that the substrates partition into 
the lipid bilayer at first.50 Afterwards, hydrophobic vacuum cleaner model assumes that 
substrates are extracted by protein. They pass through the lateral gate composed by TM 
domains 4/6 and 10/12 and interact with ∼6000 angstroms cubed binding cavity28 of P-
gp. Finally, substrates are expelled directly by P-gp into extracellular medium. The 
flippase model assumes that substrates approach binding sites from inner bilayer of 
membrane. Afterwards, they are translocated by protein to outer layer of lipid bilayer 
and released to extracellular environment via passive diffusion. Both models have 
supported evidence,54, 55 but it is difficult to distinguish them experimentally.56  
 
 
Figure 4: Hydrophobic vacuum cleaner and flippase model for P-gp transport mechanism (modified 
from Sharom).57 
 
1.2.3.2 Substrates and inhibitors 
 
Since its discovery, P-gp is well-known for its capability to interact with and to export 
a broad spectrum of structurally diverse compounds which have different 
pharmacological functions. In table 1 selected substrates of P-gp are listed, including 
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anticancer agents, HIV protease inhibitors, immunosuppressive drugs, steroids, 
fluorescent dyes and antibiotics.58 The details about interaction of P-gp with these 
compounds are not fully understood. But some physico-chemical properties including 
lipid solubility, molar refractivity, hydrogen bonding potential, cationic charge, 
presence of amine and aromatic ring were addressed as essential determinants for 
substrate binding and functionality.59, 60  
 
  Table 1: Selected substrates of P-gp 
Anti-cancer drugs Topotecan 
Paclitaxel 
Docetaxel 
Vinblastine 
Vincristine 
Doxorubicin 
Daunorubicin, 
Steroids Aldosterone 
Corticosterone 
Dexamethasone 
Antibiotics  Erythromycin 
HIV protease inhibitors Nelfinavir 
Ritonavir 
Saquinavir 
Immunosuppressive drugs Cyclosporine A 
Tacrolimus 
Fluorescent dyes Rhodamine 123 
Hoechst 33342 
Calcein 
Acetoxymethylester 
 
There are also some compounds that are able to block the efflux of P-gp and reverse 
MDR effect. These compounds are named P-gp inhibitors or modulators. From a 
historic perspective, they are classified into three generations. The first generation 
inhibitors are some existing drugs which were primarily developed for other purposes. 
For example, verapamil is an antihypertensive calcium channel blocker, and 
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cyclosporine A is an immunosuppressant. Selectivity and toxicity were always the 
weakness of these compounds which limited the further exploration.61 To overcome the 
disadvantage of first generation inhibitors, the second generation inhibitors were 
developed. For instance, dexverapamil (the R-isomer of verapamil) has less cardiac 
activity. PSC833 (a cyclosporine A analogue) lacks immunosuppressive property. These 
modifications achieved improved selectivity for P-gp and reduced toxicity in 
comparison to the parent compounds. However, they faced another challenge. They 
were found to cause pharmacokinetic alterations of co-administrated anticancer drugs 
leading to unexpected low clearance of drugs and increased toxicity.62 The third 
generation inhibitors including GF120918 and LY335979 were developed by 
quantitative structure-activity relationship (QSAR) technique, high throughput 
screening (HTS) or combinational chemistry. They did not possess the deficiencies of 
first and second generation inhibitors. Due to the promising potency and low toxicity, 
XR 9576 (tariquidar) was even applied in phase III clinical trial.63 
 
Table 2: Selected modulators/inhibitors of P-gp 
First generation Verapamil 
Cyclosporine A 
Tamoxifen 
Second generation Dexverapamil 
Valspodar (PSC-833) 
Third generation Zosuquidar (LY335979) 
Tariquidar (XR9576) 
Elacridar (GF120918) 
 
At last, it is worth to note that the discrimination between substrates and inhibitors is 
not unambiguous. For example, 5-hydroxypropafenone was able to inhibit P-gp-
mediated digoxin accumulation. But, it could also be translocated by P-gp across 
membrane.64 Therefore, it could not only be assigned as substrate but also competitive 
inhibitor of P-gp. Some selected P-gp inhibitors are given in Table 2. 
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1.2.4 ABCC1 / Multidrug Resistance associated Protein 1 (MRP1) 
 
1.2.4.1 Structure and function 
 
Multidrug Resistance associated Protein 1 (MRP1 or ABCC1) is a transporter widely 
expressed in different tissues including testis, lung, liver, cardiac and skeletal muscles, 
macrophages, intestine, choroid plexus cells and blood-brain barrier (BBB) where 
protecting brain from xenobiotics together with P-gp and ABCG2.16, 65 Unlike most 
other members of ABC transporter family, it is a 190 kDa protein containing three 
transmembrane domains (TMDs) composed by 17 transmembrane helices and two 
NBDs. In addition to the ABCB1-like central core which consists of TMD1, TMD2 and 
two NBDs, it has an extra N-terminal transmembrane domain (TMD0) which contains 
5 α-helices.66 The central core is the functional part which effluxes substrates out of 
cells. TMD0 does not participate in transportation but plays a role in maintaining 
protein in cell membrane.67 The topological structure is displayed in Figure 5. 
 
 
Figure 5: Topology model of ABCC1 (MRP1) 
 
1.2.4.2 Substrates and inhibitors 
 
Similar to P-gp, MRP1 is also able to mediate multidrug resistance. Overexpression of 
MRP1 was detected in various tumors. For example, Nooter et al. observed a very high 
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level of MRP1 mRNA expression in chronic lymphocytic leukemia.68 A few years later, 
overexpression of MRP1 and P-gp was also observed in renal cell carcinoma.69 There 
are also some studies to support MRP1 playing a role in drug resistance of non-small-
cell lung cancer, some kinds of breast cancer and prostate cancer.70  
A variety of structurally different compounds including anticancer drugs, organic 
conjugates, peptides, HIV protease inhibitors and fluorescent dyes are recognized and 
effluxed by MRP1.71 Most interestingly, several drugs and conjugated organic anions 
are only able to be transported in the presence of glutathione (GSH) which broadens 
the substrate spectrum of MRP1. But the reason why some substrates are translocated 
in a GSH-dependent way is still not well understood.72  
 
Table 3: Selected substrates of MRP171 
Anticancer drugs Daunorubicin  
Doxorubicin 
Vinblastine 
Vincristine 
SN-38 
Methotrexate 
GSH conjugates Chlorambucil-SG 
Melphalan-SG 
Leukotriene C4 
Leukotriene D4 
Hydroxynonenal-SG 
Sulfate conjugates Estrone 3-sulfate 
Peptides GSH 
GSSG 
Fluorescent dyes Calcein-AM 
Calcein 
 
Until now, there are not many potent and efficient MRP1-specific inhibitors and no 
MRP1-inhibitor has been tested in clinical trials. In early time, some nonspecific 
inhibitors for organic anion transporter including probenecid, benzbromarone and 
indomethacin were used as modulators of MRP1. However, these compounds also 
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demonstrated inhibitory effects on importers of solute carrier (SLC) family which 
hindered their further application.73 Later, several cysteinyl leukotriene receptor 1 
(CysLTR1) antagonists including MK-571,74 ONO-107875 and LY17188376 were 
identified as more specific inhibitors of MRP1. Whereas, these compounds are 
primarily designed to treat asthma and could not distinguish between other MRP 
homologs. Therefore, they are also not ideal modulators. In 2005, Norman et al. 
discovered several tricyclic isoxazoles with cyclohexyl-linker exhibiting excellent 
selectivity and inhibitory potency against MRP1. In the presence of GSH, the EC50 
values of few compounds showing no cytotoxicity were lower than 100 nM.77 
Nevertheless, to find more specific and potent inhibitors with unwanted side effects and 
toxicities, there are still much work to do. 
 
1.2.5 ABCG2 / Breast Cancer Resistance Protein (BCRP)  
 
In 1998, Ross’s group successfully cloned ABCG2 from a drug-resistant human breast 
cancer subline — MCF-7/AdrVp. They named the expressed protein as breast cancer 
resistance protein (BCRP) which conferred resistance to various anticancer drugs 
including mitoxantrone, doxorubicin and daunorubicin.78 Simultaneously, Allikmets et 
al. characterized ABCG2 gene which was abundantly expressed in placenta on 
chromosome 4q2279 and Miyake et al. successfully cloned cDNAs of ABCG2 from 
mitoxantrone-resistant S1-M1-80 human colon carcinoma cells without overexpression 
of P-glycoprotein and MRP1.80 Nowadays, ABCG2 has been well accepted as an 
important member which confers innate and acquired multidrug-resistance.  
 
1.2.5.1 Distribution and physiological roles 
 
Maliepaard et al. used specific monoclonal antibodies BXP-34 and BXP-21 to 
characterize the distribution and localization of ABCG2 protein. High expression of 
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ABCG2 was observed in placental syncytiotrophoblasts, epithelium of the small 
intestine and colon, liver canalicular membrane, ducts and lobules of breast. The 
presence of ABCG2 in epithelium of the veinous and capillary endothelium was also 
noticed, but not in arterial endothelium. These distributions indicated ABCG2 may play 
a role in transporting them back to gut lumen, regulating uptake of substrates such as 
topotecan or irinotecan and protecting fetus from xenobiotics.81 Huls et al. used 
immunohistochemical analysis to localize ABCG2 and found its expression in proximal 
tubule brush border membrane of kidney which indicated its importance in renal drug 
exceretion.82 Cooray et al. found the presence of ABCG2 at the blood-brain barrier, 
especially at the luminal surface of microvessel endothelium. It may suggest, besides 
P-gp and MRP1, ABCG2 is also important for hindering drugs accessing the brain.83 
Similarly, its expression was also shown in Sertoli cells indicating it may play a 
protective role at the blood-testis barrier.84 Asashima et al. identified its expression on 
the mouse luminal membrane of retinal capillary endothelial cells. This indicates its 
importance in restricting the accumulation of phototoxins and xenobiotics such as 
pheophorbide A and protoporphyrin IX in retinal tissue.85 In short, the wild distribution 
of ABCG2 in these studies implies that it can exert essential effects on limiting 
absorption (small intestine), mediating distribution (blood-brain, blood-testis, blood-
placental barriers) and facilitating elimination (liver, kidney and colon) of xenobiotics 
including anticancer drugs. And these physiological functions were also proven in some 
studies by using ABCG2-knockout mice.86 
Although ABCG2 has demonstrated protective roles in various normal tissues, it was 
found over-expressed in various drug-resistant cell lines including ovarian tumor cell 
line T8, mitoxantrone-selected human gastric carcinoma cell line EPG85-257RNOV, 
colon cancer cell lines S1-M1-80 and HT29, gefitinib-resistant non-small cell lung 
cancer (NSCLC) cells, human small cell lung cancer cells PC- 6/SN2-5, epirubicin-
resistant human hepatocyte carcinoma cells HLE-EP and topotecan and doxorubicin-
selected human multiple myeloma cells.87 This high expression is thought to be 
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associated with MDR in hematopoietic malignancies and solid tumors. Besides, 
Jablonski et al. observed increased P-gp and ABCG2 expression at the blood-spinal 
cord barrier in Amyotrophic lateral sclerosis (ALS). It implicated these two transporters 
may also be the obstacle inducing MDR in ALS.88 
 
1.2.5.2 Structure of ABCG2 
 
The six members of G subfamily including ABCG2 are all half transporters which 
contain only one TMD and one NBD. Membrane topology determined by epitope 
insertion and immunofluorescence demonstrated that ABCG2 contains 6 
transmembrane α-helices (Figure 6) and the arrangement of TMD-NBD is reversed in 
comparison to P-gp and MRP1.89  
 
 
Figure 6: Topology model of ABCG2 (BCRP) 
 
Due to its nature of half transporter, dimerization or oligomerization which has been 
supported by evidence from various studies is required to function as a transporter.90, 91 
The first structure of ABCG2 was determined by McDevitt et al. They used 
cryonegative stain electron microscopy to construct 3D structural data of purified 
ABCG2(R482G) at a resolution of approximately 18 Å and a tetrameric complex with 
an aqueous center was revealed by single-particle analysis.91 Later, Rosenberg et al. 
subjected ABCG2 to 2D crystallization and revealed a symmetry. The projected 
structures which were determined at 5 Å resolution indicated the existence of an 
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oligomeric complex and illustrated that ABCG2 had a more symmetric and closed 
conformation in the presence of mitoxantrone than without mitoxantrone.92 Recently, 
the first high-resolution 3D crystal structure of human ABCG2 in complex with two 
antigen-binding fragments of antibody 5D3 was determined by cryo-electron 
microscopy.31 The local resolution of TMD and fragments of 5D3 approached 3 Å, but 
NBDs were resolved at lower resolution. Therefore, the NBD homology model based 
on ABCG5/G8 heterodimer was docked into the EM density map. Albeit, these 
structural data still revealed much valuable information.  
NBD and TMD are linked by a highly charged linker which is flexible and the distance 
between NBD and membrane was shorter than other members of B-subfamily. Notably, 
NBDs are still in contact even though nucleotide is not bound to NBD. The previous 
postulations that GXXXG motif at TMD and C2 motif at NBD involved in dimerization 
and ATP binding respectively93, 94 were not supported (Figure 7A). The longest 
extracellular loop EL3 which connects TM5 and TM6 contains three cysteines (C592, 
C603, C608) and an N-glycosylation site — N596, to which two GlcNAc residues are 
attached (Figure 7B). C592 and C608 form one intramolecular disulfide bond which is 
essential for ABCG2 activity, but the intermolecular disulfide bond formed by C603s 
seems not crucial for transportation. This observation is consistent with previous 
studies.90, 95 N-glycosylation at N596 does not affect the binding of antibody fragments. 
But this site is critical for ABCG2 maturation.96 Most critically, a deep slit-like cavity 
which is suitable to accommodate hydrophobic and flat compounds was revealed. The 
residues in this cavity which contact with two cholesterols are L539, I543, V546, M549, 
F432 and F439. All of them are hydrophobic residues (Figure 7C). Besides, another 
smaller cavity below EL3 was also observed. These two cavities are separated by two 
leucine residues which form a plug between them. Previous biochemical studies have 
supported the existence of multiple binding sites.86 Due to less hydrophobic surface and 
unfavorable substrate-binding conformation of cavity 2, cavity 1 might be the place 
where binding sites locate.   
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Figure 7: Structure of ABCG2 (PDB ID: 5NJ3).31 A: Ribbon diagram of ABCG2 dimers. B: Top 
view of EL3 loops. C: The left picture demonstrates two cavities on TMD, silver helix (part of TM5) 
and yellow helix (part of TM2) are the area cholesterols bound. The right picture displays calculated 
molecular surface of ABCG2 dimers by MOE 2015.   
 
1.2.5.3 Substrates and inhibitors 
 
A wide spectrum of compounds is reported to be substrates of ABCG2. Among them 
are some anticancer drugs including mitoxantrone, flavopiridol, camptothecin 
derivatives and several tyrosine kinase inhibitors (imatinib, gefitinib and nilotinib). 
Several other drugs including prazosin, cimetidine, rosuvastatin, glyburide, 
sulfasalazine and several nucleotide analogs such as lamivudine and AZT could be 
effluxed by ABCG2.97 But ABCG2 is not able to export vinblastine, cisplatin and 
paclitaxel out of cells.98 Some chemical toxicants including protoporphyrin IX, some 
fluorescence probes including Hoechst 33342, BODIPY-prazosin and pheophorbide A, 
some organic conjugates of xenobiotics and conjugated organic anions including 
dehydroepiandrosterone and estrone-3-sulfate are also ABCG2 substrates.97 Some of 
them are overlapping with substrates of P-gp or MRP1. Selected substrates of ABCG2 
are listed in Table 4.  
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Table 4: Selected substrates of ABCG287 
Topoisomerase inhibitors Daunorubicin 
Doxobucincin 
Mitoxantrone 
Etoposide 
Becatecarin 
Tyrosine kinase inhibitors Gefitinib 
Erlotinib 
Nilotinib 
Conjugates of xenobiotics Estrone 3-sulfate 
SN-38-glucuronide 
Troglitazone sulfate 
Fluorescent dyes Hoechst 33342 
pheophorbide A 
BODIPY-prazosin 
Lysotracker green 
Others Diclofenac 
Rosuvastatin 
Nicardipine 
 
To overcome MDR mediated by ABCG2, a few array of inhibitors with various 
structures have been identified and developed. Some selected ABCG2 inhibitors are 
presented in Table 5. Gupta et al. reported some HIV protease inhibitors including 
ritonavir, saquinavir and nelfinavir to be effective ABCG2 inhibitors, but not 
substrates.99 Zhang et al. discovered that dipyridamole and several calcium channel 
blockers including nicardipine, nitrendipine and nimodipine could effectively inhibit 
ABCG2-mediated mitoxantrone efflux.100 A typical selective ABCG2 inhibitor is 
fumitremorgin C (FTC) obtained from the fungi Aspergillus fumigatus. It did not show 
inhibition of P-gp and MRP1,101 but its neurotoxicity hindered its further application in 
vivo. Therefore, several analogues of FTC including Ko132, Ko134 and Ko143 were 
developed and showed lower neurotoxicity, higher inhibitory potency and selectivity 
for ABCG2.102 Except the abovementioned compounds, many derivatives of various 
scaffolds including tariquidar,103 chalcone,104 chromone105 and flavone106 were also 
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synthesized and tested as potent and selective ABCG2 inhibitors.  
 
Table 5: Selected ABCG2 inhibitors86 
HIV protease inhibitors Saquinavir  
Nelfinavir  
Lopinavir 
Calcium channel blockers 
 
Nicardipine 
Nimodipine 
Nitrendipine 
Tyrosine kinase inhibitors Gefitinib  
Imatinib  
Erlotinib  
Nilotinib  
Lapatinib 
Other drugs Novobiocin 
Fumitremorgin C 
 
An interesting family of compounds in Table 5 are tyrosine kinase inhibitors (TKIs). 
TKIs were initially designed as specific and selective anticancer agents for inhibiting 
targets like epidermal growth factor receptor or vascular endothelial growth factor 
receptor to stop transducing signal in cell proliferation. But later some of them were 
also reported with obviously inhibitory activity on ABCG2.  
Nakamura et al. reported that topotecan, SN-38 and mitoxantrone resistance were 
effectively reversed by ten micromoles of gefitinib in three multidrug-resistant cancer 
cell lines overexpressing ABCG2.107 Imatinib mesylate was reported to be able to 
reverse resistance towards topotecan and SN-38 in ABCG2 overexpression cells.108 
Both of them are also substrates of ABCG2. Dai et al. observed increasing accumulation 
of doxorubicin or mitoxantrone in ABCB1- or ABCG2-overexpressing cells in 
treatment with lapatinib and the transport of methotrexate was also inhibited.109 Mi et 
al. reported apatinib to significantly increase the intracellular accumulation of 
rhodamine 123 and doxorubicin in three different cell lines overexpressing ABCG2. 
And it reversed resistance of ABCB1 and ABCG2 mediated by directly inhibiting them 
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but not by blocking AKT or ERK1/2 pathways or downregulating expression of ABCB1 
and ABCG2.110 Lapatinib (GW572016), GW583340, GW2974, canertinib and erlotinib 
were found to be able to circumvent MDR by inhibiting the activity of P-gp and 
ABCG2.109, 111, 112 Canertinib (CI1033) was found to enhance cytotoxicity of 7-ethyl-
10-hydroxycamptothecin and topotecan in cancer cells by inhibiting ABCG2-mediated 
drug efflux.113 Many other TKIs which are able to interact with ABCG2 are reviewed 
elsewhere.114, 115 The structures of selected TKIs which have also been reported as 
ABCG2 modulators are displayed in Figure 8.  
The mechanism of inhibition is not fully understood. Some ABCG2 inhibitors are called 
“general” inhibitors that inhibit ATPase activity of the transporter such as FTC and 
Ko143. Some others are “substrate-dependent” inhibitors that are also ABCG2 
substrates. The latter series of modulators may interact with ABCG2 (i) at the same 
binding site of one class of substrates, (ii) or at allosteric sites to induce conformational 
changes in the large binding pocket that subsequently affect transportation of certain 
substrates.86 Due to the complex mechanism of inhibition, predicting and screening 
novel ABCG2 modulators is still a challenge. Further studies are required for 
developing more potent compounds which are able to be applied in the clinic.  
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Figure 8: Structures of selected TKIs which are reported to be ABCG2 inhibitors116 
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1.3 Biochemical evaluation of ABCG2 inhibitors 
 
In the following chapters, different types of compounds were synthesized as ABCG2 
inhibitors. To compare and evaluate the inhibitory effects of different inhibitors, 
Hoechst 33342 and pheophorbide A accumulation assays were carried out. 
Hoechst 33342 is a bis-benzimidazole fluorescent dye which binds to cell membrane 
and the minor groove of double-stranded DNA in live or fixed cells. It can be efficiently 
excited by ultraviolet light (361nm when bound to double-stranded DNA) and emits 
blue fluorescence at 460-490 nm wavelength. Although it can bind with any nucleic 
acids in DNA strands, binding with AT (adenine-thymine) regions enhances 
fluorescence obviously. The exact emission spectra are dependent on the ratios of dyes 
to base pairs. Pheophorbide A is a photosensitizer for photodynamic therapy and its 
fluorescence emission does not require to bind to DNA. The absorption maximum of 
pheophorbide A is at 395 nm and the emission maximum at 670 nm. 
In table 4, we introduced both of them as substrates of ABCG2. They will be effluxed 
by ABCG2 leading to weaker intracellular fluorescence in ABCG2-overexpressing 
cells than in normal cells. Inhibition of ABCG2 will increase the intensity of 
fluorescence owing to higher intracellular concentration of Hoechst 33342 or 
pheophorbide A (Figure 9). Therefore, quantitatively evaluating inhibitory effects of 
different inhibitors is possible by detecting intensity of intracellular fluorescence. A 
representative concentration-response curve of Ko143 is displayed in Figure 10. 
Alongside the increase of concentration of Ko143, the intracellular fluorescence is 
intensified until it reaches a plateau.  
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Figure 9: Accumulation of Hoechst 33342 and pheophorbide A. 
 
 
Figure 10: Concentration-response curve of Ko143 in pheophorbide A assay 
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The curve can give two important parameters which are useful for evaluating inhibitory 
activities of various inhibitors. One parameter is IC50 value which is the inflection point 
of curve and shown in Figure 10. The other is plateau value of maximal inhibition which 
demonstrates the maximal inhibitory effect of a compound. After comparing the 
maximal fluorescence values of tested inhibitor and reference compound, Imax value can 
be calculated via equation: 
 
Imax(%) =
𝐹max(𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟) − 𝐹min(𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑜𝑟)
𝐹max(𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒) − 𝐹min(𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒)
× 100% 
 
For example, Figure 11 shows two concentration-response curves. Purple line belongs 
to Ko143 and green line belongs to compound LJY-114. We set Ko143 as reference 
compound which means its Imax was set as 100% and its span (Fmax-Fmin) is 447. But the 
span of LJY-114 is only 187. According to the equation, Imax of LJY-114 is 42%. It is 
only a partial inhibitor. Although the pIC50 value of LJY-114 is -7.32 which is lower 
than -7.108 of Ko143, LJY-114 is still obviously less potent than Ko143. 
 
 
Figure 11: Concentration-response curve of LJY-114 and Ko143 in pheophrobid A assay 
 
The compound with both higher Imax and lower IC50 value is regarded as more potent 
ABCG2 inhibitor.  
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In comparison to Hoechst 33342 assay, pheophorbide A assay has three advantages. (1) 
The range of Hoechst 33342 emitting wavelength is at 460-490 nm which is overlapped 
with some compounds which also have fluorescence properties. But pheophorbide A 
emits at 670 nm which is never reached by all tested compounds in this thesis. (2) 
Hoechst 33342 is not only transported by ABCG2, but also by P-gp. But pheophorbide 
A is a specific ABCG2 substrate. Therefore, the source of error derived from P-gp 
exportation is excluded. (3) The measurement of fluorescence is applied only in healthy 
cells which are detected on a FACSCalibur flow cytometer. All of these factors lead to 
higher accuracy of biochemical results. But the measurement process of pheophorbide 
A assay is also time-consuming, Hoechst 33342 assay is faster. Therefore, we applied 
an evaluating strategy for all synthesized compounds. The compounds were tested in 
Hoechst 33342 assay at first. After analysis, some interesting modulators were selected 
to be tested in pheophorbide A assay. The detailed biochemical data of every modulator 
are provided in following chapters.  
 
All biological work presented in this thesis was done by Katja Silberman.  
  
2 Aim of the work 
 
28 
 
2 Aim of the work 
 
In introduction chapter, we have presented some tyrosine kinase inhibitors that also 
demonstrated ABCG2 inhibition (Figure 8). After comparing structures of these 
selected TKIs, it is noticed that most of them shared the same scaffold — 4-
anilinoquinazoline. Inspired by this observation, much work has been done in our group 
to investigate potent ABCG2 inhibitors.  
 
 
Figure 12: The essential features (red) of 4-anlinoquinazolin derivatives for ABCG2 inhibition. 
 
Pick et al. determined the potency of seven different TKIs (gefitinib, erlotinib, AG1478, 
PD158780, PD153035, nilotinib and imatinib) for overcoming resistance of ABCG2, 
ABCB1 and ABCC1.117 As a result, these compounds obviously displayed higher 
affinity towards ABCG2 than ABCB1 and ABCC1. In both Hoechst 33342 and 
pheophorbide A assays, all of them yielded IC50 values which were less than 10 μM and 
PD158780 even reached nanomolar level. Subsequently, Juvale et al. adopted 4-
anilinoquinazoline as scaffold and investigated dozens of derivatives as novel ABCG2 
inhibitors.118, 119 Several variations at positions 2, 4, 6 and 7 of quinazoline ring were 
carried out. When both position 6 and 7 were substituted by methoxy, the inhibitory 
activities decreased in comparison to unsubstituted compounds. When position 2 was 
substituted by phenyl, 3,4-dimethoxyphenyl or substituted aniline, the potency was 
significantly improved. However, some weakness including cytotoxicity and potential 
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solubility problem limited the further exploration. At position 4, different substituents 
on aniline moiety were applied. In general, meta-substituted aniline produced higher 
activity than corresponding ortho- or para-substituted aniline. NO2, CN, CF3 were 
found to be optimum substituents. Afterwards, Spindler et al. further investigated 
position 3 and 4.120 Replacing quinazoline scaffold as quinoline apparently decreased 
potency against ABCG2 as well as replacing N of aniline moiety at position 4 by O or 
S. Besides, Krapf et al. has done more variations in the scaffold.121-123 At position 4, 
phenyl of aniline moiety was replaced by cyclohexane ring and a drastic decrease of 
activity was observed. Meanwhile, the replacement of the hydrogen atom of NH linker 
at position 4 by methyl group drastically decreased the inhibitory efficiency. Therefore, 
hydrogen atom, nitrogen atom and phenyl of aniline moiety were all proven crucial for 
interaction with ABCG2. Furthermore, the influence of different substitutions was also 
explored. Substitution in meta and para positions led to higher potencies than ortho. It 
might be attributed to reduced planarity derived from ortho substitution which resulted 
in more twisted conformation. Planarity is regarded as an important feature of potent 
ABCG2 inhibitors. Whereas, the electronic effect of the substituents did not exert 
obvious effect on activity as well as steric requirement. No apparent correlation 
between IC50 value and bulkiness of substituents was demonstrated. Cyano, nitro 
(electron-withdrawing group) and hydroxyl (electron-donating group) were all potent 
substituents no matter at meta or para position. But when both aromatic rings at position 
2 and 4 were substituted, the combination of substituents with opposite electronic 
effects was favorable. For example, the combination of 3,4-dimethoxy and nitro group 
led to highly potent ABCG2 inhibitors with IC50 values below 100 nM. Besides, phenyl 
at position 2 was replaced by o-, m- and p- pyridyl, thienyl and pyrrolyl. Although they 
led to higher solubility and lower cytotoxicity, the potency on ABCG2 inhibition was 
not improved. Correlation between log P and IC50 values of many substances was 
studied. Although membrane permeability would prefer more lipophilic compounds, no 
clear correlation was observed. Several compounds which had similar log P values 
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showed different inhibitory activities and vice versa. Besides, swapping substituents at 
at position 2 and 4 did not lead to distinct activity. This might indicate the 
interchangeability of substituents at corresponding aromatic systems. Replacing carbon 
at position 8 by nitrogen did not show negative effect on potency. When position 6 was 
substituted by nitro group but not amine or amide, the activity was improved. 
Replacement of the left benzene ring of quinazoline scaffold by a methyl group had no 
negative effect on the inhibitory efficiency. 
In summary, the essential features of 4-anlinoquonazolin derivatives for ABCG2 
inhibition are depicted in Figure 12. Phenyl ring at position 2, N at position 3, NH linker 
and phenyl ring of aniline at position 4 are indispensable parts. Removal of any of them 
would lead to apparent decrease of activity. Ortho substitution at position 2 and position 
4 should be avoided as well as methoxy substituents at position 6 and 7.  
In this thesis, we adopted the results described above and did other modifications which 
are briefly illustrated below. 
 
Figure 13: Overview of all projects. 
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1. In project 1, the importance of a nitrogen atom at position 1 of the quinazoline 
scaffold was investigated. We exchanged carbon at position 2 and nitrogen at 
position 1 in quinazoline scaffold and synthesized dozens of mono- or bis- 
substituted phthalazine derivatives to investigate the potency of these 
compounds as ABCG2 inhibitors. Due to the unfavorable effect of ortho 
substitution on quinazoline derivatives, we only carried out substitution at meta 
and para position for phthalazine derivatives. The results are discussed in detail 
in phthalazine chapter.  
2. In project 2, the influence of replacing linker at position 4 was investigated. As 
mentioned before, NH and phenyl of aniline moiety are all crucial features. 
Planarity was also an important characteristic of potent ABCG2 inhibitors. We 
applied a strategy which not only preserved the essential features but also 
improved the planarity of molecular conformation — replacement of NH linker 
between aromatic ring B and D by amide and urea linker. The results are 
discussed in detail in quinazoline chapter. 
3. In project 3, we continued the work of our colleague on pyrimidine derivatives. 
In comparison to corresponding quinazoline derivatives, several pyrimidine 
derivatives with a methyl group at position 6 improved solubility and 
demonstrated similar inhibitory effects on ABCG2. Inspired by this preliminary 
study, we introduced a broader spectrum of substituents on aniline moiety and 
investigated the activities of derivatives. The results are discussed in detail in 
pyrimidine I chapter. 
4. In project 4, potential modifications at position 6 of pyrimidine scaffold were 
investigated. As mentioned before, replacement of carbon of quinazoline ring 
as nitrogen did not exhibit any negative effect on ABCG2 inhibition. Therefore, 
methyl group at position 6 of pyrimidine ring was altered while other critical 
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features were preserved. The results are discussed in detail in pyrimidine II 
chapter. 
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3 Project I: Phthalazine derivatives as 
ABCG2 inhibitors 
 
3.1 Overview 
 
The previous studies revealed the influence of variation at position 2, 3, 4, 6, 7 and 8 of 
quinazoline scaffold on ABCG2 inhibtion, but the effect of variation at position 1 was 
not clear. Therefore, in this chapter, we introduced anilinophthalazine as novel scaffold 
of ABCG2 inhibitors. It preserves N at position 3 and aniline moiety at position 4 which 
were proven crucial for ABCG2 inhibition. 
Phthalazine derivatives were reported to possess different biological activities. Some 
of them have been used in the clinic. Hydralazine, patented in 1949, was used to treat 
high blood pressure and heart failure. Budralazine was an antihypertensive drug due to 
its vasodilator property.  Zopolrestat showed potential use in prevention of diabetes 
by inhibiting aldose reductase.  Azelastine was an antihistaminic drug and often used 
for treatment of allergic rhinitis. These successful samples suggest phthalazine is a 
potent drug-like scaffold. The synthesis and biological investigation of its derivatives 
are discussed below. 
 
Figure 14: Selected drugs with phthalazine scaffold 
3 Project I: Phthalazine derivatives as ABCG2 inhibitors 
34 
 
3.2 Synthesis 
 
The modification was divided into two parts. On one hand, amination was only carried 
out at position 4. Position 1 of phthalazine scaffold was unsubstituted or substituted by 
Ph or Cl. On the other hand, both position 1 and 4 were substituted with anilines. The 
aniline moiety at position 1 might compensate for the loss of phenyl ring at position 2 
of 4-anilinoquinazoline scaffold which was also proven essential for inhibiting ABCG2. 
The general synthesis scheme is described in Scheme 1 and the reaction mechanism in 
Scheme 2.   
 
Scheme 1: General synthesis scheme of anilinophthalazine derivatives* 
*: Reagents and conditions for synthesis of phthalazine derivatives (X = Ph or H ): (i) POCl3, 
reflux, 8-9 h (ii) i-PrOH, microwave, 70 - 110 °C, 30 min. (iii) i-PrOH, reflux, overnight. 
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Phthalazones (commercially available) were chlorinated using phosphorus oxychloride 
to afford corresponding chlorophthalazines. Subsequently, nucleophilic heteroaromatic 
substitution was performed on the obtained chlorinated phthalazine to produce various 
substituted anilinophthalazines. Substituents were selected according to potency of 
corresponding quinazoline derivatives and were only introduced at meta- or para- 
position of aniline moiety. In case of 1,4-dichlorophthalazine, ratio of 1,4-
dichlorophthalazine to aniline determined products with mono- or bis-substitution. The 
mechanism is described below. 
 
Scheme 2: Proposed mechanism for synthesis of anilinophthalazine derivatives. 
 
Chlorination of phthalazone is achieved by treatment with phosphorus oxychloride 
which is widely used in activating Cl formation. Amide of phthalazone reacts with 
phosphorus oxychloride to produce an electrophilic iminium cation at first. 
Subsequently, this imninium cation is attacked by chloride to give imidoyl chlorides 
cation which is deprotonated to afford chlorophthalazine.  
Amination of chlorinated phthalazine is generally assumed to proceed via SNAr2 
mechanism.124-126 This mechanism is supported by spectroscopic, synthetic, and kinetic 
studies.127 Due to the electrophile property of carbon of imidoyl chloride, it is attacked 
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by nitrogen of aniline to produce an unstable cyclohexadienide intermediate. This step 
is postulated as rate determining. Afterwards, chloride is quickly eliminated to give 
final compounds.   
In 1971, Hill et al. published a study about the kinetics of the methoxydechlorination 
of a series of 1-chloro-4-substituted phthalazines and related compounds.124 They found 
the reaction was quite sensitive to the nature of X at position 4 of phthalazine ring. 
Decreased electron density on the ring facilitated reaction. This is also probably 
applicable to our reaction. The details about synthesis and potential pitfalls are 
described in experimental section. 
 
3.3 Results and Discussion 
 
The inhibitory potency of synthesized phthalazine derivatives was investigated in 
Hoechst 33342 accumulation assay. ABCG2 overexpressing MDCK II BCRP and 
parental cell line were used in biological test. More information about Hoechst 33342 
accumulation assay is described in introduction chapter. WK-X-24 (XR9577) was used 
as a standard inhibitor due to its easy availability and lower cost than Ko143. The 
activity data of monosubstituted and bis-substituted phthalazine derivatives are shown 
in Tables 6 and 7. The potency of compounds was evaluated not only by IC50 value, but 
also by maximal inhibition which is discussed in introduction chapter. When the 
maximal plateau of a partial inhibitor is low enough, it is not worth to report IC50. 
Therefore, to simplify discussion, all compounds with Imax less than 50% are regarded 
as inactive. 
 
3.3.1 Biological investigation of monosubstituted phthalazine derivatives 
 
Firstly, position 1 of phthalazine scaffold was unsubstituted and we only modified 
position 4 with different substituted anilines. The study of quinazoline derivatives  
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Table 6: Inhibitory potency of synthesized monosubstituted phthalazine derivatives against 
ABCG2 in the Hoechst 33342 accumulation assay. 
 
No. X R IC50 ± SD
* [μM] Imax± SD# [%] 
2 H 3,4-OCH3 n.a. 16 ± 2 
3 H 3-Br n.a. 16 ± 2 
4 H 3-CN n.a. 14 ± 1 
5 H 4-F n.a. 11 ± 2 
6 H 4-NO2 n.a. 15 ± 3 
7 Ph 3,4-OCH3 4.18 ± 0.64 62 ± 4 
8 Ph 3-OH 6.26 ± 1.44 - a 
10 Cl 3,4-OCH3 1.26 ± 0.18 74 ± 10 
11 Cl 3-OCH3 n.a. 34 ± 5 
12 Cl 3-Br n.a. 46 ± 4 
13 Cl 4-F n.a. 29 ± 7 
14 Cl 3-CN n.a. 24 ± 6 
15 Cl 4-NO2 n.a. 40 ± 7 
16 Cl 3-NO2 n.a. 46 ± 9 
17 Cl 3-OH n.a. 42 ± 5 
18 Cl 4-CN n.a. 26 ± 6 
WK-X-24 - - 0.704 ± 0.147 100 
*: Data are expressed as mean ± SD (n = 3) 
#: Percentage of inhibition with regard to WK-X-24 
a: plateau of curve was fixed to top of Ko143.  
n.a. = not active 
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showed when R is on meta or para position of aniline moiety, compounds are generally 
more active than ortho positon substituted compounds. Thus, 3,4-dimethoxy, 4-fluoro,  
4-nitro, 3-bromo and 3-cyano were initially introduced as substituents. However, their 
negligible maximal responses revealed all of them had no inhibitory effects on ABCG2. 
It suggested, except substituted aniline at position 4 and N at position 3, some other 
indispensable parts were missing. 
Next, position 1 was also included in the modification. As described before, when a 
phenyl ring is introduced at position 2 of quinazoline scaffold, the inhibitory activity 
against ABCG2 is significantly improved. Therefore, we also took Ph as priority for 
modifying position 1 of phthalazine scaffold. Besides, chlorine was introduced as the 
other choice. 3,4-dimethoxy and 3-methoxy were firstly chosen as substituents at the 
aniline ring, because methoxy in different series of compounds was reported to play a 
role in ABCG2 inhibition.128-130 Interestingly, substantial difference of inhibition was 
observed. Compound 7 and 10 (both bearing 3,4- dimethoxy group) displayed 62% and 
74% maximal inhibition respectively. Whereas, compound 11 (bearing 3-methoxy 
group) could only achieve 34%. Both compound 7 and 10 demonstrated significantly 
promoted maximal inhibition than compound 2. All compounds with substitution at 
position 1 (7 to 11) displayed improved inhibitory effects compared to unsubstituted 
compounds (2 to 6). Therefore, it is reasonable to assume that X at position 1 of 
phthalazine scaffold is also a necessary part for ABCG2 inhibition. Nevertheless, 
phenyl ring did not improve activity as much as chlorine did. Compound 10 containing 
Cl at position 1 was more active than 7 containing Ph at position 1. An explanation is 
attributed to planarity which is thought as an important property for designing ABCG2 
inhibitors.131 Due to the steric hindrance, Ph does not prefer to share same plane with 
phthalazine scaffold and steric strain in compound 7 and 8 were regarded as an 
unfavorable feature for ABCG2 inhibition.  
Afterwards, the moderate inhibitory effect of compound 10 motivated us to further 
explore the influence of aniline ring while keeping the substituent at position 1 as 
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chlorine. Seven more structurally similar compounds (12 to 18) were synthesized. 
Although the positive role of Cl is evident in compound 12 to 15 by comparison to 
compounds 3 to 6, they are still partial inhibitors. All of their Imax data were lower than 
50%. Hence, substituting position 1 with Cl is still not a very effective strategy.  
Instead of replacing Cl as new element, we decided to elongate the substituent at 
position 1 of phthalazine scaffold. Bis-substituted derivatives were synthesized. The 
aniline moiety at position 1 might also be a substitute for the crucial Ph at position 2 of 
quinazoline scaffold. The biological data are shown below. 
 
3.3.2 Biological investigation of bis-substituted derivatives 
 
As mentioned before, 3,4-OMe and 3-OMe bis-substituted compounds were explored 
initially. Unlike monosubstitution, 3,4-OMe didn’t show distinct advantage over 3-
OMe. Bis-substituted compound 19 (3,4-OMe) showed lower IC50 value than 20 (3-
OMe), but its maximal plateau was not as high as the latter one. Comparing both 
monosubstituted and bis-substituted compounds led to an interesting observation. 
Comparing compound 10 versus 19 (3,4-OMe), bis-substituted compound 19 
demonstrated only slightly improved activity than monosubstituted compound 10. 
Whereas, in compound 11 versus 20 (3-OMe), the activity of compound 20 was 
considerably increased and its maximal inhibition was comparable to WK-X-24. It 
might indicate the number of methoxy groups might be a factor that influences the 
activity. Inspired by potency of compound 20, eight more bis-substituted compounds 
were synthesized subsequently. 
As shown in table 7, compound 21 (4-F) displayed low inhibitory activity towards 
ABCG2. The Imax data of compounds 22, 23 and 24 were negligible. It might be owing 
to their poor solubility or lipophilicity. However, 3-CF3 and 3-Br bis-substituted 
derivatives (25 and 26) displayed complete inhibition and high potency. The latter one 
was even more potent than the standard inhibitor. Although, 3-CF3, 3-Br and 3-OMe 
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have different electrostatic effect on aniline ring, compounds 20, 25 and 26 exhibit 
comparable ABCG2 inhibition results. Therefore, it is reasonable to assume that 
electrostatic properties (electron-withdrawing or electron donating) of substituents in 
aniline moiety are not essential for ABCG2 inhibition.  
 
Table 7: Inhibitory potency of synthesized bis-substituted phthalazine derivatives against ABCG2 in 
the Hoechst 33342 accumulation assay. 
 
No. R IC50 ± SD* [μM] Imax ± SD# [%] 
19 3,4-OCH3 1.01 ± 0.07 76 ± 17 
20 3-OCH3 3.13 ± 0.33 93 ± 5 
21 4-F n.a. 20 ± 4 
22 3-NO2 n.a. 0 
23 4-NO2 n.a. 0 
24 3-OH n.a. 0 
25 3-CF3 1.70 ± 0.18 94 ± 8 
26 3-Br 0.652 ± 0.099 96 ± 30 
27 3-CN n.a. 25 ± 4 
28 4-CN 1.01 ± 0.17 61 ± 18 
WK-X-24 - 0.704 ± 0.147 100 
*: Data are expressed as mean ± SD (n = 3) 
#: Percentage of inhibition with regard to WK-X-24 
n.a. = not active 
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At last, compounds 27 (3-CN) and 28 (4-CN) were synthesized. While compound 28 is 
a moderate ABCG2 inhibitor, compound 27 is apparently inactive. Due to the similar 
lipophilicity and electrostatic property of them, the substantial difference in inhibitory 
potency might be attributed to steric effect.  
 
Table 8: Comparative study of selected phthalazine and quinazoline derivatives against ABCG2 in 
the Hoechst 33342 accumulation assay. 
 
 
 
R IC50 ± SD (μM) IC50 ± SD# (μM) 
3,4-OCH3 1.01 ± 0.07 0.19 ± 0.01 
3-OCH3 3.13 ± 0.33 1.32 ± 0.10 
3-CF3 1.70 ± 0.18 0.25 ± 0.10 
3-Br 0.652 ± 0.099 0.57 ± 0.04 
3-CN n.a. 0.14 ± 0.04 
#: IC50 value taken from reference.
118 
n.a. = not active 
 
In summary, some phthalazine derivatives were synthesized and evaluated as ABCG2 
inhibitors. Several factors that might exert effects on the activity are discussed below: 
(i) variation of substituents at position 1 of phthalazine scaffold showed apparent 
influence on ABCG2 inhibition. (ii) Bis-substituted phthalazine derivatives 
demonstrated higher affinity towards ABCG2 than monosubstituted derivatives.  (iii) 
As substituents on aniline moiety, 3,4-dimethoxy was more favorable than 3-methoxy 
in the monosubstituted series. But in bis-substituted series, they did not show 
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substantial difference.  (iv) Lipophilicity and steric effect, but not electrostatic 
property, might be important determinants in these series of compounds for ABCG2 
inhibition.  
Although several compounds (10, 19, 20, 25 and 26) in this series displayed apparent 
inhibitory effects against ABCG2 and compound 26 was even more potent than WK-
X-24, the comparative study revealed that phthalazine did not show an advantage in 
comparison to quinazoline scaffold. In table 8, it is obviously seen that all of the 
selected potent phthalazine derivatives were less potent than the corresponding 
quinazoline derivatives. Therefore, swapping N and C of quinazoline scaffold at 
position 1 and 2 might not be an effective strategy. Nitrogen at position 1 might also be 
an essential component for ABCG2 inhibition. In the next chapter, we further explored 
quinazoline derivatives. 
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4 Project II: Quinazoline derivatives as 
ABCG2 inhibitors 
 
4.1 Overview 
 
In view of high-affinity of 4-anilino-2-phenylquinazoline derivatives towards ABCG2, 
we stopped phthalazine exploration and continued to investigate quinazonlines. 
Quinazoline, a heterocyclic compound, is an important skeleton in medicinal chemistry. 
Its derivatives have displayed a broad spectrum of therapeutic and pharmacological 
properties such as antihypertensive,132 anticonvulsant,133 antimalarial,134 antibacterial 
and anti-inflammatory.135 A variety of quinazoline derivatives were also developed as 
potent anticancer drugs.  
Some of these anticancer drugs based on the quinazoline scaffold were reported as 
modulators of ABC transporters. In previous chapters, it was described that many TKIs 
with quinazoline scaffold were potent ABCG2 inhibitors. From the structure-activity-
relationship presented, planarity was thought to be an important descriptor for 
designing potent ABCG2 inhibitors. In some series of compounds, more planarity 
correlated with improved ABCG2 affinity. Thus, we decided to keep all of the crucial 
components described before and increase planarity of quinazoline derivatives.  
2-phenyl-4-anilinoquinazoline derivatives were shown to possess excellent potency as 
ABCG2 inhibitors. Since the hybridization type of nitrogen in aniline is between sp2 
and sp3, quinazoline scaffold does not share the same plane with aniline ring at position 
4. To increase planarity, we introduced amide and urea linkers at position 4. Thus, a 
planer conformation would be preferred. The synthesis scheme and biological activities 
are discussed below. 
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4.2 Synthesis 
 
Novel quinazoline derivatives were synthesized in two steps (Scheme 3). In step 1, 
anthranilonitrile and benzonitrile reacted with strong base at high temperature to 
produce 4-amino-2-phenylquinazoline. In step 2, 4-amino-2-phenylquinazoline either 
condensed with substituted benzoic acid or substituted phenyl isocyanate under mild 
conditions to afford final products. Substituents were selected from the potent 4-
anilino-2-phenylquinazoline derivatives and were only introduced at meta- or para- 
position of aniline moiety. The mechanism of each step is described below. 
 
 
Scheme 3: Synthesis of 2-phenylquinazoline derivatives.* 
*: Reagents and conditions for synthesis of 2-phenylquinazoline derivatives: (i) t-BuOK, 150 watt 
microwave irradiation, 170 °C, 5 mins. (ii) TBTU, DIPEA, DMF, 85°C, overnight (iii) anhydrous 
THF, RT, overnight. 
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4.2.1 Synthesis of 4-amino-2-phenylquinazoline 
 
Scheme 4: Proposed synthesis mechanism of 4-amino-2-phenylquinazoline adapted from Ogata et 
al. 136-138 
 
The preparation of 4-amino-2-phenylquinazoline was performed following the base-
catalyzed synthetic strategy described by Seijas et al.139 They simplified the synthesis 
by carrying out reaction under microwave condition. Anthranilonitrile, benzonitrile and 
potassium tert-butoxide reacted at high temperature until no starting materials were 
observed. After protonation and purification, final 4-amino-2-phenylquinazoline was 
obtained. The details about experiment procedures and potential pitfalls are described 
in experiment section. 
The synthesis mechanism of 4-amino-2-phenylquinazoline is depicted in Scheme 4. It 
was adapted from the work of Ogata et al. who had done much kinetic studies about 
formation of different aromatic amines from dicyandiamide and nitriles.136-138 Firstly, 
treatment of 2-aminobenzonitrile with strong base potassium tert-butoxide results in an 
equilibrium between 2-aminobenzonitrile and its deprotonated anion. Due to 
mesomeric effect, the anion is relatively stable. Afterwards, the intermediate anion 
(nucleophile reagent) attacks nitrile leading to an intermediate amidine. This 
intermolecular amine-nitrile condensation is the rate-determining step. Subsequently, a 
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six-membered ring closure occurs due to the second, intramolecular, amine-nitrile 
condensation reaction. At last, final product is obtained after protonation by alcohol. 
Although the equilibrium between starting material and amine anion is undoubtedly 
favorable to starting material, the intermediate amidine is removed from equilibrium by 
conversion into the aromatic and stable 4-aminoquinazoline system.  
 
4.2.2 Formation of amide linker 
 
The second step is to build the amide linker at position 4 of quinazoline scaffold. Many 
papers about amide bond formation have been published.140, 141 It usually starts by 
activating carboxylic acid which means converting OH of the acid into a good leaving 
group. In our reaction, TBTU was used as activating reagent. Afterwards, condensation 
is achieved by treatment with desired amines. The details about experiment procedures 
and potential pitfalls are described in experimental section.   
  
 
Scheme 5: Mechanism of forming amide bond which was adapted from Valeur et al.141 
 
The coupling mechanism is depicted in Scheme 5. Substituted benzoic acid was 
deprotonated by organic base to afford benzonate anion which attacks uronium center 
of TBTU. A novel uronium intermediate is obtained. Subsequently, the left 1H-
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benzotriazole-1-hydroxy ion attacks back to carbonyl center but not uronium center of 
the intermediate to afford 1-benzoyloxybenzotriazole. This intermediate ester is similar 
to TBTU. They both contained 1H-benzo[d][1,2,3]triazol-1-ol which is a good leaving 
group. Therefore, it could easily be attacked by amine group of 4-amino-2-
phenylquinazoline to obtain final product. The driving force of whole reaction is the 
generation of the urea by-product. 
 
4.2.3. Formation of urea linker.  
 
Except amide linker, several compounds with urea as linker at position 4 were 
synthesized. 2-phenyl-4-aminoquinazoline and substituted phenyl isocyanate reacted in 
anhydrous THF at room temperature overnight. After filtration and recrystallization, 
final products were obtained. The low solubility of the products in THF simplified the 
isolation and purification. 
The mechanism is displayed in Scheme 6. Due to higher electronegativity of N and O, 
isocyanate is an electrophile group with C as electrophile center. As such, it is reactive 
to a variety of nucleophiles including alcohols, amines, and even water. Therefore, 
amine group of 2-phenyl-4-aminoquinazoline could easily attack isocyanate resulting 
in an intermediate which finally afford urea products. 
 
 
Scheme 6: Proposed mechanism of urea linker formation. 
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4.3. Results and discussion 
 
The inhibitory potency of synthesized quinazoline derivatives was investigated in 
Hoechst 33342 accumulation and pheophorbide A assays. ABCG2 overexpressing 
MDCK II BCRP and parental cell line were used. More information about Hoechst 
33342 accumulation and pheophorbide A assay is described in introduction chapter. The 
activity data of quinazoline derivatives are summarized in Table 9. The potency of 
compounds was evaluated not only by IC50 value, but also by maximal inhibition which 
was discussed in introduction chapter. When the maximal plateau of a partial inhibitor 
is low enough, it is not worth to report IC50. Therefore, to simplify discussion, all 
compounds with Imax less than 50% are regarded as inactive. 
Due to the poor solubility of substances with urea linker at position 4, they are not able 
to be tested in vitro. Hence, only the activity results of compounds with amide linker 
are shown here (Table 9). 
3,4-OMe and 3-OMe were introduced as substituents at first. In Hoechst 33342 assay, 
compound 30 (3,4-OMe) was found emitting strong fluorescence in high concentration, 
and its emitting spectrum was overlapped with Hoechst 33342 emitting spectrum. 
Therefore, the determined Imax was not accurate. This phenomenon was also observed 
in compound 32 (4-OC2H5), but not in compound 31 (3-OMe). So it is reasonable to 
assume that para position in aniline ring contribute more to strong fluorescence. 
Although the accurate Imax was not accessible in Hoechst 33342 assay for compound 
30 and 32, it could be used for primary screening. When both of their maximal 
inhibition were set as 100% which meant the top plateau of positive control, the IC50 
value of compound 32 was about 10-fold higher than compound 30. It indicated 
compound 32 was apparently less active than compound 30. On the contrary, compound 
31 exhibited no substantial difference in potency in comparison to compound 30. Both 
of them displayed higher affinity to ABCG2 than corresponding phthalazine derivatives 
(compound 19 and 20). 
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Table 9: Inhibitory potencies of synthesized quinazoline derivatives against ABCG2 in the Hoechst 
33342 and pheophorbide A accumulation assays. 
 
No. R 
Hoechst 33342 pheophorbide A 
IC50 ± SD* 
[μM] 
Imax ± SD#  
[%] 
IC50 ± SD*  
[μM] 
Imax ± SD# 
[%] 
30 3,4-OCH3 0.743 ± 0.056 100 a 0.830 ± 0.152 87 ± 12 
31 3-OCH3 0.909 ± 0.181 87 ± 16 1.040 ± 0.032 75 ± 14 
32 4-OC2H5 7.066 ± 2.426 100 a - - 
33 4-OCH3, 3-NO2 n.a. < 30% - - 
34 3-Br n.a. < 30% - - 
35 4-CF3 n.a. < 30% - - 
36 4-CN n.a. < 30% - - 
37 3-CN 0.239 ± 0.033 75 ± 9 0.585 ± 0.036 58 ± 4 
Ko143 - 0.221 ± 0.024 100 0.276 ± 0.040 100 
*: Data are expressed as mean ± SD (n = 3) 
#: Percentage of inhibition with regard to Ko143 
a: plateau of curve was fixed to top of Ko143 
n.a. = not active 
 
Hence, 5 more compounds were synthesized containing different substituents at meta 
and para position of aniline ring. Unfortunately, compounds 33 to 36 did not exert 
satisfying inhibitory effect against ABCG2 even up to a concentration of 10 μM. 
However, when the cyano group was moved to meta position, compound 37 (3-CN) 
which shared similar chemical property with compound 36 (4-CN) turned out to be a 
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good ABCG2 modulator. This observation is opposite to what was described in 
phthalazine chapter. In bis-substituted phthalazine derivatives, compound 28 (4-CN) 
was a moderate ABCG2 inhibitor, but compound 27 (3-CN) was inactive. 
To accurately measure the activity, pheophorbide A assay was performed for 
compounds 30, 31 and 37, which showed IC50 values below 1 μM in Hoechst 33342 
assay. The emitting wavelength range of pheophorbide A was not overlapping with 
emitting wavelength range of them. Therefore, Imax values would be accurately 
displayed. By comparison to Hoechst 33342 assay, all these three compounds 
demonstrated slightly decreased maximal response and slightly increased IC50 value in 
pheophorbide A assay. No significant difference in activity results in both assays were 
observed. 
 
Table 10: Comparative study of selected quinazoline derivatives with NH or amide linker at position 
4 against ABCG2 in the Hoechst 33342 accumulation assay. 
 
  
R IC50 ± SD (μM) IC50 ± SD# (μM) 
3,4-OCH3 0.743 ± 0.056 0.19 ± 0.01 
3-OCH3 0.909 ± 0.181 1.32 ± 0.10 
4-CF3 1.70 ± 0.18 1.53 ± 0.13 
3-Br n.a. 0.57 ± 0.04 
3-CN 0.239 ± 0.033 0.14 ± 0.04 
#: IC50 value taken from reference
118. 
 
In table 10, the potency of selected compounds is compared to corresponding 4-anilino-
2-phenylquinazoline derivatives in the Hoechst 33342 accumulation assay. When R was 
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3-OCH3, amide linker slightly improved the inhibitory effect. But all of other 
compounds with amide linker at position 4 were less potent than corresponding 
compounds with NH linker. Therefore, replacing NH linker by amide at position 4 
might not be an effective strategy for improving ABCG2 inhibitory effect. 
Despite the general decreased activity, there is an interesting phenomenon that is worth 
to notice. In phthalazine derivatives, we observed 4-CN bis-substituted compound 28 
was moderately active, but 3-CN was inactive. In 2-phenyl-4-anilinoquinazoline series, 
both 3-CN and 4-CN were highly potent derivatives. In this series, compound 37 (3-
CN) was a potent ABCG2 inhibitor, while compound 36 (4-CN) was inactive. Altering 
position of CN group in aniline moiety leads to significant difference in activity. It is 
interesting for us to explain. 
In 2004, Chang et.al reported that when 4-amido-2,6-diphenylpyrimidine derivatives 
were synthesized, a 1H signal in 16 ppm region was seen in NMR(CDCl3) spectra.142 
They reasonably speculated that amide bond might have two tautomers. 1H peak at 16 
and 10 ppm region might be attributed to iminol and amide form respectively. 
Interestingly, in our CDCl3 NMR spectra, a 16 ppm signal was also observed. We 
thought intramolecular bond between H of amide and N at position 3 was formed. This 
resulted in an unusual deshielding effect on H of amide group. Correspondingly, the 10 
ppm area was empty. Therefore, our compounds may only exist in iminol form in CDCl3. 
To further confirm this assumption, IR spectroscopy of compounds 30, 31, 36 and 37 
were tested. In all spectral, no peak could be seen in 1605-2000 cm-1 area. Whereas, in 
IR spectral of some 4-quinolinamide derivatives,143 typical strong peak caused by 
carbonyl stretch vibration could be observed in range 1650-1720 cm-1. This might 
suggest that carbonyl group was not existing in solid phase. Meanwhile, in our spectral, 
the peaks at 3423-3427 cm-1 area (X-H stretching) were all medium and broad. It might 
indicate the existence of hydrogen bond. Hence, it is reasonable to postulate that the 
iminol form, but not amide form, might be the dominating tautomer in solid phase. This 
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assumption is also consistent with what was reported in synthesis of 1-substituted-3-(2-
phenylquinazolin-4-yl)-thioureas.144 
 
Figure 15: Illustration of potential steric hinderance for quinazoline derivatives. 
 
Based on all of these information, a hypothesis was generated. In Figure 15, the cyano 
group of inactive compound (36) is red. Three other substances demonstrated high-
affinity to ABCG2, and their cyano substituents are green. If we overlap all of them, 
the red CN group occupies a unique region, this might mean an area with steric 
hindrance. 
Despite the unambiguous experimental evidence supporting the existence of iminol 
form, it should still be noted that this is just a way to help us to explain the interesting 
phenomenon which happened on 3-CN and 4-CN substituted derivatives. When ligand 
is dissolved for biological test and bounded to ABCG2, which tautomer and 
conformation is used? It still remains to be determined.  
In summary, the biological data of this series of compounds generally demonstrated 
decreased activity of ABCG2 inhibition compared to 4-anilino-2-phenylquinazoline 
derivatives. Therefore, the original assumption of increasing planarity at position 4 
4 Project II: Quinazoline derivatives as ABCG2 inhibitors 
 
53 
 
might not be effective. Although planarity is an important descriptor, molecules with 
absolute planarity in 3D conformation might also not be favorable for ABCG2 
inhibition.   
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5 Project III: Pyrimidine derivatives as 
ABCG2 inhibitors 
 
5.1 Overview  
 
In the last chapter, we investigated the function of linker at position 4 of quinazoline 
scaffold. Increasing planarity by replacing NH by amide or urea did not show positive 
effect on activity. Therefore, we decided to maintain NH as linker at position 4 and 
explore modification in other area.  
Pyrimidine is the right six-membered aromatic ring of quinazoline. Krapf et al. replaced 
left benzene ring of quinazoline by methyl group and synthesized several pyrimidine 
derivatives as ABCG2 inhibitors.121 The preliminary results showed removing the left 
benzne ring of quinazoline scaffold slightly improved potency of ABCG2 inhibition. 
IC50 value of 3-((2-phenylquinazolin-4-yl)amino)benzonitrile and  3-((6-methyl-2-
phenylpyrimidine-4-yl)amino)benzonitrile in Hoechst 33342 assay were 140 nM and 
122 nM respectively. The other advantage of pyrimidine in comparison to quinazoline 
is the improved solubility. Several quinazoline derivatives possessed poor aqueous 
solubility limiting their further application. In this chapter, we continue to investigate 
pyrimidine derivatives as potential ABCG2 inhibitors. 
 
5.2 Synthesis 
 
As in Scheme 7 depicted, 4-anilino-6-methyl-2-phenylpyrimidine derivatives were 
synthesized in three steps. In step 1, benzamidine is condensed with ethyl acetoacetate 
in freshly prepared sodium ethoxide solution to form pyrimidine scaffold. In step 2, 4-
hydroxyl-6-methyl-2-phenylprimidine was chlorinated to yield 4-chloro-6-methyl-2-
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phenylprimidine. In step 3, the chlorinated pyrimidine was treated with different 
substituted aniline to afford final products. 
 
Scheme 7: Synthesis scheme of pyrimidine derivatives. * 
*: Reagents and conditions for synthesis of pyrimidine derivatives: (i) NaOEt/EtOH, reflux, 
overnight. (ii) reflux, 8-9 h. (iii) i-PrOH, microwave, 110 °C, 30 min. 
 
5.2.1 Pinner pyrimidine synthesis 
 
In the 1880s, Pinner performed different condensation reactions of substituted amidines 
with acetoacetic ester to afford 2-substituted-6-hydroxy-4-methylpyrimidine.145 
Afterwards, numerous variations were developed such as reactions of amidines with β-
keto esters, malonic esters, and β-diketones. In this chapter, 4-hydroxyl-6-methyl-2-
phenylpyrimidine was synthesized by classical condensation approach. The details 
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about experimental procedures and factors which affect yield of reaction were described 
in experimental section.  
Although Pinner pyrimidine synthesis has been widely used in synthesis of pyrimidine 
derivatives, the reaction mechanism is still not fully elucidated. Katritzky and Yousaf 
have done nuclear magnetic resonances studies to reveal the detailed mechanistic 
pathways of reactions including condensation of methyl acetoacetate with 
benzamidine.146 But the reaction mechanism they proposed was not based on basic 
reaction system. Fandrick et al. conducted react-IR to analyze the condensation of 
amidines and activated olefins in the presence of alkoxide.147 In their proposed 
mechanism, aromatization was addressed as rate-limiting step. We combined both of 
their research work and proposed possible mechanism in synthesis of 4-hydroxyl-6-
methyl-2-phenylpyrimidine (Scheme 8). 
 
 
Scheme 8: Possible mechanism in synthesis of 4-hydroxyl-6-methyl-2-phenylpyrimidine 
 
Sodium was dissolved in ethanol to prepare fresh alkoxide which neutralized 
benzamidine hydrochloride to afford free benzamidine. The established pKa values of 
ethanol and benzamidine in DMSO are 29.8148 and 26.7149 respectively, the equilibrium 
should be towards benzamidine anion with ethoxide in DMSO. But, when solvent was 
altered to methanol, Fandrick et al. revealed through spectroscopy assessment that the 
free base amidine was dominating in the presence of tert-butoxide, amidine anion was 
only observable. Therefore, it is reasonable to postulate the nucleophilic reagent which 
condensed with ethyl acetoactetate in our reaction system was benzamidine but not 
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benzamidine anion. The nucleophilic addition between benzamidine and ethyl 
acetoacetate leads to an intermediate with a six-member ring. It would be quickly 
neutralized to hydroxypyrimidinone which is already observed in NMR study. At last, 
water is easily eliminated by base to give pyrimidine aromatic ring which is more stable 
and 4-hydroxyl-6-methyl-2-phenylpyrimidine is obtained. 
 
5.2.2 Chlorination of 4-hydroxyl-6-methyl-2-phenylpyrimidine 
 
The hydroxyl group at position 4 of 4-hydroxyl-6-methyl-2-phenylpyrimidine is 
substituted by chlorine via a chlorination reaction using POCl3. The reaction 
mechanism is analogous to what described in phthalazine chapter. 
 
 
5.2.3 Amination of 4-chlorine-6-methyl-2-phenylpyrimidine 
 
Final compounds were obtained via nucleophilic aromatic substitution of 4-chlorine-6-
methyl-2-phenylpyrimidine by different substituted anilines. The reaction mechanism 
is analogous to what described in phthalazine chapter. If the reaction was not initiated, 
a little hydrochloride acid was added to the mixture to catalyze reaction. 
 
5.3 Results and discussion 
 
The inhibitory potency of synthesized pyrimidine derivatives was investigated in 
Hoechst 33342 accumulation and pheophorbide A assays. ABCG2 overexpressing 
MDCK II BCRP and parental cell line were used. More information about Hoechst 
33342 accumulation and pheophorbide A assay is described in introduction chapter. The 
activity data of pyrimidine derivatives are shown in Table 11 and 12. The potency of 
compounds was evaluated not only by IC50 value, but also by maximal inhibition.  
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Table 11: Inhibitory potencies of synthesized pyrimidine derivatives against ABCG2 in the Hoechst 
33342 and pheophorbide A accumulation assays. 
 
No. R1 R2 
Hoechst 33342 pheophorbide A 
IC50 ± SD* 
[μM] 
Imax ± SD# 
[%] 
IC50 ± SD* 
[μM] 
Imax ± SD# 
[%] 
45 b H H 0.648 ± 0.149 80-110 n.t. n.t. 
46 H CH2CN 2.54 ±0.47 100 a 3.64 ± 0.50 100 a 
47 b H CN 0.128 ± 0.032 80-110 n.t. n.t. 
48 CH2OH H 4.31 ± 0.99 100 a 2.52 ± 0.19 100 a 
49 OH H 0.257 ± 0.055 74 ± 13 0.518± 0.055 59 ± 5 
50 F H 1.14 ± 0.32 100 a n.t. n.t. 
51 Cl H 0.823 ± 0.164 100 a n.t. n.t. 
52 Br H 0.902 ± 0.166 100 a 0.391± 0.078 83 ± 5 
53 OCH3 H n.t. n.t. 0.506 ± 0.081  100 a 
54 OCH3 Br 0.287 ± 0.075 100 a 0.330 ± 0.045 53 ± 5 
55 F OCH3 0.865 ± 0.105 100 a 1.32 ± 0.20 100 a 
56 CF3 OCH3 n.t. n.t. 0.547 ± 0.061 83 ± 8 
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57 b CN H 0.122 ± 0.024 80-110 n.t. n.t. 
58 CN CN 0.188 ± 0.017 117 ± 18 0.551 ± 0.076 100 a 
59 CN F 0.307 ± 0.014 100 a 0.086 ± 0.008 59 ± 10 
60 Br CN 0.119 ± 0.011 90 ± 10 0.060 ± 0.006 40 ± 9 
61 CH3 CN 0.097 ± 0.033 106 ± 19 0.176 ± 0.021 76 ± 20 
62 CF3 CN 0.069 ± 0.001 114 ± 12 0.391 ± 0.084 92 ± 7 
63 NO2 H 0.133 ± 0.029 80 ± 8 0.146 ± 0.016 68 ± 11 
64 H NO2 0.053 ± 0.008 79 ± 8 0.156 ± 0.029 67 ± 17 
65 b NO2 OH 0.099 ± 0.017 80-110 n.t. n.t. 
66 NO2 F 1.02 ± 0.20 100 a n.t. n.t. 
67 COOH NO2 > 10µM - > 10µM - 
68 Cl NO2 0.059 ± 0.004 76 ± 16 n.t. n.t. 
Ko143 - - 0.221 ± 0.024 100 0.276 ± 0.040 100 
*: Data are expressed as mean ± SD (n = 3) 
#: Percentage of inhibition with regard to Ko143 
a: plateau of curve was fixed to top of Ko143 
b: data taken from reference121.  
n.t. = not tested 
 
As described above, substitution was only carried out at meta and/or para position of 
anline ring. The effect of inserting a methylene group between aniline ring and the 
substituent was investigated initially. It is obvious to notice that compounds 47 (4-CN) 
and 49 (3-OH) displayed excellent potency as ABCG2 inhibitors (128 nM and 257 nM), 
but compound 46 (4-CH2CN) and 48 (3-CH2OH) showed about 20-fold lower activity. 
Therefore, insertion of a methylene group at meta or para position of aniline ring 
appeared to be unfavorable for ABCG2 inhibition.  
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Next, different halogen were introduced at meta position. In Hoechst 33342 assay, they 
showed similar efficacy. In the sequence of 3-F, 3-Br, 3-Cl, the activity of 
corresponding derivative was slightly increasing from 1.136 μM to 0.823 μM.  
 
Table 12: Inhibitory potency of synthesized pyrimidine derivatives against ABCG2 in the Hoechst 
33342 and pheophorbide A accumulation assays. 
 
No. R 
Hoechst 33342 pheophorbide A 
IC50 ± SD* 
[μM] 
Imax ± SD# 
[%] 
IC50 ± SD* 
[μM] 
Imax ± SD# 
[%] 
69 
 
0.815 ± 0.112 100 a n.t. n.t. 
70 
 
0.253 ± 0.012 105 ± 7 n.t. n.t. 
71 
 
fluo - 0.152 ± 0.026 79 ± 16 
72 
 
fluo - 0.321 ± 0.095 96 ± 6 
Ko143 - 0.221 ± 0.024 100 0.276 ± 0.040 100 
*: Data are expressed as mean ± SD (n = 3) 
#: Percentage of inhibition with regard to Ko143 
a: plateau of curve was fixed to top of Ko143 
n.t. = not tested 
fluo: compound showed strong fluorescence in Hoechst 33342 assay. 
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However, taking into account the standard deviations, all three compounds were equally 
active. So the size of halogen at meta position of aniline moiety did not influence 
inhibitory potency. All of them were less potent than the unsubstituted compound 45 in 
Hoechst 33342 assay. It might indicate halogens at position 3 exhibit negative effects 
on inhibiting Hoechst 33342 efflux. But, in pheophorbide A assay, an interesting result 
was observed. The inhibitory efficacy of compound 52 (3-Br) was even comparable 
with positive control, only a little lower than Ko143. This inspired us to continue the 
exploration of halogens. 
Given the positive impact of methoxy group in some scaffolds on ABCG2 inhibition, 
compound 53 (3-OCH3) was synthesized at first and reached similar inhibitory effect 
as compound 52 in pheophorbide A assay. Owing to positive effects of 3-Br and 3-
OCH3 on inhibiting pheophorbide A efflux, the strategy of combining methoxy group 
and halogen was applied. In Hoechst 33342 assay, IC50 value of compound 54 (3-OCH3, 
4-Br) was 0.287 μM, which was comparable to compound 49 (3-OH). But, in 
pheophorbide A assay, it produced only partial inhibition of pheophorbide A efflux. Its 
maximal plateau was only half of Ko143’s. This might suggest Br is an unfavorable 
group at position 4. Next, the position of halogen and methoxyl group was swapped. 
The 3-F, 4-OCH3 disubstituted compound 55 yielded increased IC50 values in both 
assays. After comparison with 3-F monosubstituted compound 50, 4-OCH3 contributed 
slightly positive to inhibitory activity. Therefore, it might be 3-F resulting in decreased 
potency. Subsequently, fluorine at position 3 was replaced by CF3. Compound 56 (3-
CF3, 4-OCH3) showed more potent activity than 55 in pheophorbide A assay. It might 
indicate that CF3 is a more preferred substituent at position 3 than F and 3-F might 
exhibit negative effect on inhibition. Although compounds 49 and 54 displayed higher 
activity towards ABCG2 than unsubstituted compound 45, they were still only half as 
potent as compounds 57 (3-CN) and 47 (4-CN). Introducing both methoxy and halogen 
together might not a very effective strategy for improving inhibitory potency. Therefore, 
we continued to explore substances containing cyano and nitro group.  
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Initially, 3,4-CN was introduced at aniline moiety. In contrast to the monosubstituted  
3-CN and 4-CN compounds, no improvement was obtained. In Hoechst 33342 assay, 
its increased maximal inhibitory plateau was accompanied by decreased IC50 value. 
Subsequently, pyrimidine analogs with combination of cyano and other substituents 
were examined. In comparison to compounds 49 and 54, compound 59 (3-CN, 4-F) 
demonstrated slightly decreased potency (IC50 = 0.307 μM) in Hoechst 33342 assay, 
but reached slightly improved activity in pheophorbide A assay. This phenomenon 
happened more obviously to compound 60 (3-Br, 4-CN). It was 2-fold more potent than 
compounds 49, 54 and 59 in inhibiting efflux of Hoechst 33342, but less active and was 
only as partial inhibitor in pheophorbide A assay. When R1 residue of compound 49 was 
altered to Br or para position as in compound 52 was substituted by CN, the inhibitory 
activity against ABCG2 was modulated to opposite direction in these two assays. This 
observation might be attributed to different binding sites of Hoechst 33342 and 
pheophorbide A on ABCG2. 
Compounds 57, 58 and 59 shared the same R1 residue — CN, but different substituents 
at R2. When H and CN occupied para position, similar inhibitory effect was observed. 
Both of them were more active than fluorine in Hoechst 33342 assay. Similarly, R1 of 
compounds 52 and 60 were both bromine, but compound 60 containing CN as R2 was 
apparently more active in Hoechst 33342 assay than compound 52 which had no 
substituent at para position. Thus, it is reasonable to presume that both R1 and R2 
contribute to the interaction with ABCG2 in Hoechst 33342 assay. And this conclusion 
could also be applied in pheophorbide A assay (comparing compounds 49, 52 and 60). 
Therefore, we decided to investigate more substances with meta and para disubstituted 
combinations at aniline moiety.  
Considering the positive effect of CN at para position of aniline ring in Hoechst 33342 
assay, compounds 61 and 62 were synthesized. In comparison to compound 60, R2 was 
kept as CN, but R1 was replaced by CH3 and CF3 respectively. In sequence of 
compounds 47 (3-H, 4-CN), 60 (3-Br, 4-CN), 61 (3-CH3, 4-CN) and 62 (3-CF3, 4-CN), 
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the inhibitory activity was improved from 0.122 μM to 0.069 μM and accompanied by 
increased Imax in Hoechst 33342 assay. Compound 62 was about 3-fold more potent 
than Ko143. In pheophorbide A assay, the maximal response was also dramatically 
increased from 40% for compound 60 to 92% in case of compound 62, and the 
inhibitory efficacy of compounds 61 and 62 were comparable to Ko143 in the 
pheophorbide A assay.  
Next, owing to the excellent ABCG2 inhibitory activity of nitro group in case of 
quinazoline derivatives, some pyrimidine analogs with nitro group as R1 or R2 were 
also investigated. Monosubstituted derivatives were synthesized at first. Compound 63 
(3-NO2) and 64 (4-NO2) demonstrated almost the same maximal response (80% in 
Hoechst 33342, 68% in pheophorbide A assay). But the affinity results against ABCG2 
were different. In pheophord A assay, they were equipotent. But in Hoechst 33342 assay, 
compound 64 was about 2.5-fold more potent than compound 63, which was slightly 
less potent than compounds 57 (3-CN) and 65 (3-NO2, 4-OH). To further improve the 
activity, fluorine was introduced as R2 residue in compound 66. However, this 
modification led to a drastic decrease of the modulatory potency against ABCG2. 
Therefore, fluoro might be an unfavorable group at para position of anline moiety. The 
other evidence was from the results of compounds 59 (3-CN, 4-F; IC50 = 0.307 μM) 
and 57 (3-CN, 4-H; IC50 = 0.122 μM),  
Afterwards, R2 was kept as nitro group and modification was only done at meta position. 
To improve the solubility of compounds containing nitro group, COOH was introduced 
as R1. However, compound 67 was totally inactive. But when Cl was introduced instead, 
compound 68 was as potent as 64, and the solubility was obviously improved. Despite 
their excellent IC50 values, the maximal inhibition of compounds bearing a nitro group 
were all lower than Imax of Ko143. 
The high activity of compounds 61, 62 and 68 showed that the disubstituted strategy 
was applicable. Furthermore, R1 and R2 were connected by a ring. Initially, 1,4-dioxane 
ring was introduced. Compound 69 was less active than 45 (unsubstituted aniline 
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moiety). The decreased activity might be attributed to the broken planarity of 1,4-
dioxane moiety. Subsequently, only planar rings were introduced. Compound 70 with 
phthalimide moiety (IC50 = 0.253 μM) was equipotent to Ko143 in Hoechst 33342 assay. 
Pyridine and pyrazine ring were introduced at last. In Hoechst 33342 assay, they were 
found to show fluorencence and maximal inhibition was not accessible. In 
pheophorbide A assay, compounds 71 and 72 demonstrated similar inhibitory effects as 
compounds 61 and 62 respectively. They both displayed comparable inhibitory activity 
to Ko143. Removing one nitrogen of pyrazine moiety resulted in a decreased IC50 value 
and Imax. 
In summary, a series of compounds with 2-phenylpyrimidine scaffold were synthesized. 
Several compounds demonstrated excellent inhibitory potency against ABCG2. Cyano, 
and nitro were favorable substituents at both meta and para position of aniline ring. 
Different halogen applied at meta position as substituents produced similar inhibitory 
effects. Introducing 3-CH2R, 3-F, 4-CH2R, 4-F and 4-Br at aniline ring resulted in 
decreased activity. Both R1 and R2 are essential parts for interacting with ABCG2 in 
Hoechst 33342 and pheophorbide A assay, but the same variation in structure might 
lead to obviously different potency in two assays. Modifying aniline ring with 
disubstitutes and introducing an aromatic ring at R1 and R2 might be effective strategies 
for development of potent ABCG2 inhibitors. In the next chapter, we further explored 
some compounds with 2-phenylpyrimidine scaffold as potent ABCG2 inhibitors. 
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6 Project IV: Novel pyrimidine derivatives as 
ABCG2 inhibitors 
 
6.1 Introduction 
 
In the last chapter, we synthesized and evaluated dozens of 4-anilino-6-methyl-2-
phenylpyrimidine derivatives as ABCG2 inhibitors. Several of them displayed 
excellent inhibitory activities. Therefore, we continued to explore potent pyrimidine 
derivatives in this chapter. 
As described before, Pick et al. had investigated 6 TKIs with quinazoline scaffold as 
ABCG2 inhibitors, and an interesting result was observed. PD153035 and PD158780 
shared similar chemical structure. Both of them contain pyrimidine core and 3-
bromaniline at position 4. However, their activities were different. PD158780 was 
approximately 7-fold more potent than PD153035 as ABCG2 inhibitor in both Hoechst 
33342 and pheophorbide A assays. This could only be attributed to the different 
component of structure at position 6 and 7 of quinazoline ring (red bold bond in Figure 
16). It might indicate potential interaction of this area with ABCG2. Thus, modification 
at position 5 or 6 of pyrimidine ring might be worth to be investigated.  
For the compounds investigated in this chapter, the critical features of quinazoline and 
pyrimidine derivatives for ABCG2 inhibition were preserved. Pyrimidine core and 
phenyl at position 2 were not modified. Due to easy availability and high potency, 4-
cyanoaniline was substituted at position 4. Considering the difficulty of synthesis, 
modification was finally focused on position 6. The methyl group of 4-anilino-6-
methyl-2-phenylpyrimidine scaffold was replaced by chlorine, phenyl, various amines 
or anilines. 
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Figure 16: Inhibitory potencies of PD153035 and PD158780 against ABCG2 (data from Pick et 
al.)117 
 
6.2 Synthesis  
 
As depicted in Scheme 9, novel 4-anilino-2-phenylpyrimidine derivatives were 
synthesized in four steps. In step 1, benzamidine was condensed with diethyl malonate 
in freshly prepared sodium ethoxide solution to form pyrimidine scaffold. In step 2, 2-
phenylpyrimidine-4,6-diol was chlorinated to yield 4,6-dichloro-2-phenylpyrimidine. 
In step 3, chlorinated 2-phenylpyrimidine was treated with 1 equivalent of 4-
cyanoaniline to afford monosubstituted product 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile. In step 4, 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile was first reacted with various amines to produce 6-amin-4-
anilino-2-phenylpyrimidine derivatives. Afterwards, it was treated with phenylboronic 
acid via Suzuki coupling to produce 4-((2,6-diphenylpyrimidin-4-
yl)amino)benzonitrile. Lastly, different aminophenols reacted with it to afford 4-((6-
((hydroxyphenyl)amino)-2-phenylpyrimidin-4-yl)amino)benzonitriles. The 
mechanism of each step is illustrated below. 
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Scheme 9: Synthesis scheme of novel pyrimidine derivatives.* 
*: Reagents and conditions for synthesis of pyrimidine derivatives: (i) NaOEt/EtOH, reflux, 
overnight. (ii) reflux, 8-9 h. (iii) i-PrOH, reflux, HCl (catalyst), ratio = 1:1 (iv) a: i-PrOH , 
120 °C, 0.5 h; b: Pd(t-Bu3P)2, dioxane:2M K2CO3 = 3:1, 90 °C, 7 h, argon; c: i-PrOH, 110 °C, 
HCl (catalyst). 
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6.2.1 Pinner pyrimidine synthesis 
 
The reaction mechanism of Pinner pyrimidine synthesis is analogous to what 
described in last chapter and illustrated below. The β-keto ester which reacted with the 
benzamidine was replaced by malonic ester. Thus, a six-membered ring with double 
amide bonds were obtained after deprotonation. Owing to stability issue, this six-
membered ring is prone to rearrangement to pyrimidine ring. Therefore, 2-
phenylpyrimidine-4,6-diol was obtained finally.  
 
 
Scheme 10: Possible mechanism in synthesis of 2-phenylpyrimidine-4,6-diol 
 
6.2.2 Chlorination of 2-phenylpyrimidine-4,6-diol 
 
The two hydroxyl groups at position 4 and 6 of 2-phenylpyrimidine-4,6-diol were 
substituted by chlorines via a chlorination reaction using POCl3. The reaction 
mechanism is analogous to what is described in phthalazine chapter. 
 
6.2.3 Amination of 4,6-dichloro-2-phenylpyrimidine 
 
4-((6-chloro-2-phenylpyrimidin-4-yl)amino)benzonitrile was obtained via nucleophilic 
aromatic substitution of 4,6-dichloro-2-phenylpyrimidine with 4-cyanoaniline in ratio 
1:1. The reaction mechanism is analogous to what is described in phthalazine chapter. 
If the reaction was not initiated, a little hydrochloride acid was added to the mixture to 
catalyze reaction. 
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6.2.4 Modification at position 6 of 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile 
 
6.2.4.1 Amination at position 6  
 
Various 4-((6-amino-2-phenylpyrimidin-4-yl)amino)benzonitriles were obtained via 
nucleophilic aromatic substitution of 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile by corresponding amines. The reaction mechanism is analogous 
to previous amination steps. But due to the high nucleophilicity of applied amines, 
hydrochloride acid was not necessary to be used as catalyst. 
 
6.2.4.2 Suzuki coupling  
 
4-((2,6-diphenylpyrimidin-4-yl)amino)benzonitrile was synthesized via Suzuki cross-
coupling. The Suzuki reaction involves an organohalide with an organoborane to 
produce coupled product in the presence of a palladium catalyst and base. It has been 
widely used in formation of aryl-aryl bond. The catalyst and base in this reaction are 
bis(tri-tert-butylphosphine)palladium(0) and potassium hydroxide respectively. The 
mechanism is illustrated below. It starts with oxidation addition of Cl-pyrimidine bond 
at position 6 to the catalyst Pd(0) to give a Pd(II) complex. This step is probably the 
rate-determining step. Subsequently, the hydroxide base attacks this complex and 
replaces chloride to give more reactive organopalladium hydroxide complex. On the 
other hand, phenylboronic acid is basified by another hydroxide ion to form borate 
which makes phenyl more nucleophilic. Afterwards, transmetalation follows. Phenyl 
group on borate replaces hydroxyl group on organopalladium hydroxide complex to 
give a diorganopalladium complex. This complex undergoes reductive elimination in 
which palladium catalyst is regenerated leading to restart of the catalytic cycle and the 
final coupled product 4-((2,6-diphenylpyrimidin-4-yl)amino)benzonitrile is obtained. 
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Scheme 11: Possible mechanism in synthsis of 4-((2,6-diphenylpyrimidin-4-yl)amino)benzonitrile. 
 
6.2.4.3 Synthesis of three 4-((6-((hydroxyphenyl)amino)-2-phenylpyrimidin-4-
yl)amino)benzonitriles 
 
Three 4-((6-((hydroxyphenyl)amino)-2-phenylpyrimidin-4-yl)amino)benzonitriles 
were obtained via nucleophilic aromatic substitution of 4-((6-chloro-2-
phenylpyrimidin-4-yl)amino)benzonitrile by 2, 3 or 4-aminophenol (ratio 1:1) in the 
presence of catalytic amounts of hydrochloride acid. The reaction mechanism is 
analogous to what is described in previous amination steps.  
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6.3 Results and discussion 
 
The inhibitory potency of novel synthesized pyrimidine derivatives was investigated in 
Hoechst 33342 and pheophorbide A accumulation assays. ABCG2 overexpressing 
MDCK II BCRP and parental cell line were used. More information about Hoechst 
33342 and pheophorbide A assays is described in introduction chapter. The activity data 
of pyrimidine derivatives are shown in Table 13 and 14. The potency of compounds 
was evaluated not only by IC50 value, but also by maximal inhibition.  
 
Table 13: Inhibitory potencies of compound 75 and 47 against ABCG2 in the Hoechst 33342 
accumulation assay. 
 
No. X 
Hoechst 33342 
IC50 ± SD* [μM] Imax ± SD# [%] 
75 Cl 0.105 ± 0.029 81 ± 11 
47a CH3 0.128 ± 0.032 80-110 
Ko143 - 0.221 ± 0.024 100 
a: data taken from literature.121  
*: Data are expressed as mean ± SD (n = 3) 
#: Percentage of inhibition with regard to Ko143 
 
Firstly, compound 75 was investigated in Hoechst 33342 assay and demonstrated 
slightly better inhibitory activity than compound 47 which contains methyl group at 
position 6. It indicated the applicability of modification at position 6. Next, we tried to 
investigated activities of several other derivatives with NH linker as X in Hoechst  
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Table 14: Inhibitory potenciy of synthesized novel pyrimidine derivatives against ABCG2 in the 
pheophorbide A accumulation assay. 
 
No. X n R 
pheophorbide A 
IC50 ± SD* [μM] Imax ± SD# [%] 
76 NH 0 CH3 0.147 ± 0.054 68 ± 13 
77 NH 1 (CH3)2 0.777 ± 0.180 101 ± 11 
78 NH 2 CH3 0.299 ± 0.077 89 ± 13 
79 NH 3 CH3 0.502 ± 0.060  73 ± 15 
80 - 0 Ph n.e. n.e. 
81 NH 0 Ph 0.170 ± 0.018 84 ± 24 
82 NH 1 Ph 0.285 ± 0.044 99 ± 20 
83 NH 3 Ph 0.099 ± 0.029 61 ± 12 
84 NH 4 Ph 0.150 ± 0.037 61 ± 3 
85 NH 1 2-Pyridiyl 0.210 ± 0.006 88 ± 8 
86 NH 1 3-Pyridiyl 0.375 ± 0.041 91 ± 7 
87 NH 1 4-Pyridiyl 0.435 ± 0.003 78 ± 19 
88 NH 0 2-OH Ph 0.224 ± 0.023 86 ± 17 
89 NH 0 3-OH Ph 0.610 ± 0.049 66 ± 16 
90 NH 0 4-OH Ph 0.392 ± 0.073 76 ± 7 
91 NH 0 4-CN Ph 0.135 ± 0.025 60 ± 5 
Ko143 - - - 0.276 ± 0.040 100 
*: Data are expressed as mean ± SD (n = 3) 
#: Percentage of inhibition with regard to Ko143 
n.e. = no effect 
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33342 assay, but all of them displayed strong fluorescence which might lead to 
inaccurate results. Therefore, we investigated all of the remaining compounds only in 
pheophorbide A assay.   
Because methyl was the starting point of our investigation at position 6, the influence 
of various aliphatic alkyl chains on potency was explored. Compound 76 (methylamino) 
and 78 (n-propylamino) displayed low IC50 values (lower than 0.3 μM). High maximal 
inhibition (higher than 80%) was reached by compounds 77 and 78. Hence, compound 
78 is a potent ABCG2 inhibitor. Next, the terminal group of aliphatic chain was replaced 
by phenyl to improve potential lipophilic interactions. Compound 80 with no linker 
between phenyl and pyrimidine scaffold exhibited no inhibitory effect. Whereas, 
compound 81 containing the NH linker at position 6 displayed higher potency than 78. 
This difference suggested the importance of linker between pyrimidine ring and phenyl 
moiety. Afterwards, 1 to 4 CH2 were inserted between NH and phenyl to explore the 
best length of linker. As a result, compounds 81 (n=0) and 82 (n=1) possessed high 
potency against ABCG2. But maximal inhibition of compounds 83 (n=3) and 84 (n=4) 
only reached 61%. As observed for purely aliphatic compounds (79), it might indicate 
that long aliphatic chains (n>2) lead to decreased maximal inhibition. The most 
effective distance between Ph and NH might be one or two bonds. Therefore, n was 
chosen as 0 and 1 in the following investigation. In last chapter, we have explored the 
effects of various lipophilic substituents on aniline ring at position 4, and it is easy to 
observe the symmetry of position 4 and 6 in chemical structure. Therefore, we did not 
focus on investigation of lipophilic interaction at position 6 again, but on potential polar 
interaction. 2, 3 and 4-picolylamino group were tested at first. The results showed 
compound 85 (2-picolylamino) was the most potent one amongst them and 4-
picolylamino (87) least. Afterwards, they were replaced by 2, 3, and 4-hydroxylanilino 
moieties. Here, 2-hydroxylanilino was the most potent residue, and 3-hydroxylanilino 
least. It is inconsistent with the observation at position 4, the results of these 6 
compounds might suggest ortho area, but not meta and para, is more favorable for polar 
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residue of phenyl ring at position 6 of these compounds for ABCG2 inhibition. In 
addition, bis-4-cyano substituted compound 91 was also tested. Although the IC50 value 
was lower, the maximal inhibition was also decreased. The final seven compounds 
possess more hydrophilic properties than compounds 81 and 82, but the inhibitory 
effects were not improved. Hence, improved polarity of moiety at position 6 lead to 
higher solubility, but might not lead to higher activity against ABCG2.   
In summary, the influence of different moieties at position 6 of pyrimidine scaffold 
was investigated. Chlorine, methyl and appropriate amines displayed high activity 
against ABCG2. When position 6 was substituted by amines, the length between NH 
and end residue of chain is critical. Increased polar potential at this position might not 
result in improved inhibitory effect. By comparison to the most potent four 
compounds in last chapter, compound 81 was comparable with 71 and more active 
than 61. Compound 82 demonstrated higher efficacy than compounds 62 and 72 in 
inhibition of pheophorbide A efflux. Although the improvement of activity was not 
significant, modification at position 6 was still beneficial. 
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7 Summary 
 
In the current study, we synthesized dozens of structurally different series of 
compounds which were biologically evaluated as potential selective ABCG2 inhibitors. 
These substances were all phthalazine, quinazoline or pyrimidine derivatives and 
divided into four projects. Hoechst 33342 and pheophorbide A accumulation assays 
were carried out by my colleague Katja Silbermann to determine their inhibitory 
efficacy to reverse multi-drug resistance mediated by ABCG2. A brief summary of 
results from each project is given below. 
 
7.1 Project 1 
 
In the first project, the critical features of 4-anilinoquinazonine derivatives for ABCG2 
inhibition were preserved and a series of phthalazine derivatives were synthesized to 
investigate the potential influence of variation at position 1. At first, position 4 was 
aminated by various anilines which showed good activity in case of quinazoline 
derivatives and position 1 was unsubstituted. Unfortunately, all of this first series of 
compounds did not only show difficulty in synthesis, but also displayed low maximal 
inhibition (less than 20%). Afterwards, position 1 was also included in modification. It 
was substituted by chlorine or phenyl. Simultaneously, position 4 was aminated by 3-
methoxyl or 3,4-dimethoxylaniline. As a result, the combination of Ph, 3,4-OCH3 and 
Cl, 3,4-OCH3 displayed moderate inhibitory effects, the latter one being more active. 
Therefore, several more compounds with Cl at position 1 and substituted aniline at 
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position 4 were also synthesized. But all of them were inactive. At this point, it is 
reasonable to presume variation at position 1 is crucial for ABCG2 inhibition, but Cl is 
not a favorable substituent. Instead of replacing Cl by other atoms, we decided to 
elongate the length of substituent at position 1 and synthesized bis-anilinosubstituted 
derivatives whose aniline moiety at position 1 might serve as a replacement of critical 
phenyl ring at position 2 of 4-anilino-2-phenylquinazoline derivatives. Finally, 
compounds 19, 20 and 25 demonstrated moderate inhibitory activity. The potency of 
compound 26 was even comparable with standard inhibitor WK-X-24.  
In this series of compounds, we also discovered two phenomena which were also 
observed elsewhere. (i) Methoxyl is a favorable substituent. (ii) lipophilicity and steric 
effect, but not electrostatic properties, were essential descriptors. However, the 
comparative study showed that phthalazine derivatives were generally less active than 
corresponding quinazoline derivatives. It might indicate swapping N (position 1) and 
C (position 2) of quinazoline scaffold is not an effective strategy. Therefore, we turned 
our direction back to quinazoline in next project.  
 
7.2 Project 2 
 
The previous studies suggested variation at 2-phenylquinazoline scaffold might not 
result in improved activity. Therefore, this scaffold was preserved. Planarity has been 
shown as an essential feature of potent ABCG2 inhibitors with various scaffolds. So, in 
the second project, the NH linker at position 4 of 4-anilino-2-phenylquinazoline 
scaffold was replaced by amide or urea moiety leading to increased planarity of 
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molecular conformation. Due to the solubility problem, compounds with urea linker 
could not biologically evaluated. Eight compounds containing amide linker at position 
4 were tested in Hoechst 33342 and pheophorbide A assays, but the results were 
disappointing. Half of them were inactive (Imax < 30%), the other half showed moderate 
activity, but none of them was comparable to Ko143. By comparison to corresponding 
4-anilino-2-phenylquinazoline derivatives, they were generally less active. Therefore, 
improving molecular conformation to absolute planarity might not be an effective 
strategy, certain conformational flexibility might also be necessary for designing potent 
inhibitors. 
In addition, an interesting phenomenon was observed: altering the position of cyano 
substituents on aniline moiety resulted in obviously different inhibitory effects. After 
collecting spectral evidence, we presumed that a steric hindrance area might exist for 
this series of compounds.  
 
7.3 Project 3 
 
In project 3, we continued the investigations of Krapf et al. on pyrimidine derivatives 
as potential ABCG2 inhibitors. 2-phenylpyrimidine ring which contains critical 
features was preserved. Position 6 of pyrimidine core was substituted as methyl and a 
variety of substituents was introduced on aniline moiety at position 4. Removing the 
left benzene ring of quinazoline scaffold improved aqueous solubility. All of the 
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derivatives were evaluated in both Hoechst 33342 accumulation and pheophorbide A 
assays.  
At first, when CH2 was inserted at meta or para position of aniline moiety, the activities 
were significantly decreased. Afterwards, halogen was inserted at meta position. 
Bromine displayed excellent inhibitory potency in pheophorbide A assay. Inspired by 
this result, combination of halogen and methoxy was applied. All of the 4 compounds 
containing OCH3 at meta or para position did not show improved activity. Therefore, 
we turned our direction back to CN and NO2 substituents. Most of compounds with 
cyano substituent demonstrated excellent inhibitory effects as well as nitro derivatives. 
But the latter series of compounds did not reach full inhibition. The most potent 
substances were compounds 61 and 62. In comparison to Ko143, they are 2-3 fold more 
potent in Hoechst 33342 assay and displayed comparable efficiency to inhibit 
pheophorbide A efflux. 
Due to the importance of both R1 and R2 for interacting with ABCG2, we applied a 
strategy to fuse R1 and R2 substituents into a 5- or 6-membered ring. As a result, 
compounds 71 (pyridine moiety) and 72 (pyrazine moiety) showed comparable 
inhibitory activities as Ko143 in pheophorbide A assay. These active compounds 
promoted us to continue the exploration of 2-phenylpyrimidine derivatives. 
 
7.4 Project 4 
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The different inhibitory potency of PD153035 and PD158780 inspired us to investigate 
the potential influence of area around position 5 and 6 of pyrimidine ring. Due to the 
easy availability and high activity, position 4 was preserved as 4-cyanoaniline. 
Considering the difficulty of synthesis, position 6 was selected as the modification point. 
The methyl group in last series of derivatives was replaced by chlorine, phenyl and 
various amines or anilines. 
In the beginning, 4 aliphatic amino residues with various lengths were introduced at 
position 6. Compound 78 (n-propylamino) displayed slightly decreased potency than 
Ko143. To improve the potential lipophilic interaction, phenyl was introduced in the 
end of various aliphatic chains. As a result, compound 80 in which phenyl was directly 
attached to pyrimidine ring showed no inhibitory effect. But compound 81 and 82 in 
which phenyl was connected to pyrimidine scaffold via NH and NHCH2 respectively 
demonstrated comparable inhibitory activities as Ko143. Therefore, the efficient 
number of n might be 0 or 1. Next, X was preserved as NH and n was decided as 0 or 
1, the phenyl group was replaced by pyridines and phenols to investigate potential polar 
interactions. However, none of them showed increased potency which might indicate 
the disadvantage of polar modification. By comparison to results of 4-anilino-6-methyl-
2-phenylpyrimidine derivatives, certain modification at position 6 of pyrimidine core 
might slightly improve the inhibitory potency.  
 
ABCG2 is one of important proteins which are associated with multi-drug resistance. 
All of these four projects involving various phthalazine, quinazoline and pyrimidine 
derivatives were aiming to find potent ABCG2 inhibitors. The biological data show 
pyrimidine is a promising scaffold which might be more potent than quinazoline and it 
is worth to further investigation. Other biological investigations such as cytotoxicity of 
compounds in this study are on the way.
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8 Experimental section 
 
8.1 Materials and methods  
 
Chemicals: All chemicals were purchased from Acros Organics (Belgium), Alfa Aesar 
(Germany), Sigma-Aldrich (Germany) or Merck (Germany). 
 
Chromatography: 
Thin layer chromatography (TLC): The reaction progress was monitored by 
analytical thin layer chromatography (TLC) on silica gel plates (Silica Gel 60 F254, 
Merck). For detection, 254 nm and 366 nm UV light were used. 
 
Column chromatography: For certain compounds, column chromatography was 
performed for final purification. Silica gel 60 (40-63 µm) obtained from Merck was 
used as stationary phase. Eluting system is described in corresponding synthesis step. 
 
NMR-Spectroscopy: Structures of all compounds were confirmed by NMR. NMR 
spectra were recorded in DMSO-d6 or CDCl3.  All 1H NMR spectra and 13C NMR 
were obtained on a Bruker Advance 500 (500 MHz in 1H spectra and 126 MHz in 13C 
spectra) or Bruker Advance 600 (600 MHz in 1H spectra and 151 MHz in 13C spectra). 
 
Fourier-transform infrared spectroscopy (FTIR): For certain compounds, IR 
spectra were recorded with a FTIR spectrometer ALPHA from Bruker in ATR mode. 
The spectra were subsequently evaluated with the Opus software and converted into 
transmission spectra. 
 
Microwave synthesis: The microwave syntheses were performed in microwave 
Discover SP produced by CEM.  
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Liquid chromatography–mass spectrometry (LC-MS): The purities of selected 
compounds were determined by ESI−mass spectra obtained on an LC-MS instrument 
(Applied Biosystems API 2000 LC-MS/MS, HPLC Agilent 1100). 
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8.2 Synthesis procedures 
 
8.2.1.1: Synthesis of 1-chlorophthalazine (1) 
 
450 mg 1(2H)-phthalazinone and 1.5 ml phosphorus oxychloride were filled into a 10 
ml microwave vessel. The slurry was slowly heated up to 80 °C and maintained at that 
temperature for 30 min in microwave reactor. When TLC indicated reaction was 
completed, the mixture was allowed to cool to room temperature and was transferred 
carefully onto crushed ice portion by portion. After ice had melt, the solution was stirred 
for 0.5 hour and slowly basified with saturated sodium carbonate solution until no 
bubbles were observed (pH = 8-9). The temperature of solution should always be kept 
under 10 °C. Yellow precipitate fell out, and was extracted by 50 ml dichloromethane 
3 times. The organic layer was washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure at 40 °C. Further purification was performed by column 
chromatography with DCM/MeOH = 20:1 as eluent to yield pale yellow crystals (197 
mg; 39 %). 
 
 
Molecular Weight: 164.59 
1H NMR (600 MHz, CDCl3) δ: 9.45 (d, J = 0.9 Hz, 1H), 8.32 (ddd, J = 1.3, 2.2, 7.8 Hz, 
1H), 8.05 – 7.98 (m, 3H). 
13C NMR (151 MHz, CDCl3) δ: 155.60, 151.37, 133.98, 133.69, 128.34, 126.84, 126.27, 
125.31. 
 
In work-up process, hydrolysis and reversion of 1-chlorophthalazine may be observed 
at high temperature and aqueous acidic conditions as well as dimerization and 
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oligomerization. Moreover, degradation may also take place at room temperature. This 
inherent instability was also described elsewhere.150, 151 Therefore, it is advised to use 
freshly purified 1-chlorophthalazine for next step. 
 
Figure 17: Proposed dimers adapted from Achmatowicz et al.150 
 
8.2.1.2: Synthesis of 1-anilinephthalazine or 1-aniline-4-phenylphthalazine 
derivatives 
 
1-Chloro-4-phenylphthalazine was bought from commercial source and 1-
chlorophthalazine was freshly prepared. A mixture of 1 mmol phthalazine and 1 mmol 
substituted aniline was dissolved in 3 ml isopropanol. The mixture was heated to 70 °C 
at 60 W irradiation and maintained for 10 mins in microwave reactor. After cooling, the 
precipitate was filtered off and washed with acetonitrile 3 times. Subsequently, it was 
washed with saturated sodium carbonate solution and distilled water for 3 times 
respectively. Further purification was performed by recrystallization or column 
chromatography. 
 
N-(3,4-dimethoxyphenyl)phthalazin-1-amine (2) 
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Molecular Weight: 281.32 
 
The title compound was synthesized from 1-chloroquinazoline (156 mg, 0.95 mmol) 
and 3,4-dimethoxyaniline (155 mg, 1.01 mmol) as described in the general procedure 
above. Further purification was performed by column chromatography with DCM to 
DCM/MeOH = 50:1 as eluent, yellow solid (44 mg, 16.5 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.07 (s, 1H), 8.99 (s, 1H), 8.56 (d, J = 8.0 Hz, 1H), 
8.03 – 7.90 (m, 3H), 7.58 – 7.50 (m, 2H), 6.96 (d, J = 8.7 Hz, 1H), 3.79 (s, 3H), 3.76 
(s, 3H). 
13C NMR (126 MHz, DMSO) δ: 152.35, 148.47, 144.81, 144.45, 134.12, 131.83, 
131.66, 127.09, 126.42, 121.92, 118.00, 113.31, 112.09, 106.76, 55.85, 55.50. 
 
N-(3-bromophenyl)phthalazin-1-amine (3) 
 
Molecular Weight: 300.16 
 
The title compound was synthesized from 1-chloroquinazoline (152 mg, 0.93 mmol) 
and 3-bromoaniline (196 mg, 1.14 mmol) as described in the general procedure above. 
Further purification was performed by recrystallization from EtOH/H2O, beige solid 
(68.5 mg, 24.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.30 (s, 1H), 9.19 (d, J = 1.0 Hz, 1H), 8.59 (dd, J = 
1.0, 8.2 Hz, 1H), 8.37 (t, J = 2.0 Hz, 1H), 8.08 – 7.97 (m, 3H), 7.94 (ddd, J = 1.0, 2.2, 
8.4 Hz, 1H), 7.32 (t, J = 8.1 Hz, 1H), 7.21 (ddd, J = 0.9, 2.0, 7.9 Hz, 1H). 
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13C NMR (126 MHz, DMSO) δ: 152.05, 145.95, 142.35, 132.23, 132.07, 130.29, 
127.19, 126.67, 124.42, 122.52, 122.04, 121.26, 119.13, 118.21. 
 
3-(phthalazin-1-ylamino)benzonitrile (4) 
 
Molecular Weight: 246.27 
 
The title compound was synthesized from 1-chloroquinazoline (96 mg, 0.58 mmol) and 
3-cyanoaniline (130 mg, 1.10 mmol) as described in the general procedure above. 
Further purification was performed by column chromatography with DCM to 
DCM/MeOH = 50:1 as eluent, beige solid (11.7 mg, 8.2 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.48 (s, 1H), 9.22 (d, J = 0.9 Hz, 1H), 8.59 (d, J = 
8.8 Hz, 1H), 8.54 (t, J = 1.9 Hz, 1H), 8.22 (ddd, J = 8.4, 2.3, 1.1 Hz, 1H), 8.10 – 7.98 
(m, 3H), 7.58 (t, J = 8.0 Hz, 1H), 7.47 (dt, J = 7.6, 1.3 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ: 152.00, 146.20, 141.53, 132.31, 132.13, 129.78, 
127.20, 126.69, 125.22, 124.82, 122.88, 122.01, 119.01, 118.20, 111.18. 
 
N-(4-fluorophenyl)phthalazin-1-amine (5) 
 
Molecular Weight: 239.25 
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The title compound was synthesized from 1-chloroquinazoline (299 mg, 1.82 mmol) 
and 4-fluoroaniline (248 mg, 2.23 mmol) as described in the general procedure above. 
Further purification was performed by recrystallization from EtOH/H2O, beige solid 
(15.5 mg, 3.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.17 (s, 1H), 9.12 (s, 1H), 8.58 – 8.55 (m, 1H), 8.06 
– 7.90 (m, 5H), 7.24 – 7.15 (m, 2H). 
13C NMR (126 MHz, DMSO) δ: 157.53 (d, J = 238.8 Hz), 152.19, 145.34, 136.88, 
132.00, 131.82, 127.14, 126.50, 122.72 (d, J = 7.7 Hz), 122.00, 118.01, 114.80 (d, J = 
22.1 Hz). 
 
N-(4-nitrophenyl)phthalazin-1-amine (6) 
 
Molecular Weight: 266.26 
 
The title compound was synthesized from 1-chloroquinazoline (77 mg, 0.47 mmol) and 
4-nitroaniline (77 mg, 0.56 mmol) as described in the general procedure above. Further 
purification was performed by column chromatography with DCM to DCM/MeOH = 
50:1 as eluent, yellow solid (13.3 mg, 10.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.86 (s, 1H), 9.32 (s, 1H), 8.62 (d, J = 8.5 Hz, 1H), 
8.29 – 8.22 (m, 4H), 8.13 (dd, J = 7.9, 1.3 Hz, 1H), 8.09 – 8.01 (m, 2H). 
13C NMR (126 MHz, DMSO) δ: 147.39, 147.05, 140.67, 139.99, 132.56, 132.35, 
127.33, 126.79, 124.80, 122.22, 118.98, 118.64. 
 
N-(3,4-dimethoxyphenyl)-4-phenylphthalazin-1-amine (7) 
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Molecular Weight: 357.41 
 
The title compound was synthesized from 1-chloro-4-phenylphthalazine (47 mg, 0.20 
mmol) and 3,4-dimethoxyaniline (46 mg, 0.30 mmol) as described in the general 
procedure above. Further purification was performed by recrystallization from 
EtOH/H2O, dark grey solid (15.5 mg, 3.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.10 (s, 1H), 8.64 (d, J = 8.2 Hz, 1H), 8.01 (ddd, J 
= 8.3, 6.9, 1.4 Hz, 1H), 7.92 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.86 (dd, J = 8.3, 1.4 Hz, 
1H), 7.68 – 7.61 (m, 3H), 7.60 – 7.50 (m, 4H), 6.98 (d, J = 8.7 Hz, 1H), 3.80 (s, 3H), 
3.77 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 152.86, 151.91, 148.49, 144.49, 136.82, 134.16, 
131.95, 131.39, 129.59, 128.40, 128.32, 125.65, 125.62, 122.47, 118.25, 113.33, 112.09, 
106.80, 55.86, 55.52. 
 
3-((4-phenylphthalazin-1-yl)amino)phenol (8) 
 
Molecular Weight: 313.36  
8 Experimental section 
 
88 
 
The title compound was synthesized from 1-chloro-4-phenylphthalazine (45 mg, 0.19 
mmol) and 3-aminophenol (22 mg, 0.20 mmol) as described in the general procedure 
above. Further purification was performed by recrystallization from ethyl 
acetate/cyclohexane, yellow solid (8.1 mg, 13.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.32 (s, 1H), 9.13 (s, 1H), 8.66 (d, J = 8.4 Hz, 1H), 
8.01 (ddd, J = 8.3, 6.9, 1.3 Hz, 1H), 7.93 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 7.89 – 7.87 
(m, 1H), 7.68 – 7.65 (m, 2H), 7.61 (t, J = 2.2 Hz, 1H), 7.60 – 7.53 (m, 3H), 7.31 (ddd, 
J = 8.1, 2.1, 0.9 Hz, 1H), 7.13 (t, J = 8.1 Hz, 1H), 6.46 (ddd, J = 8.0, 2.4, 0.9 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ: 157.45, 153.25, 151.83, 141.68, 136.78, 132.08, 
131.49, 129.62, 128.89, 128.50, 128.38, 125.69, 125.68, 122.70, 118.48, 111.63, 109.36, 
107.95. 
 
8.2.1.3: Synthesis of 1,4-dicholorphthalazine  
 
15 g 2,3-dihydrophthalazine-1,4-dione was added into 30 ml POCl3. The reaction was 
refluxed for 8-9 hours until it was complete. Excess POCl3 was removed under reduced 
pressure. The oily residue was transfer onto crushed ice portion by portion, while 
keeping the temperature of solution below 10 °C. Subsequently, 1 M NaOH was added 
until pH = 8-9 and a yellow solid precipitated. After filtering off the precipitate, it was 
washed with 100 ml distilled water 3 times. Further purification was performed by 
column chromatography with DCM as eluent to yield pale yellow or white needle 
crystals (4.23g, 22 %). 
Different from 1-chlorophthalazine, 1,4-dicholorphthalazine was stored under no 
special condition, no stability issues were displayed in the first few weeks. The right 
pure product should be pale yellow or white needle crystals. Nevertheless, red products 
with little impurity inside might also be applicable for next step. 
 
1,4-dichlorophthalazine (9) 
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Molecular Weight: 199.03 
1H NMR (500 MHz, DMSO-d6) δ: 8.39 – 8.35 (m, 2H), 8.30 – 8.26 (m, 2H). 
13C NMR (126 MHz, DMSO) δ: 154.83, 135.80, 126.81, 125.79. 
 
8.2.1.2: Synthesis of 1-chloro-4-anilinophthalazine derivatives. 
 
1 equivalent 1,4-dichlorophthalazine was added into 5 ml isopropanol. The mixture was 
heated up to 70 °C and no solid was visible. On the other hand, 1 equivalent of 
substituted aniline was dissolved in 10-15 ml isopropanol. Aniline solution was added 
to hot 1,4-dichlorophthalazine solution drop by drop. If initiation of reaction was not 
observed, 0.1 equivalent of conc. HCl was added as catalyst. After the completion of 
reaction which was monitored by TLC, the precipitate was filtered off and washed with 
saturated sodium bicarbonate solution 3 times and distilled water 3 times. Further 
purification was performed by column chromatography. 
Tip: A little amount of hydrochloric acid (0.1 equi.) catalyzes and speeds up reaction, 
especially when aniline was substituted by electro withdrawing group. This observation 
was consistent with what was described by Banks.125 He performed various 
condensation reactions between haloheterocycles with aniline, and it was found that 
condensation occurred only under acidic conditions, while little or no reaction was 
noticed under alkaline conditions. In addition, this was also a proof that the rate 
determining step of this reaction was addition but not elimination step.  
In 1-chlorophthalazine synthesis, we described acidic aqueous condition would lead to 
hydrolysis and oligomerization. But here, acid could also catalyze the desired reaction 
between chlorinated phthalazine and substituted aniline. Hydrogen ion seemed a two-
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edged sword. To lead reaction to our desired direction, the amount of acid in reaction 
system should always be taken into account as well as temperature. High concentration 
of acid may easily result in unexpected products. 
 
4-chloro-N-(3,4-dimethoxyphenyl)phthalazin-1-amine (10) 
 
Molecular Weight: 315.76 
 
The title compound was synthesized from 1,4-dichlorophthalazine (259 mg, 1.30 mmol) 
and 3,4-dimethoxylaniline (199 mg, 1.30 mmol) as described in the general procedure 
above. Green solid (294.1 mg, 71.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.20 (s, 1H), 8.64 (d, J = 7.6 Hz, 1H), 8.15 (dd, J = 
7.5, 1.9 Hz, 1H), 8.11 – 8.05 (m, 2H), 7.50 (d, J = 2.5 Hz, 1H), 7.44 (dd, J = 8.6, 2.5 
Hz, 1H), 6.97 (d, J = 8.6 Hz, 1H), 3.78 (s, 3H), 3.77 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 152.91, 148.47, 145.80, 144.90, 133.38, 133.21, 
132.88, 125.55, 124.67, 123.05, 120.37, 113.80, 111.96, 107.08, 55.80, 55.51. 
 
4-chloro-N-(3-methoxyphenyl)phthalazin-1-amine (11) 
 
Molecular Weight: 285.73 
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The title compound was synthesized from 1,4-dichlorophthalazine (104 mg, 0.52 mmol) 
and 3-methoxylaniline (67.4 mg, 0.44 mmol) as described in the general procedure 
above. Further purification was performed by column chromatography with ethyl 
acetate/petroleum ether (40-60 °C) = 1:2 as eluent, beige solid (38.3 mg, 53.5 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.28 (s, 1H), 8.67 – 8.64 (m, 1H), 8.18 – 8.15 (m, 
1H), 8.12 – 8.06 (m, 2H), 7.57 (t, J = 2.2 Hz, 1H), 7.48 (ddd, J = 0.9, 2.2, 8.2 Hz, 1H), 
7.26 (t, J = 8.2 Hz, 1H), 6.65 (ddd, J = 0.9, 2.5, 8.2 Hz, 1H), 3.77 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 159.61, 152.96, 146.68, 141.37, 133.53, 133.17, 
129.29, 125.79, 124.90, 123.36, 120.69, 113.63, 108.31, 107.15, 55.19. 
 
N-(3-bromophenyl)-4-chlorophthalazin-1-amine (12) 
 
Molecular Weight: 334.60 
 
The title compound was synthesized from 1,4-dichlorophthalazine (231 mg, 1.16 mmol) 
and 3-bromoaniline (210 mg, 1.22 mmol) as described in the general procedure above. 
Further purification was performed by recrystallization from isopropanol, white solid 
(90.5 mg, 27.1 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.46 (s, 1H), 8.68 – 8.64 (m, 1H), 8.26 (t, J = 2.0 
Hz, 1H), 8.20 (dd, J = 1.6, 7.8 Hz, 1H), 8.16 – 8.08 (m, 2H), 7.88 (ddd, J = 0.9, 2.0, 8.2 
Hz, 1H), 7.34 (t, J = 8.0 Hz, 1H), 7.24 (ddd, J = 1.0, 2.0, 8.1 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ: 152.58, 147.07, 141.74, 133.55, 133.18, 130.34, 
125.68, 125.04, 124.83, 123.17, 123.03, 121.24, 120.52, 119.59. 
 
4-chloro-N-(4-fluorophenyl)phthalazin-1-amine (13) 
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Molecular Weight: 273.70 
 
The title compound was synthesized from 1,4-dichlorophthalazine (101 mg, 0.51 mmol) 
and 4-fluoroaniline (56 mg, 0.51 mmol) as described in the general procedure above. 
Further purification was performed by column chromatography with ethyl 
acetate/petroleum ether (40-60 °C) = 1:1 as eluent, pale yellow solid (60.0 mg, 43.0 %). 
1H NMR (500 MHz, DMSO-d6) δ: 11.26 (s, 1H), 9.10 (dd, J = 2.0, 7.3 Hz, 1H), 8.28 – 
8.18 (m, 3H), 7.76 – 7.71 (m, 2H), 7.37 – 7.31 (m, 2H). 
13C NMR (126 MHz, DMSO) δ: 160.14 (d, J = 242.9 Hz), 152.08, 145.49, 135.40, 
134.00, 133.08, 126.40 (d, J = 8.2 Hz), 126.31, 125.63, 125.24, 121.62, 116.15 (d, J = 
22.6 Hz). 
 
3-((4-chlorophthalazin-1-yl)amino)benzonitrile (14) 
 
Molecular Weight: 280.72 
 
The title compound was synthesized from 1,4-dichlorophthalazine (135 mg, 0.68 mmol) 
and 3-cyanoaniline (89 mg, 0.76 mmol) as described in the general procedure above. 
Further purification was performed by recrystallization from isopropanol, white solid 
(73.4 mg, 38.6 %). 
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1H NMR (500 MHz, DMSO-d6) δ: 9.61 (s, 1H), 8.64 (dd, J = 7.7, 1.6 Hz, 1H), 8.42 (t, 
J = 1.9 Hz, 1H), 8.21 – 8.18 (m, 1H), 8.16 – 8.09 (m, 3H), 7.58 (t, J = 7.9 Hz, 1H), 7.49 
(dt, J = 7.6, 1.3 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ: 152.72, 147.55, 141.16, 133.84, 133.43, 130.04, 
126.01, 125.89, 125.46, 125.06, 123.59, 123.34, 120.69, 119.06, 111.44. 
 
4-chloro-N-(4-nitrophenyl)phthalazin-1-amine (15) 
 
Molecular Weight: 300.70 
 
The title compound was synthesized from 1,4-dichlorophthalazine (205 mg, 1.03 mmol) 
and 4-nitroaniline (145 mg, 1.05 mmol) as described in the general procedure above. 
Yellow solid (167.1 mg, 53.9 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.96 (s, 1H), 8.68 (dd, J = 1.6, 7.6 Hz, 1H), 8.28 – 
8.21 (m, 3H), 8.19 – 8.12 (m, 4H). 
13C NMR (126 MHz, DMSO) δ: 152.37, 148.34, 146.87, 141.06, 133.88, 133.42, 
125.83, 124.94, 124.74, 123.41, 120.93, 119.44. 
 
4-chloro-N-(3-nitrophenyl)phthalazin-1-amine (16) 
 
Molecular Weight: 300.70 
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The title compound was synthesized from 1,4-dichlorophthalazine (108 mg, 0.54 mmol) 
and 3-nitroaniline (75 mg, 0.54 mmol) as described in the general procedure above. 
Further purification was performed by column chromatography with ethyl 
acetate/petroleum ether (40-60 °C) = 1:3 as eluent, yellow solid (8.7 mg, 5.4 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.78 (s, 1H), 8.95 (t, J = 2.2 Hz, 1H), 8.71 – 8.69 
(m, 1H), 8.36 (ddd, J = 0.7, 2.1, 8.2 Hz, 1H), 8.24 – 8.21 (m, 1H), 8.20 – 8.12 (m, 2H), 
7.91 (ddd, J = 0.8, 2.3, 8.1 Hz, 1H), 7.67 (t, J = 8.2 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ: 152.54, 147.92, 147.54, 141.38, 133.70, 133.30, 
129.72, 126.56, 125.72, 124.91, 123.17, 120.53, 116.79, 114.60. 
 
3-((4-chlorophthalazin-1-yl)amino)phenol (17) 
 
Molecular Weight: 271.70 
 
The title compound was synthesized from 1,4-dichlorophthalazine (200 mg, 1.00 mmol) 
and 3-aminophenol (117 mg, 1.07 mmol) as described in the general procedure above. 
Pale yellow solid (102.5 mg, 37.7 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.37 (s, 1H), 9.21 (s, 1H), 8.68 – 8.65 (m, 1H), 8.19 
– 8.15 (m, 1H), 8.12 – 8.06 (m, 2H), 7.47 (t, J = 2.2 Hz, 1H), 7.25 (dd, J = 8.4, 1.1 Hz, 
1H), 7.14 (t, J = 8.0 Hz, 1H), 6.49 (ddd, J = 8.1, 2.5, 0.9 Hz, 1H). 
13C NMR (126 MHz, DMSO) δ: 157.45, 152.80, 146.31, 141.02, 133.31, 132.96, 
128.97, 125.62, 124.70, 123.26, 120.53, 112.00, 109.95, 108.35. 
 
4-((4-chlorophthalazin-1-yl)amino)benzonitrile (18) 
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Molecular Weight: 280.72 
 
The title compound was synthesized from 1,4-dichlorophthalazine (154 mg, 0.77 mmol) 
and 4-cyanoaniline (98 mg, 0.83 mmol) as described in the general procedure above. 
Further purification was performed by column chromatography with ethyl 
acetate/petroleum ether (40-60 °C) = 1:2 as eluent, beige solid (28.3 mg, 13.1 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.76 (s, 1H), 8.67 (d, J = 7.4 Hz, 1H), 8.23 (dd, J = 
1.6, 7.7 Hz, 1H), 8.18 – 8.13 (m, 2H), 8.13 – 8.09 (m, 2H), 7.83 – 7.79 (m, 2H). 
13C NMR (126 MHz, DMSO) δ: 152.47, 147.98, 144.64, 133.83, 133.39, 132.92, 
125.82, 124.95, 123.36, 120.82, 120.18, 119.36, 103.58. 
 
8.2.1.4: Synthesis of 1,4-bisanilinophthalazine derivatives 
 
A mixture of 200 mg 1,4-dichlorophthalazine, 2 equivalent of substituted aniline in 3 
ml isopropanol was heated to 110 °C in microwave for 15-30 mins. If reaction did not 
initiate, 0.1 equivalent of conc. HCl was added as catalyst. The precipitate was filtered 
off and washed with saturated sodium bicarbonate solution 3 times followed by distilled 
water 3 times. Further purification for certain compounds was performed by 
recrystallization or column chromatography. 
 
N1,N4-bis(3,4-dimethoxyphenyl)phthalazine-1,4-diamine (19) 
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Molecular Weight: 432.48 
 
The title compound was synthesized from 1,4-dichlorophthalazine (126 mg, 0.63 mmol) 
and 3,4-dimethoxylaniline (241 mg, 1.57 mmol) as described in the general procedure 
above. Pale green solid (105 mg, 38.4 %). 
1H NMR (500 MHz, DMSO-d6) δ: 8.55 (s, 2H), 8.49 – 8.44 (m, 2H), 7.98 – 7.94 (m, 
2H), 7.46 – 7.42 (m, 4H), 6.90 (d, J = 8.5 Hz, 2H), 3.76 (s, 6H), 3.74 (s, 6H). 
13C NMR (126 MHz, DMSO) δ: 148.61, 148.46, 143.53, 135.64, 131.13, 122.65, 
120.47, 112.41, 111.78, 105.60, 55.97, 55.48. 
 
N1,N4-bis(3-methoxyphenyl)phthalazine-1,4-diamine (20) 
 
Molecular Weight: 372.43 
 
The title compound was synthesized from 1,4-dichlorophthalazine (106 mg, 0.53 mmol) 
and 3-methoxylaniline (147 mg, 1.20 mmol) as described in the general procedure 
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above. Further purification was performed by column chromatography with ethyl 
acetate/petroleum ether (40-60 °C) = 1:1 as eluent, pale yellow solid (150.6 mg, 76.0 %). 
1H NMR (500 MHz, DMSO-d6) δ: 8.78 (s, 2H), 8.50 (dd, J = 3.3, 6.2 Hz, 2H), 7.99 (dd, 
J = 3.1, 6.2 Hz, 2H), 7.50 (t, J = 2.4 Hz, 2H), 7.45 (dd, J = 2.0, 7.9 Hz, 2H), 7.20 (t, J 
= 8.1 Hz, 2H), 6.53 (dd, J = 2.5, 8.1 Hz, 2H), 3.76 (s, 6H). 
13C NMR (126 MHz, DMSO) δ: 159.52, 148.58, 143.01, 131.39, 129.01, 122.80, 
120.65, 111.84, 106.10, 105.23, 54.91. 
 
N1,N4-bis(4-fluorophenyl)phthalazine-1,4-diamine (21) 
 
Molecular Weight: 348.36 
 
The title compound was synthesized from 1,4-dichlorophthalazine (125 mg, 0.63 mmol) 
and 4-fluoroaniline (195 mg, 1.76 mmol) as described in the general procedure above. 
Pale yellow solid (209 mg, 79.0 %). 
1H NMR (500 MHz, DMSO-d6) δ: 8.83 (s, 2H), 8.51 (dd, J = 6.2, 3.3 Hz, 2H), 7.99 (dd, 
J = 6.2, 3.2 Hz, 2H), 7.87 (dd, J = 9.1, 4.8 Hz, 4H), 7.17 – 7.11 (m, 4H). 
13C NMR (126 MHz, DMSO) δ: 156.79 (d, J = 237.2 Hz), 148.49, 138.09, 131.40, 
122.78, 121.16 (d, J = 7.7 Hz), 120.45, 114.70 (d, J = 22.0 Hz). 
 
N1,N4-bis(3-nitrophenyl)phthalazine-1,4-diamine (22) 
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Molecular Weight: 402.37 
 
The title compound was synthesized from 1,4-dichlorophthalazine (149 mg, 0.75 mmol) 
and 3-nitroaniline (253 mg, 1.83 mmol) as described in the general procedure above. 
Red solid (90 mg, 29.9 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.42 (s, 2H), 8.58 (dd, J = 3.4, 6.2 Hz, 2H), 8.34 (d, 
J = 8.3 Hz, 2H), 8.08 (dd, J = 3.5, 6.3 Hz, 2H), 7.82 – 7.78 (m, 4H), 7.61 (t, J = 8.2 Hz, 
2H). 
13C NMR (126 MHz, DMSO) δ: 148.70, 148.05, 142.76, 132.01, 129.66, 125.24, 
122.86, 120.55, 115.27, 113.10. 
 
N1,N4-bis(4-nitrophenyl)phthalazine-1,4-diamine (23) 
  
Molecular Weight: 402.37 
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The title compound was synthesized from 1,4-dichlorophthalazine (140 mg, 0.70 mmol) 
and 4-nitroaniline (242 mg, 1.75 mmol) as described in the general procedure above. 
Pale grey solid (80 mg, 28.3 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.77 (s, 2H), 8.57 (dd, J = 6.2, 3.3 Hz, 2H), 8.24 (d, 
J = 8.9 Hz, 4H), 8.12 – 8.08 (m, 6H). 
13C NMR (126 MHz, DMSO) δ: 148.87, 148.12, 140.00, 132.28, 124.98, 123.04, 
120.85, 117.95. 
 
3,3'-(phthalazine-1,4-diylbis(azanediyl))diphenol (24) 
 
Molecular Weight: 344.37 
 
The title compound was synthesized from 1,4-dichlorophthalazine (120 mg, 0.60 mmol) 
and 3-aminophenol (168 mg, 1.54 mmol) as described in the general procedure above. 
Further purification was performed by column chromatography with CHCl3/MeOH = 
3:1 as eluent, yellow solid (62.7 mg, 30.3 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.19 (s, 2H), 8.65 (s, 2H), 8.49 (dd, J = 3.3, 6.2 Hz, 
2H), 7.97 (dd, J = 3.2, 6.2 Hz, 2H), 7.50 (t, J = 2.2 Hz, 2H), 7.16 (ddd, J = 1.0, 2.1, 8.1 
Hz, 2H), 7.06 (t, J = 8.0 Hz, 2H), 6.35 (ddd, J = 1.0, 2.4, 8.0 Hz, 2H). 
13C NMR (126 MHz, DMSO) δ: 157.45, 148.50, 142.93, 131.29, 128.82, 122.85, 
120.66, 110.31, 108.01, 106.42. 
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N1,N4-bis(3-(trifluoromethyl)phenyl)phthalazine-1,4-diamine (25) 
 
Molecular Weight: 448.37 
 
The title compound was synthesized from 1,4-dichlorophthalazine (112 mg, 0.56 mmol) 
and 3-trifluoroamine (250 mg, 1.55 mmol) as described in the general procedure above. 
Further purification was performed by recrystallization from DMF/H2O, yellow solid 
(45.5 mg, 18.0 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.99 (s, 2H), 8.76 (s, 2H), 8.21 – 8.14 (m, 4H), 8.07 
(d, J = 8.2 Hz, 2H), 7.63 (t, J = 8.0 Hz, 2H), 7.44 (d, J = 5.9 Hz, 2H). 
13C NMR (126 MHz, DMSO) δ: 162.23, 148.34, 140.37, 133.35, 130.01, 129.62 (q, J 
= 32.0 Hz), 124.11, 121.65, 124.17 (q, J = 272.5 Hz), 119.62, 117.54. 
 
N1,N4-bis(3-bromophenyl)phthalazine-1,4-diamine (26) 
 
Molecular Weight: 470.17 
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The title compound was synthesized from 1,4-dichlorophthalazine (142 mg, 0.71 mmol) 
and 3-bromoaniline (376 mg, 2.19 mmol) as described in the general procedure above. 
Further purification was performed by recrystallization from 75% EtOH, white solid 
(41.0 mg, 12.3 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.02 (s, 2H), 8.51 (dd, J = 6.2, 3.3 Hz, 2H), 8.19 (t, 
J = 2.0 Hz, 2H), 8.04 – 8.01 (m, 2H), 7.83 (ddd, J = 8.3, 2.1, 0.9 Hz, 2H), 7.27 (t, J = 
8.1 Hz, 2H), 7.11 (ddd, J = 7.9, 1.9, 0.9 Hz, 2H). 
13C NMR (126 MHz, DMSO) δ: 148.72, 143.49, 131.93, 130.47, 123.47, 122.99, 
121.51, 121.43, 120.73, 118.21, 40.24, 39.78, 39.63, 39.34. 
 
3,3'-(phthalazine-1,4-diylbis(azanediyl))dibenzonitrile (27) 
 
Molecular Weight: 362.40 
 
The title compound was synthesized from 1,4-dichlorophthalazine (201 mg, 1.01 mmol) 
and 3-cyanoaniline (300 mg, 2.54 mmol) as described in the general procedure above. 
Further purification was performed by recrystallization from DMF/H2O, yellow solid 
(215.1 mg, 59.4 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.23 (s, 2H), 8.53 (dd, J = 6.2, 3.2 Hz, 2H), 8.38 (t, 
J = 2.0 Hz, 2H), 8.15 (dd, J = 8.4, 2.4 Hz, 2H), 8.06 (dd, J = 6.3, 3.2 Hz, 2H), 7.53 (t, 
J = 8.0 Hz, 2H), 7.38 (d, J = 7.6 Hz, 1H). 
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13C NMR (126 MHz, DMSO) δ: 148.64, 142.39, 131.91, 129.79, 124.17, 123.78, 
122.82, 121.66, 120.53, 119.16, 111.18. 
 
4,4'-(phthalazine-1,4-diylbis(azanediyl))dibenzonitrile (28) 
 
Molecular Weight: 362.40 
 
The title compound was synthesized from 1,4-dichlorophthalazine (194 mg, 0.98 mmol) 
and 4-cyanoaniline (294 mg, 2.49 mmol) as described in the general procedure above. 
Yellow solid (226 mg, 64.0 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.47 (s, 2H), 8.54 (dd, J = 6.2, 3.3 Hz, 2H), 8.09 – 
8.04 (m, 6H), 7.77 – 7.74 (m, 4H). 
13C NMR (126 MHz, DMSO) δ: 148.75, 145.96, 132.92, 132.11, 122.98, 120.80, 
119.70, 118.70, 101.81. 
 
8.2.2.1: Synthesis of 2-phenylquinazolin-4-amine (29) 
 
A mixture of anthranilonitrile (2.316g, 19.6 mmol), benzonitrile (2.127g, 20.6 mmol) 
and potassium tert-butoxide (209 mg, 1.86 mmol) was added in 10 ml microwave vial 
and heated to 170 °C in microwave reactor (300 W) until no starting materials were 
observed by TLC. The crude product was purified by recrystallization from methanol 
(1.496g, 34.5 %). 
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Molecular Weight: 221.26 
 
1H NMR (500 MHz, DMSO-d6) δ: 8.48 – 8.44 (m, 2H), 8.24 (dt, J = 0.8, 8.2 Hz, 1H), 
7.83 – 7.74 (m, 4H), 7.52 – 7.44 (m, 4H). 
13C NMR (126 MHz, DMSO) δ: 162.04, 159.68, 150.34, 138.55, 132.89, 129.85, 
128.08, 127.77, 127.62, 125.06, 123.53, 113.22. 
 
8.2.2.2: Synthesis of quinazoline derivatives with amide linker 
 
To a stirred solution of 1 eq benzoic acid in DMF (0.5 M final concentration) was added 
1.1 eq TBTU and 5 eq DIPEA. The reaction mixture was stirred for 10 mins at room 
temperature. Afterwards, 1 eq 2-phenyl-4-aminoquinazoline was added. The solution 
was stirred at 85°C overnight. After the completion of reaction which was monitored 
by TLC, the mixture was quenched with water, extracted by DCM, and washed with 
aqueous NaHCO3, 10% w/v aqueous citric acid and brine sequentially. The organic 
layer was dried with Na2SO4 and evaporated under reduced pressure to afford the crude 
product. Further purification was performed by column chromatography.  
 
3,4-dimethoxy-N-(2-phenylquinazolin-4-yl)benzamide (30) 
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Molecular Weight: 385.42 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (79 mg, 0.36 
mmol) and 3,4-dimethoxybenzoic acid (59 mg, 0.33 mmol) as described in the general 
procedure above. Further purification was performed by column chromatography with 
DCM as eluent, beige solid (19.9 mg, 15.8 %). 
1H NMR (600 MHz, Chloroform-d) δ: 16.03 (s, 1H), 8.70 (s, 1H), 8.28 (s, 2H), 8.16 (s, 
1H), 7.94 – 7.84 (m, 3H), 7.60 – 7.56 (m, 4H), 6.95 (d, J = 8.4 Hz, 1H), 4.01 (s, 3H), 
3.96 (s, 3H).  
13C NMR (126 MHz, DMSO) δ 166.70, 159.31, 159.13, 152.42, 151.73, 148.37, 137.20, 
134.37, 130.77, 128.56, 128.04, 126.89, 125.90, 125.58, 122.29, 117.67, 111.65, 111.02, 
79.12, 55.74, 55.66. 
 
3-methoxy-N-(2-phenylquinazolin-4-yl)benzamide (31) 
 
Molecular Weight: 355.40 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (173 mg, 0.78 
mmol) and 3-methoxybenzoic acid (107 mg, 0.70 mmol) as described in the general 
procedure above. Further purification was performed by column chromatography with 
DCM as eluent, yellow solid (52.9 mg, 21.1 %). 
1H NMR (600 MHz, Chloroform-d) δ 16.02 (s, 1H), 8.69 (s, 1H), 8.30 (s, 2H), 8.04 (s, 
1H), 7.93 (s, 2H), 7.87 (t, J = 6.9 Hz, 1H), 7.62 – 7.54 (m, 4H), 7.41 (t, J = 7.9 Hz, 1H), 
7.12 (dd, J = 8.1, 2.7 Hz, 1H), 3.91 (s, 3H). 
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13C NMR (151 MHz, DMSO) δ: 158.64, 157.93, 148.45, 134.37, 131.00, 128.30, 
128.23, 126.97, 126.51, 126.29, 125.19, 121.10, 117.99, 112.90, 76.20, 75.98, 75.77, 
54.47. 
 
4-ethoxy-N-(2-phenylquinazolin-4-yl)benzamide (32) 
 
Molecular Weight: 369.42 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (177 mg, 0.80 
mmol) and 4-ethoxybenzoic acid (124 mg, 0.74 mmol) as described in the general 
procedure above. Further purification was performed by column chromatography with 
DCM as eluent, beige solid (20.1 mg, 7.3 %). 
1H NMR (600 MHz, Chloroform-d) δ 16.05 (s, 1H), 8.67 (s, 1H), 8.36 (s, 2H), 8.27 (s, 
2H), 7.90 (s, 1H), 7.84 (t, J = 6.9 Hz, 1H), 7.57 – 7.54 (m, 4H), 6.95 (d, J = 8.6 Hz, 
2H), 4.10 (q, J = 7.0 Hz, 2H), 1.44 (t, J = 7.0 Hz, 3H). 
13C NMR (151 MHz, CDCl3) δ 161.65, 157.60, 148.52, 134.11, 130.85, 130.72, 128.18, 
127.02, 126.34, 126.23, 126.21, 125.17, 118.90, 112.98, 62.65, 13.73. 
 
4-methoxy-3-nitro-N-(2-phenylquinazolin-4-yl)benzamide (33) 
 
Molecular Weight: 400.39 
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The title compound was synthesized from 2-phenylquinazolin-4-amine (286 mg, 1.29 
mmol) and 4-methoxy-3-nitrobenzoic acid (218 mg, 1.10 mmol) as described in the 
general procedure above. Further purification was performed by column 
chromatography with DCM as eluent, white solid (26.4 mg, 6.0 %). 
1H NMR (500 MHz, DMSO-d6) δ: 11.44 (s, 1H), 8.63 (s, 1H), 8.44 (s, 2H), 8.35 (d, J 
= 7.3 Hz, 1H), 8.21 (s, 1H), 8.08 – 7.98 (m, 2H), 7.68 (t, J = 7.6 Hz, 1H), 7.57 – 7.51 
(m, 4H), 4.05 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 165.45, 159.21, 158.90, 154.98, 151.93, 139.00, 
137.30, 134.73, 131.00, 128.76, 128.26, 128.15, 127.18, 125.89, 125.67, 117.48, 114.46, 
57.42. 
 
3-bromo-N-(2-phenylquinazolin-4-yl)benzamide (34) 
 
Molecular Weight: 404.27 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (305 mg, 1.38 
mmol) and 3-bromobenzoic acid (246 mg, 1.23 mmol) as described in the general 
procedure above. Further purification was performed by column chromatography with 
DCM as eluent, white solid (122.3 mg, 24.7 %). 
1H NMR (600 MHz, Chloroform-d) δ: 15.99 (s, 1H), 8.77 (s, 1H), 8.61 (s, 1H), 8.37 (d, 
J = 7.5 Hz, 1H), 8.27 (d, J = 4.4 Hz, 2H), 7.94 – 7.89 (m, 2H), 7.69 (d, J = 8.1 Hz, 1H), 
7.65 – 7.58 (m, 4H), 7.38 (t, J = 7.8 Hz, 1H). 
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13C NMR (151 MHz, CDCl3) δ 178.02, 158.31, 148.45, 148.07, 138.46, 134.58, 134.09, 
131.80, 131.09, 131.00, 128.73, 128.34, 127.30, 127.21, 126.68, 125.95, 125.28, 
121.40, 118.85. 
 
N-(2-phenylquinazolin-4-yl)-4-(trifluoromethyl)benzamide (35) 
 
Molecular Weight: 393.37 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (158 mg, 0.72 
mmol) and 4-trifluorobenzoic acid (122 mg, 0.64 mmol) as described in the general 
procedure above. Further purification was performed by column chromatography with 
DCM as eluent, white solid (26.3 mg, 10.4 %). 
1H NMR (600 MHz, Chloroform-d) δ 15.85 (s, 1H), 8.63 (d, J = 8.0 Hz, 1H), 8.43 (d, 
J = 8.0 Hz, 2H), 8.15 – 8.10 (m, 2H), 7.81 – 7.74 (m, 2H), 7.62 (d, J = 8.1 Hz, 2H), 
7.52 – 7.44 (m, 4H). 
13C NMR (151 MHz, CDCl3) δ 178.11, 158.44, 148.50, 148.03, 139.58, 134.64, 132.50 
(q, J = 32.3 Hz), 131.13, 130.93, 128.99, 128.35, 127.29, 127.25, 126.70, 125.93, 
125.21, 124.33 (q, J = 272.6 Hz), 124.11 (q, J = 3.8 Hz), 118.81.  
 
4-cyano-N-(2-phenylquinazolin-4-yl)benzamide (36) 
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Molecular Weight: 350.38 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (198 mg, 0.89 
mmol) and 4-cyanobenzoic acid (126 mg, 0.85 mmol) as described in the general 
procedure above. Further purification was performed by column chromatography with 
DCM as eluent, white solid (16.5 mg, 5.5 %). 
1H NMR (500 MHz, DMSO-d6) δ: 11.83 (s, 1H), 8.37 – 8.33 (m, 2H), 8.24 – 8.19 (m, 
3H), 7.93 – 7.89 (m, 2H), 7.87 – 7.79 (m, 2H), 7.51 – 7.43 (m, 4H). 
13C NMR (126 MHz, DMSO) δ: 167.42, 164.55, 159.19, 151.22, 142.80, 138.42, 
132.97, 131.90, 130.02, 129.12, 128.16, 127.91, 127.45, 125.99, 125.46, 118.80, 118.75, 
112.37. 
 
3-cyano-N-(2-phenylquinazolin-4-yl)benzamide (37) 
 
Molecular Weight: 350.38 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (289 mg, 1.31 
mmol) and 3-cyanobenzoic acid (182 mg, 1.24 mmol) as described in the general 
procedure above. Further purification was performed by column chromatography with 
DCM as eluent, white solid (16.5 mg, 5.5 %). 
1H NMR (500 MHz, DMSO-d6) δ 11.52 (s, 1H), 8.51 (s, 1H), 8.37 (d, J = 6.8 Hz, 2H), 
8.29 (s, 2H), 8.12 (dt, J = 1.3, 7.8 Hz, 1H), 8.08 – 7.99 (m, 2H), 7.78 (td, J = 0.6, 7.8 
Hz, 1H), 7.69 (t, J = 7.4 Hz, 1H), 7.53 (s, 3H). 
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13C NMR (126 MHz, DMSO) δ: 166.22, 158.89, 158.39, 151.73, 137.06, 135.42, 
134.55, 132.95, 132.07, 130.81, 129.83, 128.53, 128.09, 127.92, 127.04, 125.49, 118.16, 
116.93, 111.60. 
 
8.2.2.3: Synthesis of quinazoline derivatives with urea linker 
 
Corresponding phenyl isocyanate was dissolved in 3-5 ml anhydrous THF. Afterwards, 
the solution was added dropwise to a solution of 1 equivalent 2-phenyl-4-
aminoquinazoline in 10 ml anhydrous THF at room temperature. The reaction mixture 
was stirred at room temperature overnight. The precipitate was filtered off and washed 
with THF 3 times to give crude product. Further purification was performed by 
recrystallizaion from DMF/MeOH. 
 
1-phenyl-3-(2-phenylquinazolin-4-yl)urea (38) 
 
Molecular Weight: 340.39 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (197 mg, 0.89 
mmol) and phenyl isocyanate (116 mg, 0.98 mmol) as described in the general 
procedure above. White solid (47.5 mg, 15.7 %). 
1H NMR (500 MHz, DMSO-d6) δ: 12.22 (s, 1H), 10.57 (s, 1H), 8.75 (d, J = 8.3 Hz, 
1H), 8.43 – 8.38 (m, 2H), 8.00 – 7.96 (m, 2H), 7.71 – 7.59 (m, 6H), 7.43 (t, J = 7.8 Hz, 
2H), 7.14 (tt, J = 1.2, 7.3 Hz, 1H). 
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13C NMR (126 MHz, DMSO) δ: 157.63, 157.52, 151.62, 150.58, 138.16, 137.46, 
134.48, 130.84, 129.13, 128.79, 128.29, 127.77, 127.10, 123.60, 123.48, 119.53, 113.55. 
 
1-(3-methoxyphenyl)-3-(2-phenylquinazolin-4-yl)urea (39) 
 
Molecular Weight: 370.41 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (133 mg, 0.60 
mmol) and 3-methoxyphenyl isocyanate (91 mg, 0.61 mmol) as described in the general 
procedure above. White solid (81.2 mg, 36.3 %). 
1H NMR (500 MHz, DMSO-d6) δ: 12.24 (s, 1H), 10.56 (s, 1H), 8.75 (d, J = 8.3 Hz, 
1H), 8.42 – 8.39 (m, 2H), 7.99 (d, J = 3.7 Hz, 2H), 7.70 – 7.66 (m, 1H), 7.63 – 7.60 (m, 
3H), 7.33 (t, J = 8.1 Hz, 1H), 7.28 (t, J = 2.2 Hz, 1H), 7.25 (ddd, J = 1.0, 2.0, 7.9 Hz, 
1H), 6.72 (ddd, J = 1.0, 2.5, 8.2 Hz, 1H), 3.79 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 159.81, 157.62, 157.46, 151.47, 150.59, 139.28, 
137.47, 134.53, 130.88, 129.96, 128.76, 128.31, 127.80, 127.15, 123.58, 113.46, 111.71, 
109.09, 105.27, 55.06. 
 
1-(3-bromophenyl)-3-(2-phenylquinazolin-4-yl)urea (40) 
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Molecular Weight: 419.28 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (104 mg, 0.47 
mmol) and 3-bromophenyl isocyanate (97 mg, 0.49 mmol) as described in the general 
procedure above. White solid (24.8 mg, 12.6 %). 
 
1H NMR (500 MHz, DMSO-d6) δ: 12.34 (s, 1H), 10.64 (s, 1H), 8.72 (d, J = 8.4 Hz, 
1H), 8.40 (dd, J = 3.0, 6.7 Hz, 2H), 7.99 (s, 3H), 7.68 (dt, J = 4.1, 8.3 Hz, 1H), 7.64 – 
7.56 (m, 4H), 7.41 – 7.30 (m, 2H). 
 
1-(3-cyanophenyl)-3-(2-phenylquinazolin-4-yl)urea (41) 
 
Molecular Weight: 365.40 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (100 mg, 0.45 
mmol) and 3-cyanophenyl isocyanate (65 mg, 0.45 mmol) as described in the general 
procedure above. White solid (27.0 mg, 16.4 %). 
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1H NMR (500 MHz, DMSO-d6) δ: 12.35 (s, 1H), 10.71 (s, 1H), 8.73 (d, J = 8.3 Hz, 
1H), 8.42 – 8.39 (m, 2H), 8.16 (t, J = 1.8 Hz, 1H), 8.00 (d, J = 3.9 Hz, 2H), 7.86 (d, J 
= 8.0 Hz, 1H), 7.71 – 7.58 (m, 6H). 
 
1-(2-nitrophenyl)-3-(2-phenylquinazolin-4-yl)urea (42) 
 
Molecular Weight: 385.38 
 
The title compound was synthesized from 2-phenylquinazolin-4-amine (105 mg, 0.48 
mmol) and 2-nitrophenyl isocyanate (81 mg, 0.49 mmol) as described in the general 
procedure above. Yellow solid (16.8 mg, 9.2 %). 
1H NMR (500 MHz, DMSO-d6) δ: 12.42 (s, 1H), 10.81 (s, 1H), 8.71 (d, J = 8.4 Hz, 
1H), 8.39 – 8.35 (m, 2H), 8.16 (dd, J = 1.3, 8.3 Hz, 1H), 8.12 (dd, J = 1.5, 8.2 Hz, 1H), 
8.02 – 7.98 (m, 2H), 7.82 (ddd, J = 1.6, 7.4, 8.6 Hz, 1H), 7.69 (ddd, J = 3.3, 4.9, 8.3 Hz, 
1H), 7.55 – 7.47 (m, 3H), 7.43 (ddd, J = 1.4, 7.3, 8.5 Hz, 1H). 
 
8.2.3.1: Synthesis of 6-methyl-2-phenylpyrimidin-4-ol (43) 
 
0.304 g (13.2 mmol) sodium was dissolved in 50 ml ethanol to afford sodium ethoxide 
solution. Subsequently, 1.31 g (10.88 mmol) benzamidine which was dissolved in 10 
ml ethanol and 1.428 g (10.97 mmol) ethyl acetoacetate were added into sodium 
ethoxide solution respectively. The resulting mixture was heated to reflux overnight and 
cooled down to room temperature. After solvent was removed under reduced pressure, 
20 ml water was added to the solid and the mixture was acidified with concentrated 
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HCl to pH 5-6. The formed precipitate was vacuum filtered and washed with water 3 
times. Finally, the obtained crude residue was recrystallized from DMF/H2O to give 6-
methyl-2-phenylpyrimidin-4-ol as white solid (1.22 g; 60.1 %). 
 
 
Molecular Weight: 186.21 
 
1H NMR (500 MHz, DMSO-d6) δ: 12.49 (s, 1H), 8.13 – 8.09 (m, 2H), 7.58 – 7.55 (m, 
1H), 7.53 – 7.49 (m, 2H), 6.20 (s, 1H), 2.28 (d, J = 0.9 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 164.56, 163.59, 156.92, 132.71, 131.42, 128.51, 
127.68, 109.87, 23.45. 
 
8.2.3.2: Synthesis of 4-chloro-6-methyl-2-phenylpyrimidine (44) 
 
1.035 g (5.07 mmol) 6-methyl-2-phenylpyrimidin-4-ol was added into 20 ml POCl3. 
The reaction was refluxed until the reaction was complete. Excess POCl3 was removed 
under reduced pressure. The oily residue was transfer onto crushed ice portion by 
portion, while keeping the temperature of solution below 10 °C. Ethyl acetate was used 
to extract products 3 times. The organic layer was washed with saturated NaHCO3, 
saturated NaCl solution and dried over magnesium sulfate. After filtration, ethyl acetate 
was removed under reduced pressure. Final purification was performed by column 
chromatography with ethyl acetate/petroleum ether (40-60 °C) = 1:8 as eluent to yield 
white crystals (yield: 0.782 g; 75.4 %). 
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Molecular Weight: 204.66 
 
1H NMR (600 MHz, Chloroform-d) δ: 8.47 – 8.44 (m, 2H), 7.52 – 7.47 (m, 3H), 7.11 
(s, 1H), 2.60 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: (151 MHz, CDCl3) δ 169.02, 165.05, 161.69, 136.27, 
131.53, 128.75, 128.73, 118.59, 24.14. 
 
8.2.3.3: Synthesis of 4-anilino-6-methyl-2-phenylpyrimidine derivatives 
 
A mixture of 1 equivalent 4-chloro-6-methyl-2-phenylpyrimidine, 1 equivalent of 
substituted aniline in 3 ml isopropanol was heated to 110 °C in microwave for 15-30 
mins. If reaction did not initiate, 0.1 equivalent of conc. HCl was added as catalyst. The 
precipitate was filtered off and washed with saturated sodium bicarbonate solution 3 
times followed by distilled water 3 times. Further purification for certain compounds 
was performed by recrystallization or column chromatography. 
 
2-(4-((6-methyl-2-phenylpyrimidin-4-yl)amino)phenyl)acetonitrile (46) 
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The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (105 
mg, 0.51 mmol) and 2-(4-aminophenyl)acetonitrile (65 mg, 0.49 mmol) as described in 
the general procedure above. White solid (113.4 mg, 76.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.58 (s, 1H), 8.37 – 8.33 (m, 2H), 7.81 – 7.76 (m, 
2H), 7.53 – 7.48 (m, 3H), 7.36 (d, J = 8.6 Hz, 2H), 6.58 (d, J = 0.8 Hz, 1H), 3.99 (s, 
2H), 2.39 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 164.87, 162.40, 160.59, 139.46, 137.89, 130.24, 
128.51, 128.35, 127.61, 124.50, 120.02, 119.37, 103.46, 23.77, 21.77. 
LC-MS (m/z) Calcd. for C19H16N4 [M+1]+ : 301.14, Found: 301.0, Purity: 98.6 %.  
 
(3-((6-methyl-2-phenylpyrimidin-4-yl)amino)phenyl)methanol (48) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (103 
mg, 0.50 mmol) and (4-aminophenyl)methanol (62 mg, 0.50 mmol) as described in the 
general procedure above. White solid (83.1 mg, 56.9 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.81 (s, 1H), 8.39 – 8.33 (m, 2H), 7.82 (s, 1H), 7.61 
(dt, J = 1.6, 8.0 Hz, 1H), 7.55 – 7.49 (m, 3H), 7.33 (t, J = 7.8 Hz, 1H), 7.01 (d, J = 7.5 
Hz, 1H), 6.63 (s, 1H), 5.21 (s, 1H), 4.55 (s, 2H), 2.42 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 163.23, 161.78, 160.76, 143.34, 139.43, 136.70, 
130.70, 128.42, 127.86, 120.65, 118.33, 118.18, 103.38, 62.84, 22.98. 
LC-MS (m/z) Calcd. for C18H17N3O [M+1]+ : 292.14, Found: 292.1, Purity: 98.6 %. 
 
3-((6-methyl-2-phenylpyrimidin-4-yl)amino)phenol (49) 
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The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (210 
mg, 1.03 mmol) and 3-bromoaniline(113 mg, 1.04 mmol) as described in the general 
procedure above. Further purification was performed by recrystallization from 
chloroform/n-Hexane, white solid (122.9 mg, 43.3 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.36 (s, 2H), 8.39 – 8.34 (m, 2H), 7.52 – 7.46 (m, 
3H), 7.26 (dd, J = 1.6, 2.7 Hz, 1H), 7.17 – 7.11 (m, 2H), 6.56 (d, J = 0.7 Hz, 1H), 6.45 
(dt, J = 2.3, 6.6 Hz, 1H), 2.38 (d, J = 0.6 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 164.64, 162.45, 160.74, 157.74, 141.03, 137.99, 
130.16, 129.36, 128.28, 127.68, 110.55, 109.47, 106.88, 103.32, 23.79. 
LC-MS (m/z) Calcd. for C17H15N3O [M+1]+ : 278.12, Found: 278.1, Purity: 99.2 %. 
 
N-(3-fluorophenyl)-6-methyl-2-phenylpyrimidin-4-amine (50) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (193 
mg, 0.94 mmol) and 3-fluoroaniline(108 mg, 0.97 mmol) as described in the general 
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procedure above. Further purification was performed by recrystallization from n-
hexane, white solid (134.1 mg, 50.9 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.73 (s, 1H), 8.37 – 8.32 (m, 2H), 7.86 (dt, J = 2.3, 
12.2 Hz, 1H), 7.55 – 7.48 (m, 3H), 7.46 (ddd, J = 1.0, 2.0, 8.3 Hz, 1H), 7.39 (td, J = 
6.9, 8.2 Hz, 1H), 6.84 (tdd, J = 0.9, 2.6, 8.5 Hz, 1H), 6.61 (d, J = 0.8 Hz, 1H), 2.41 (d, 
J = 0.6 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 165.17, 162.44, 161.76 (d, J = 240.6 Hz), 160.47, 
142.00, 137.86, 130.35, 130.26 (d, J = 9.6 Hz), 128.41, 127.54, 115.12, 108.19 (d, J = 
21.5 Hz), 106.05 (d, J = 26.2 Hz), 
103.91, 23.80. 
LC-MS (m/z) Calcd. for C17H14FN3 [M+1]+ : 280.12, Found: 280.1, Purity: 97.9 %. 
 
N-(3-chlorophenyl)-6-methyl-2-phenylpyrimidin-4-amine (51) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (168 
mg, 0.82 mmol) and 3-chloroaniline(102 mg, 0.80 mmol) as described in the general 
procedure above. Further purification was performed by recrystallization from n-
hexane, white solid (148.7 mg, 62.7 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.72 (s, 1H), 8.39 – 8.31 (m, 2H), 8.11 (t, J = 2.1 
Hz, 1H), 7.62 (ddd, J = 0.9, 2.1, 8.3 Hz, 1H), 7.56 – 7.46 (m, 3H), 7.39 (t, J = 8.1 Hz, 
1H), 7.07 (ddd, J = 0.9, 2.2, 8.0 Hz, 1H), 6.60 (d, J = 0.8 Hz, 1H), 2.41 (d, J = 0.6 Hz, 
3H). 
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13C NMR (126 MHz, DMSO) δ: 165.22, 162.37, 160.40, 141.64, 137.82, 133.03, 
130.38, 130.34, 128.39, 127.54, 121.42, 118.90, 117.69, 103.93, 23.80. 
LC-MS (m/z) Calcd. for C17H14ClN3 [M+1]+ : 296.09, Found: 296.2, Purity: 98.8 %. 
 
N-(3-bromophenyl)-6-methyl-2-phenylpyrimidin-4-amine (52) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (123 
mg, 0.60 mmol) and 3-bromoaniline(102 mg, 0.60 mmol) as described in the general 
procedure above. Further purification was performed by recrystallization from n-
hexane, white solid (44.7 mg, 22.1 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.71 (s, 1H), 8.38 – 8.32 (m, 2H), 8.29 (t, J = 2.0 
Hz, 1H), 7.65 (ddd, J = 0.9, 2.1, 8.2 Hz, 1H), 7.56 – 7.47 (m, 3H), 7.33 (t, J = 8.1 Hz, 
1H), 7.20 (ddd, J = 0.9, 1.9, 7.9 Hz, 1H), 6.59 (d, J = 0.7 Hz, 1H), 2.41 (d, J = 0.7 Hz, 
3H). 
13C NMR (126 MHz, DMSO) δ: 165.22, 162.34, 160.36, 141.78, 137.80, 130.63, 
130.39, 128.38, 127.55, 124.28, 121.83, 121.53, 118.04, 103.93, 23.81. 
LC-MS (m/z) Calcd. for C17H14BrN3 [M+1]+ : 340.04, Found: 340.0, Purity: 98.6 %.  
 
N-(3-methoxyphenyl)-6-methyl-2-phenylpyrimidin-4-amine (53) 
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The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (182 
mg, 0.89 mmol) and 3-methoxyaniline(186 mg, 1.51 mmol) as described in the general 
procedure above. Further purification was performed by recrystallization from 
isopropanol, white solid (23.6 mg, 9.1 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.51 (s, 1H), 8.38 – 8.34 (m, 2H), 7.59 (t, J = 2.1 
Hz, 1H), 7.53 – 7.47 (m, 3H), 7.29 – 7.22 (m, 2H), 6.61 (ddd, J = 1.7, 2.5, 7.6 Hz, 1H), 
6.58 (d, J = 0.8 Hz, 1H), 3.80 (s, 3H), 2.39 (d, J = 0.6 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 164.81, 162.41, 160.67, 159.62, 141.31, 138.00, 
130.24, 129.46, 128.31, 127.55, 111.83, 107.86, 105.12, 103.59, 54.94, 23.79. 
LC-MS (m/z) Calcd. for C18H17N3O [M+1]+ : 292.14, Found: 292.0, Purity: 99.5 % 
 
N-(4-bromo-3-methoxyphenyl)-6-methyl-2-phenylpyrimidin-4-amine (54) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (148 
mg, 0.72 mmol) and 4-bromo-3-methoxyaniline(146 mg, 0.72 mmol) as described in 
the general procedure above. Further purification was performed by recrystallization 
from isopropanol/H2O, white solid (34.4 mg, 12.9 %). 
8 Experimental section 
 
120 
 
1H NMR (500 MHz, DMSO-d6) δ: 9.67 (s, 1H), 8.39 – 8.34 (m, 2H), 7.87 (d, J = 2.4 
Hz, 1H), 7.53 – 7.48 (m, 4H), 7.18 (dd, J = 2.4, 8.6 Hz, 1H), 6.60 (d, J = 0.8 Hz, 1H), 
2.41 (d, J = 0.6 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 165.21, 162.58, 160.62, 155.49, 141.23, 138.05, 
132.73, 130.48, 128.50, 127.75, 112.90, 104.26, 104.08, 102.49, 56.06, 23.95. 
LC-MS (m/z) Calcd. for C18H16BrN3O [M+1]+ : 370.05, Found: 370.0, Purity: 99.3 %. 
 
N-(3-fluoro-4-methoxyphenyl)-6-methyl-2-phenylpyrimidin-4-amine (55) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (91 
mg, 0.45 mmol) and 3-fluoro-4-methoxyaniline (60 mg, 0.42 mmol) as described in the 
general procedure above. White solid (84.0 mg, 64.1 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.49 (s, 1H), 8.35 – 8.30 (m, 2H), 7.76 (dd, J = 2.6, 
13.9 Hz, 1H), 7.53 – 7.47 (m, 3H), 7.41 (ddd, J = 1.4, 2.6, 8.9 Hz, 1H), 7.19 (dd, J = 
8.9, 9.8 Hz, 1H), 6.52 (d, J = 0.7 Hz, 1H), 3.84 (s, 3H), 2.38 (d, J = 0.6 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 164.77, 162.40, 160.56, 151.04 (d, J = 241.9 Hz), 
142.23 (d, J = 10.6 Hz), 137.97, 133.56 (d, J = 9.6 Hz), 130.24, 128.34, 127.52, 115.69, 
114.37 (d, J = 3.0 Hz), 108.33 (d, J = 22.7 Hz), 103.16, 56.28, 23.77. 
LC-MS (m/z) Calcd. for C18H16FN3O [M+1]+ : 310.13, Found: 310.1, Purity: 99.6 %. 
 
N-(4-methoxy-3-(trifluoromethyl)phenyl)-6-methyl-2-phenylpyrimidin-4-amine 
(56) 
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The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (53 
mg, 0.26 mmol) and 3-trifluoro-4-methoxyaniline (49 mg, 0.26 mmol) as described in 
the general procedure above. Brown solid (73.8 mg, 80.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 11.13 (s, 1H), 8.29 – 8.22 (m, 3H), 7.91 (d, J = 8.8 
Hz, 1H), 7.67 (t, J = 7.4 Hz, 1H), 7.61 (t, J = 7.6 Hz, 2H), 7.37 (d, J = 9.0 Hz, 1H), 6.81 
(s, 1H), 3.91 (s, 3H), 2.53 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 160.64, 160.60, 159.88, 153.61, 132.52, 130.88, 
128.80, 128.42, 126.71, 123.50 (q, J = 272.5 Hz), 119.89, 116.78 (q, J = 27.5, 28.3 Hz), 
113.69, 104.01, 56.39, 20.31.  
LC-MS (m/z) Calcd. for C19H16F3N3O [M+1]+ : 360.12, Found: 360.0, Purity: 98.3 %. 
 
4-((6-methyl-2-phenylpyrimidin-4-yl)amino)phthalonitrile (58) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (145 
mg, 0.71 mmol) and 3,4-dicyanoaniline (101 mg, 0.70 mmol) as described in the 
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general procedure above. Further purification was performed by recrystallization from 
ethanol/H2O, white solid (13.6 mg, 6.2 %). 
1H NMR (500 MHz, DMSO-d6) δ: 10.35 (s, 1H), 8.54 (d, J = 2.2 Hz, 1H), 8.33 – 8.30 
(m, 2H), 8.15 (dd, J = 2.2, 8.8 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 7.53 – 7.50 (m, 3H), 
6.69 (s, 1H), 2.45 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 166.44, 162.47, 159.77, 144.84, 137.38, 134.88, 
130.68, 128.51, 127.64, 122.81, 122.53, 116.41, 116.05, 115.29, 105.28, 105.11, 23.86. 
LC-MS (m/z) Calcd. for C19H13N5 [M+1]+ : 312.12, Found: 312.2, Purity: 92.2 %. 
 
2-fluoro-5-((6-methyl-2-phenylpyrimidin-4-yl)amino)benzonitrile (59) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (101 
mg, 0.49 mmol) and 3-cyano-4-fluoroaniline(66 mg, 0.48 mmol) as described in the 
general procedure above. White solid (117.6 mg, 80.1 %).   
1H NMR (500 MHz, DMSO-d6) δ: 9.84 (s, 1H), 8.34 – 8.29 (m, 3H), 8.02 (ddd, J = 2.8, 
4.8, 9.2 Hz, 1H), 7.56 – 7.47 (m, 4H), 6.59 (s, 1H), 2.41 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 165.45, 162.35, 160.21, 157.34 (d, J = 250.7 Hz), 
137.71, 137.31 (d, J = 2.4 Hz), 130.42, 128.38, 127.56, 126.67 (d, J = 7.8 Hz), 123.15, 
116.98 (d, J = 20.6 Hz), 114.13, 103.77, 99.77 (d, J = 16.1 Hz), 23.80. 
LC-MS (m/z) Calcd. for C18H13FN4 [M+1]+ : 305.11, Found: 305.1, Purity: 97.6 %. 
 
2-bromo-4-((6-methyl-2-phenylpyrimidin-4-yl)amino)benzonitrile (60) 
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The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (102 
mg, 0.50 mmol) and 3-bromo-4-cyanoaniline (97 mg, 0.49 mmol) as described in the 
general procedure above. White solid (93.4 mg, 52.1 %). 
1H NMR (500 MHz, DMSO-d6) δ: 10.94 (s, 1H), 8.57 (s, 1H), 8.32 – 8.29 (m, 2H), 
7.93 – 7.87 (m, 2H), 7.63 – 7.55 (m, 3H), 6.85 (s, 1H), 2.51 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 163.28, 161.39, 160.27, 144.78, 135.29, 131.57, 
128.71, 128.05, 124.86, 122.84, 118.61, 117.65, 106.71, 105.29, 22.41.  
LC-MS (m/z) Calcd. for C18H13BrN4 [M+1]+ : 365.03, Found: 365.0, Purity: 97.7 %. 
 
2-methyl-4-((6-methyl-2-phenylpyrimidin-4-yl)amino)benzonitrile (61) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (149 
mg, 0.73 mmol) and 4-cyano-3-methylaniline (95 mg, 0.72 mmol) as described in the 
general procedure above. Further purification was performed by recrystallization from 
ethanol, white solid (103.9 mg, 48.3 %). 
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1H NMR (500 MHz, DMSO-d6) δ: 9.94 (s, 1H), 8.38 – 8.33 (m, 2H), 7.92 (d, J = 1.7 
Hz, 1H), 7.81 (dd, J = 2.2, 8.6 Hz, 1H), 7.73 (d, J = 8.5 Hz, 1H), 7.55 – 7.49 (m, 3H), 
6.66 (s, 1H), 2.43 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 165.68, 162.46, 160.22, 144.37, 142.29, 137.65, 
133.41, 130.46, 128.47, 127.64, 119.74, 118.50, 116.60, 104.60, 103.65, 23.83, 20.34. 
LC-MS (m/z) Calcd. for C19H16N4 [M+1]+ : 301.14, Found: 301.1, Purity: 99.1 % 
 
4-((6-methyl-2-phenylpyrimidin-4-yl)amino)-2-(trifluoromethyl)benzonitrile (62) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (153 
mg, 0.75 mmol) and 4-cyano-3-trifluoroaniline (139 mg, 0.74 mmol) as described in 
the general procedure above. Further purification was performed by recrystallization 
from ethanol, white solid (59.0 mg, 22.4 %). 
1H NMR (500 MHz, DMSO-d6) δ: 10.41 (s, 1H), 8.84 (s, 1H), 8.37 – 8.31 (m, 2H), 
8.09 (d, J = 8.7 Hz, 1H), 8.02 (d, J = 8.8 Hz, 1H), 7.57 – 7.47 (m, 3H), 6.70 (s, 1H), 
2.46 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 166.32, 162.41, 159.90, 144.95, 137.36, 136.19, 
131.70 (q, J = 31.6 Hz), 130.69, 128.46, 127.57, 122.26 (q, J = 273.2 Hz), 121.41, 
116.16, 116.10, 105.15, 99.16, 23.86. 
LC-MS (m/z) Calcd. for C19H13F3N4 [M+1]+ : 355.11, Found: 355.1, Purity: 99.0 %. 
 
6-methyl-N-(3-nitrophenyl)-2-phenylpyrimidin-4-amine (63) 
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The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (71 
mg, 0.35 mmol) and 3-nitroaniline(49 mg, 0.35 mmol) as described in the general 
procedure above. Further purification was performed by recrystallization from 
isopropanol/H2O, yellow solid (22.5 mg, 21.2 %). 
1H NMR (500 MHz, DMSO-d6) δ: 10.06 (s, 1H), 9.24 (t, J = 2.2 Hz, 1H), 8.46 – 8.42 
(m, 2H), 7.95 (ddd, J = 0.9, 2.2, 8.2 Hz, 1H), 7.86 (ddd, J = 0.9, 2.3, 8.1 Hz, 1H), 7.64 
(t, J = 8.1 Hz, 1H), 7.56 – 7.48 (m, 3H), 6.64 (d, J = 0.8 Hz, 1H), 4.30 (d, J = 4.3 Hz, 
0H), 2.44 (d, J = 0.6 Hz, 3H), 
13C NMR (126 MHz, DMSO) δ: 13C NMR (126 MHz, DMSO) δ 165.51, 162.35, 
160.30, 148.09, 141.44, 137.60, 130.52, 129.97, 128.41, 127.69, 124.95, 116.05, 113.24, 
104.30, 23.83. 
LC-MS (m/z) Calcd. for C17H14N4O2 [M+1]+ : 307.11, Found:307.1, Purity: 99.5 %. 
 
6-methyl-N-(4-nitrophenyl)-2-phenylpyrimidin-4-amine (64) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (100 
mg, 0.49 mmol) and 4-nitroaniline(68 mg, 0.49 mmol) as described in the general 
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procedure above. Further purification was performed by recrystallization from 
isopropanol/H2O, yellow solid (18.7 mg, 12.5 %). 
1H NMR (500 MHz, DMSO-d6) δ: 10.25 (s, 1H), 8.41 – 8.37 (m, 2H), 8.32 – 8.28 (m, 
2H), 8.09 – 8.05 (m, 2H), 7.57 – 7.51 (m, 3H), 6.72 (d, J = 0.7 Hz, 1H), 2.46 (d, J = 0.6 
Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 166.03, 162.55, 160.03, 146.72, 140.70, 137.47, 
130.55, 128.52, 127.78, 125.15, 118.39, 105.00, 23.86. 
LC-MS (m/z) Calcd. for C17H14N4O2 [M+1]+ : 307.11, Found: 307.2, Purity: 99.3 %. 
 
N-(4-fluoro-3-nitrophenyl)-6-methyl-2-phenylpyrimidin-4-amine (66) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (98 
mg, 0.48 mmol) and 4-fluoro-3-nitroaniline (68 mg, 0.44 mmol) as described in the 
general procedure above. Yellow solid (96.5 mg, 68.1 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.99 (s, 1H), 9.11 (dd, J = 2.8, 6.9 Hz, 1H), 8.43 – 
8.38 (m, 2H), 7.90 (ddd, J = 2.8, 3.8, 9.1 Hz, 1H), 7.58 (dd, J = 9.0, 11.2 Hz, 1H), 7.54 
– 7.48 (m, 3H), 6.60 (d, J = 0.8 Hz, 1H), 2.43 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 165.48, 162.31, 160.12, 149.49 (d, J = 257.1 Hz), 
137.56, 137.04 (d, J = 3.2 Hz), 136.22 (d, J = 7.8 Hz), 130.51, 128.38, 127.68, 126.38 
(d, J = 7.9 Hz), 118.71 (d, J = 22.1 Hz), 115.45 (d, J = 3.3 Hz), 104.06, 23.81. 
LC-MS (m/z) Calcd. for C17H13FN4O2 [M+1]+ : 325.10, Found: 324.9, Purity: 98.7 %. 
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5-((6-methyl-2-phenylpyrimidin-4-yl)amino)-2-nitrobenzoic acid (67) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (125 
mg, 0.61 mmol) and 5-amino-2-nitrobenzoic acid (111 mg, 0.61 mmol) as described in 
the general procedure above. Further purification was performed by recrystallization 
from ethanol/H2O, yellow solid (87.6 mg, 41.0 %). 
1H NMR (500 MHz, DMSO-d6) δ: 13.76 (s, 1H), 10.32 (s, 1H), 8.48 (d, J = 2.4 Hz, 
1H), 8.42 – 8.38 (m, 2H), 8.12 (d, J = 9.0 Hz, 1H), 7.96 (dd, J = 2.4, 9.0 Hz, 1H), 7.56 
– 7.49 (m, 3H), 6.70 (s, 1H), 2.46 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 166.87, 166.16, 162.40, 159.92, 145.21, 139.70, 
137.38, 130.65, 128.47, 127.75, 125.84, 119.60, 118.26, 104.99, 23.86. 
LC-MS (m/z) Calcd. for C18H14N4O4 [M+1]+ : 351.10, Found: 351.0, Purity: 98.8 %. 
 
N-(3-chloro-4-nitrophenyl)-6-methyl-2-phenylpyrimidin-4-amine (68) 
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The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (114 
mg, 0.56 mmol) and 3-chloro-4-nitroaniline(93 mg, 0.54 mmol) as described in the 
general procedure above. Pale yellow solid (75.0 mg, 41.1 %). 
1H NMR (500 MHz, DMSO-d6) δ: 11.14 (s, 1H), 8.39 (d, J = 2.3 Hz, 1H), 8.36 – 8.28 
(m, 2H), 8.22 (d, J = 9.0 Hz, 1H), 7.94 (dd, J = 2.3, 9.0 Hz, 1H), 7.64 – 7.55 (m, 3H), 
6.90 (s, 1H), 2.53 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 163.29, 161.33, 160.27, 144.61, 140.48, 135.06, 
131.63, 128.73, 128.12, 127.72, 126.96, 121.13, 118.25, 105.35, 22.24. 
LC-MS (m/z) Calcd. for C17H13ClN4O2 [M+1]+ : 341.07, Found:341.2, Purity: 98.0 %. 
 
N-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-6-methyl-2-phenylpyrimidin-4-amine 
(69) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (102 
mg, 0.50 mmol) and 2,3-dihydrobenzo[b][1,4]dioxin-6-amine (71 mg, 0.47 mmol) as 
described in the general procedure above. Beige solid (123.8 mg, 84.2 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.65 (s, 1H), 8.34 – 8.26 (m, 2H), 7.56 – 7.48 (m, 
3H), 7.38 (s, 1H), 7.09 (dd, J = 2.5, 8.7 Hz, 1H), 6.87 (d, J = 8.7 Hz, 1H), 6.55 (s, 1H), 
4.30 – 4.20 (m, 4H), 2.39 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 161.96, 160.92, 143.26, 139.41, 133.19, 130.84, 
128.57, 127.89, 117.09, 113.90, 109.62, 103.05, 64.38, 64.09, 23.02.  
LC-MS (m/z) Calcd. for C19H17N3O2 [M+1]+ : 320.13, Found: 319.8, Purity: 98.8 %. 
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5-((6-methyl-2-phenylpyrimidin-4-yl)amino)isoindoline-1,3-dione (70) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (100 
mg, 0.49 mmol) and 5-aminoisoindoline-1,3-dione (75 mg, 0.47 mmol) as described in 
the general procedure above. Yellow solid (31.7 mg, 20.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 11.17 (s, 1H), 10.58 (s, 1H), 8.46 (d, J = 1.9 Hz, 
1H), 8.35 (dd, J = 1.9, 7.8 Hz, 2H), 8.06 (dd, J = 1.9, 8.3 Hz, 1H), 7.83 (d, J = 8.2 Hz, 
1H), 7.61 – 7.51 (m, 3H), 6.78 (s, 1H), 2.48 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 169.20, 169.02, 161.98, 160.51, 145.45, 136.42, 
134.42, 131.30, 128.76, 128.08, 125.47, 124.22, 123.86, 113.21, 104.98, 23.09. 
LC-MS (m/z) Calcd. for C19H14N4O2 [M+1]+ : 331.11, Found: 331.1, Purity: 95.9 %. 
 
N-(6-methyl-2-phenylpyrimidin-4-yl)quinolin-6-amine (71) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (55 
mg, 0.27 mmol) and quinolin-6-amine (46 mg, 0.32 mmol) as described in the general 
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procedure above. Further purification was performed by recrystallization from ethyl 
acetate/n-hexane, yellow solid (13.5 mg, 16.2 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.88 (s, 1H), 8.76 (dd, J = 1.7, 4.2 Hz, 1H), 8.56 (d, 
J = 2.4 Hz, 1H), 8.43 – 8.39 (m, 2H), 8.31 – 8.28 (m, 1H), 8.03 – 7.94 (m, 2H), 7.57 – 
7.47 (m, 4H), 6.69 (d, J = 0.8 Hz, 1H), 2.43 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 165.15, 162.54, 160.62, 148.44, 144.24, 138.10, 
137.89, 135.14, 130.32, 129.41, 128.52, 128.47, 127.68, 124.18, 121.74, 114.56, 
103.89,23.85. 
LC-MS (m/z) Calcd. for C20H16N4 [M+1]+ : 313.14, Found: 313.2, Purity: 99.0 %. 
 
N-(6-methyl-2-phenylpyrimidin-4-yl)quinoxalin-6-amine (72) 
 
 
The title compound was synthesized from 4-chloro-6-methyl-2-phenylpyrimidine (120 
mg, 0.58 mmol) and quinoxalin-6-amine (85 mg, 0.58 mmol) as described in the general 
procedure above. Further purification was performed by recrystallization from 
ethanol/H2O, brown solid (38.2 mg, 20.9 %). 
1H NMR (500 MHz, DMSO-d6) δ: 10.11 (s, 1H), 8.88 (dd, J = 2.1, 14.2 Hz, 2H), 8.78 
(d, J = 1.8 Hz, 1H), 8.45 – 8.42 (m, 2H), 8.08 – 8.02 (m, 2H), 7.57 – 7.53 (m, 3H), 6.74 
(d, J = 0.8 Hz, 1H), 2.46 (d, J = 0.6 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 165.46, 162.59, 160.48, 145.84, 143.47, 143.20, 
141.50, 138.63, 137.83, 130.51, 129.43, 128.50, 127.66, 124.48, 114.63, 104.60,23.88. 
LC-MS (m/z) Calcd. for C19H15N5 [M+1]+ : 314.13, Found: 314.0, Purity: 98.9 %. 
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8.2.4.1: Synthesis of 2-phenylpyrimidine-4,6-diol (73) 
 
5.56 g (241.7 mmol) sodium was dissolved in 200 ml ethanol to afford sodium ethoxide 
solution. Subsequently, 12.18 g (66 mmol) benzamidine hydrochloride hydrate and 
11.79 g (89 mmol) ethyl dimethyl malonate were added into sodium ethoxide solution 
respectively. The resulting mixture was heated to reflux overnight and cooled down to 
room temperature. After solvent was removed under reduced pressure, 50 ml water was 
added to the solid and the mixture was acidified with concentrated HCl to pH 5-6. The 
formed precipitate was vacuum filtered and washed with water 3 times. Finally, the 
obtained crude residue was recrystallized from DMF/H2O to give 2-phenylpyrimidine-
4,6-diol as orange solid (5.8 g; 46.7 %). 
 
Molecular Weight: 188.19 
 
1H NMR (500 MHz, DMSO-d6) δ: 11.80 (s, 2H), 8.11 – 8.07 (m, 2H), 7.60 – 7.56 (m, 
1H), 7.54 – 7.50 (m, 2H), 5.35 (s, 1H). 
13C NMR APT (126 MHz, DMSO) δ: 131.81, 128.69, 127.87, 88.46. 
 
8.2.4.2: Synthesis of 4,6-dichloro-2-phenylpyrimidine (74) 
 
5.8 g (30.8 mmol) 2-phenylpyrimidine-4,6-diol was added into 20 ml POCl3. The 
reaction was refluxed until the reaction was complete. Excess POCl3 was removed by 
reduced pressure. The oily residue was transfer onto crushed ice portion by portion, 
while keeping the temperature of solution under 10 °C. Ethyl acetate was used to extract 
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products 3 times. The organic layer was washed by saturated NaHCO3, saturated NaCl 
solution and dry over magnesium sulfate. After filtration, ethyl acetate was removed 
under reduced pressure. Final purification was performed by column chromatography 
with DCM/MeOH = 50:1 as eluent to yield white needle crystals (yield: 4.1 g; 59.4 %). 
 
 
Molecular Weight: 225.07 
 
1H NMR (600 MHz, Chloroform-d) δ: 8.44 (d, J = 7.9 Hz, 2H), 7.56 – 7.48 (m, 3H), 
7.28 (s, 1H). 
13C NMR (151 MHz, CDCl3) δ: 165.91, 162.18, 135.02, 132.40, 129.02, 128.88, 118.91. 
 
8.2.4.3 Synthesis of 4-((6-chloro-2-phenylpyrimidin-4-yl)amino)benzonitrile (75) 
 
3.04 g (13.5 mmol) 4,6-dichloro-2-phenylpyrimidine was added into 30 ml isopropanol 
and this mixture was refluxed until all 4,6-dichloro-2-phenylpyrimidine was dissolved. 
1.57 g (13.3 mmol) 4-cyanoaniline was dissolved in 30 ml isopropanol and this solution 
was added into refluxed 4,6-dichloro-2-phenylpyrimidine solution drop by drop. If 
reaction did not initiate, 0.1 equivalent of conc. HCl was added as catalyst. The 
precipitate was filtered off and washed with saturated sodium bicarbonate solution 3 
times followed by distilled water 3 times. Further purification was performed by 
column chromatography with ethyl acetate/petroleum ether (40-60 °C) = 1:2 as eluent, 
yellow solid (3.6 g, 88.2 %). 
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Molecular Weight: 306.75 
 
1H NMR (500 MHz, DMSO-d6) δ: 10.34 (s, 1H), 8.32 – 8.29 (m, 2H), 7.97 – 7.94 (m, 
2H), 7.87 – 7.84 (m, 2H), 7.58 – 7.53 (m, 3H), 6.85 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 163.70, 160.98, 158.82, 143.56, 136.07, 133.31, 
131.43, 128.72, 127.92, 119.67, 119.10, 104.52, 104.15. 
LC-MS (m/z) Calcd. for C17H11ClN4 [M+1]+ : 307.07, Found: 307.2, Purity: 97.9 %. 
 
8.2.4.3 Synthesis of novel pyrimdine derivatives. 
 
Method A: A mixture of 1 equivalent 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile, 10-20 equivalent of amine in 0.5 ml isopropanol was heated to 
120 °C in microwave for 30 mins. Further purification for certain compounds was 
performed by column chromatography with ethyl acetate/petroleum ether (40-60 °C) = 
1:2 as eluent. 
 
Method B: To a three necked round-bottom flask were added 112 mg 4-((6-chloro-2-
phenylpyrimidin-4-yl)amino)benzonitrile (0.37 mmol), 50 mg phenylboronic acid 
(0.41 mmol) and dry 8 ml Dioxane/2M K2CO3 = 3:1. The mixture was degassed by 
vacuum/Argon cycle three times. Catalyst 10 mg Pd(t-Bu3P)2 (0.02 mmol) was added 
and the mixture was degassed twice more. The mixture was heated to 85 °C for 7 h until 
TLC confirmed the completion of the reaction. It was cooled to ambient temperature, 
then the slurry was extracted with saturated NaHCO3/ethyl acetate 3 times. The 
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collected ethyl acetate solution was dried over magnesium sulfate and concentrated 
under reduced pressure. Further purification was performed by recrystallization from 
ethyl acetate/n-Hexane. 
 
Method C: A mixture of 1 equivalent 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile, 10-15 equivalent of substituted aniline in 3 ml isopropanol and 
0.1 equivalent conc. HCl was heated to 110 °C in microwave for 30 mins. The 
precipitate was filtered off and washed with saturated sodium bicarbonate solution 3 
times followed by distilled water 3 times. Further purification was performed by 
column chromatography with ethyl acetate/petroleum ether (40-60 °C) = 1:2 as eluent. 
 
4-((6-(methylamino)-2-phenylpyrimidin-4-yl)amino)benzonitrile (76) 
 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (136 mg, 0.44 mmol), methylamine hydrochloride (306 mg, 4.53 
mmol) and N, N-diisopropylethylamine (0.8 ml, 4.48 mmol)as described in the general 
procedure of method A. Yellow solid (20.7 mg, 15.5 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.57 (s, 1H), 8.32 (dd, J = 3.1, 6.6 Hz, 2H), 7.91 (d, 
J = 8.6 Hz, 2H), 7.75 – 7.68 (m, 2H), 7.51 – 7.40 (m, 3H), 7.07 (s, 1H), 5.80 (s, 1H), 
2.87 (s, 3H). 
13C NMR (126 MHz, DMSO) δ: 163.78, 162.18, 159.71, 145.64, 138.29, 133.06, 
130.03, 128.19, 127.55, 119.59, 118.26, 101.58, 27.35. 
LC-MS (m/z) Calcd. for C18H15N5 [M+1]+ : 302.13, Found:302.0, Purity: 98.3 %. 
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4-((6-(isopropylamino)-2-phenylpyrimidin-4-yl)amino)benzonitrile (77) 
 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (141 mg, 0.46 mmol) and isopropylamine (880 mg, 14.89 mmol) 
as described in the general procedure of method A. Yellow solid (100.3 mg, 66.1 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.54 (s, 1H), 8.32 – 8.29 (m, 2H), 7.89 (d, J = 8.7 
Hz, 2H), 7.74 – 7.71 (m, 2H), 7.50 – 7.46 (m, 3H), 6.99 (d, J = 7.4 Hz, 1H), 5.81 (s, 
1H), 1.21 (d, J = 6.5 Hz, 6H). 
13C NMR (126 MHz, DMSO) δ: 162.49, 162.25, 145.73, 138.42, 133.07, 130.02, 
128.22, 127.53, 119.64, 118.25, 101.50, 59.71, 41.74, 22.50, 14.06. 
LC-MS (m/z) Calcd. for C20H19N5 [M+1]+ : 330.16, Found: 330.1, Purity: 99.0 %. 
 
4-((2-phenyl-6-(propylamino)pyrimidin-4-yl)amino)benzonitrile (78) 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (168 mg, 0.55 mmol) and 1-propylamine (308 mg, 5.22 mmol) 
as described in the general procedure of method A. White solid (126.4 mg, 69.9 %). 
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1H NMR (500 MHz, DMSO-d6) δ: 9.54 (s, 1H), 8.33 – 8.28 (m, 2H), 7.90 (d, J = 8.9 
Hz, 2H), 7.75 – 7.70 (m, 2H), 7.51 – 7.45 (m, 3H), 7.14 (s, 1H), 5.83 (s, 1H), 1.61 (h, 
J = 7.4 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 163.25, 162.20, 145.68, 138.36, 133.05, 130.00, 
128.19, 127.52, 119.59, 118.24, 101.52, 42.20, 22.15, 11.52. 
LC-MS (m/z) Calcd. for C20H19N5 [M+1]+ : 330.16, Found:330.1, Purity: 99.3 %. 
 
4-((6-(butylamino)-2-phenylpyrimidin-4-yl)amino)benzonitrile (79) 
 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (125 mg, 0.41 mmol) and 1-butylamine (390 mg, 5.33 mmol) as 
described in the general procedure of method A. Brown solid (66.5 mg, 47.4 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.55 (s, 1H), 8.32 – 8.29 (m, 2H), 7.90 (d, J = 8.4 
Hz, 2H), 7.75 – 7.71 (m, 2H), 7.51 – 7.46 (m, 3H), 7.14 (s, 1H), 5.82 (s, 1H), 1.60 – 
1.54 (m, 2H), 1.39 (q, J = 7.4 Hz, 2H), 0.93 (t, J = 7.4 Hz, 3H). 
13C NMR (126 MHz, DMSO) δ: 163.25, 162.22, 145.71, 138.39, 133.09, 130.05, 
128.23, 127.54, 119.64, 118.27, 101.53, 19.68, 13.73.  
LC-MS (m/z) Calcd. for C21H21N5 [M+1]+ : 344.18, Found: 344.1, Purity: 98.9 %. 
 
4-((2,6-diphenylpyrimidin-4-yl)amino)benzonitrile (80) 
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The title compound was synthesized as described in the general procedure of method 
B. Yellow solid (63.0 mg, 49.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 10.26 (s, 1H), 8.51 – 8.48 (m, 2H), 8.21 – 8.18 (m, 
2H), 8.07 – 8.04 (m, 2H), 7.87 – 7.84 (m, 2H), 7.62 – 7.55 (m, 6H), 7.29 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 163.02, 162.22, 161.01, 144.44, 137.68, 136.81, 
133.31, 130.74, 130.63, 128.98, 128.61, 127.87, 126.61, 119.34, 119.16, 103.24, 101.47. 
LC-MS (m/z) Calcd. for C23H16N4 [M+1]+ : 349.14, Found: 349.0, Purity: 97.1 %. 
 
4-((2-phenyl-6-(phenylamino)pyrimidin-4-yl)amino)benzonitrile (81) 
 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (127 mg, 0.41 mmol) and aniline (508 mg, 5.46 mmol) as 
described in the general procedure of method C. White solid (47.6 mg, 31.8 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.77 (s, 1H), 9.37 (s, 1H), 8.36 – 8.32 (m, 2H), 7.95 
– 7.91 (m, 2H), 7.79 – 7.75 (m, 2H), 7.69 – 7.64 (m, 2H), 7.56 – 7.50 (m, 3H), 7.41 – 
7.35 (m, 2H), 7.04 (tt, J = 1.1, 7.3 Hz, 1H), 6.23 (s, 1H). 
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13C NMR (126 MHz, DMSO) δ: 162.61, 161.09, 160.17, 145.25, 140.23, 138.03, 
133.13, 130.37, 128.79, 128.42, 127.61, 122.09, 120.08, 119.49, 118.59, 102.11, 86.90. 
LC-MS (m/z) Calcd. for C23H17N5 [M+1]+ : 364.15, Found: 364.0, Purity: 99.1 %.  
 
4-((6-(benzylamino)-2-phenylpyrimidin-4-yl)amino)benzonitrile (82) 
 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (76 mg, 0.25 mmol) and benzylamine (270 mg, 2.52 mmol) as 
described in the general procedure of method A. Brown solid (25.3 mg, 27.3 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.58 (s, 1H), 8.30 (dd, J = 3.0, 6.7 Hz, 2H), 7.88 (d, 
J = 8.8 Hz, 2H), 7.75 – 7.70 (m, 3H), 7.48 (dd, J = 1.9, 5.0 Hz, 3H), 7.40 – 7.37 (m, 
2H), 7.34 (t, J = 7.6 Hz, 2H), 7.24 (t, J = 7.3 Hz, 1H), 5.86 (s, 1H), 4.60 (s, 2H). 
13C NMR (126 MHz, DMSO) δ: 163.19, 162.25, 159.77, 145.58, 140.13, 138.23, 
133.08, 130.12, 128.31, 128.25, 127.57, 127.17, 126.70, 119.60, 118.32, 101.65, 43.79. 
LC-MS (m/z) Calcd. for C24H19N5 [M+1]+ : 378.16, Found: 378.3, Purity: 96.7 %. 
 
4-((2-phenyl-6-((3-phenylpropyl)amino)pyrimidin-4-yl)amino)benzonitrile (83) 
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The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (86 mg, 0.28 mmol) and 3-phenylpropylamine (759 mg, 5.61 
mmol) as described in the general procedure of method A. White solid (70.3 mg, 
61.9 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.54 (s, 1H), 8.30 – 8.25 (m, 2H), 7.90 (d, J = 8.6 
Hz, 2H), 7.75 – 7.71 (m, 2H), 7.50 – 7.46 (m, 3H), 7.32 – 7.17 (m, 6H), 5.83 (s, 1H), 
3.36 (d, J = 18.3 Hz, 0H), 2.69 (t, J = 7.6 Hz, 2H), 1.90 (p, J = 7.3 Hz, 2H). 
13C NMR (126 MHz, DMSO) δ: 163.21, 162.19, 159.55, 145.66, 141.72, 138.31, 
133.05, 130.02, 128.28, 128.22, 128.18, 127.53, 125.67, 119.59, 118.27, 101.55, 32.62, 
30.73. 
LC-MS (m/z) Calcd. for C26H23N5 [M+1]+ : 406.20, Found: 406.3, Purity: 98.0 %. 
 
4-((2-phenyl-6-((4-phenylbutyl)amino)pyrimidin-4-yl)amino)benzonitrile (84) 
 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (130 mg, 0.42 mmol) and 4-phenylbutylamine (522 mg, 3.50 
mmol) as described in the general procedure of method A. Pale brown solid (76.8 mg, 
43.3 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.55 (s, 1H), 8.32 – 8.28 (m, 2H), 7.89 (d, J = 8.4 
Hz, 2H), 7.75 – 7.71 (m, 2H), 7.50 – 7.45 (m, 3H), 7.26 (t, J = 7.5 Hz, 2H), 7.20 (d, J 
= 6.8 Hz, 2H), 7.18 – 7.14 (m, 2H), 5.82 (s, 1H), 2.64 (t, J = 7.5 Hz, 2H), 1.71 – 1.64 
(m, 2H), 1.64 – 1.57 (m, 2H). 
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13C NMR (126 MHz, DMSO) δ: 163.23, 162.24, 145.70, 142.11, 138.38, 133.09, 
130.05, 128.25, 128.22, 128.18, 127.56, 125.61, 119.64, 118.27, 101.53, 55.99, 34.84, 
28.46, 18.52. 
LC-MS (m/z) Calcd. for C27H25N5 [M+1]+ : 420.21, Found: 420.3, Purity: 96.3 %. 
 
4-((2-phenyl-6-((pyridin-2-ylmethyl)amino)pyrimidin-4-yl)amino)benzonitrile 
(85) 
 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (95 mg, 0.31 mmol) and 2-picolylamine (585 mg, 5.39 mmol) as 
described in the general procedure of method A. Grey solid (22.0 mg, 18.8 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.60 (s, 1H), 8.54 (d, J = 4.3 Hz, 1H), 8.26 (dd, J = 
3.0, 6.6 Hz, 2H), 7.90 – 7.87 (m, 2H), 7.80 – 7.71 (m, 4H), 7.48 – 7.44 (m, 3H), 7.39 
(d, J = 7.9 Hz, 1H), 7.26 (dd, J = 5.0, 7.3 Hz, 1H), 5.91 (s, 1H), 4.68 (s, 2H). 
13C NMR (126 MHz, DMSO) δ: 163.17, 162.23, 159.81, 159.25, 148.85, 145.54, 
138.15, 136.67, 133.05, 130.10, 128.21, 127.54, 122.00, 121.01, 119.56, 118.33, 101.69, 
45.93. 
LC-MS (m/z) Calcd. for C23H18N6 [M+1]+ : 379.16, Found: 379.3, Purity: 98.5 %. 
 
4-((2-phenyl-6-((pyridin-3-ylmethyl)amino)pyrimidin-4-yl)amino)benzonitrile 
(86) 
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The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (86 mg, 0.28 mmol) and 3-picolylamine (687 mg, 6.35 mmol) as 
described in the general procedure of method A. White solid (80.3 mg, 75.8 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.59 (s, 1H), 8.63 (s, 1H), 8.45 (d, J = 3.3 Hz, 1H), 
8.32 – 8.27 (m, 2H), 7.90 – 7.87 (m, 2H), 7.79 – 7.71 (m, 4H), 7.50 – 7.46 (m, 3H), 
7.36 (ddd, J = 0.9, 4.7, 7.9 Hz, 1H), 5.89 (s, 1H), 4.63 (s, 2H). 
13C NMR (126 MHz, DMSO) δ: 163.00, 162.28, 159.75, 148.82, 148.00, 145.51, 
138.15, 134.99, 133.07, 130.15, 128.25, 127.56, 123.46, 119.56, 118.36, 101.73, 85.15, 
41.45. 
LC-MS (m/z) Calcd. for C23H18N6 [M+1]+ : 379.16, Found: 379.3, Purity: 98.9 %. 
 
4-((2-phenyl-6-((pyridin-4-ylmethyl)amino)pyrimidin-4-yl)amino)benzonitrile 
(87) 
 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (86 mg, 0.28 mmol) and 4-picolylamine (861 mg, 7.96 mmol) as 
described in the general procedure of method A. White solid (74.2 mg, 69.5 %). 
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1H NMR (500 MHz, DMSO-d6) δ: 9.60 (s, 1H), 8.52 – 8.50 (m, 2H), 8.25 (dd, J = 3.0, 
6.3 Hz, 2H), 7.90 – 7.87 (m, 2H), 7.80 (t, J = 6.1 Hz, 1H), 7.75 – 7.71 (m, 2H), 7.48 – 
7.44 (m, 3H), 7.38 – 7.35 (m, 2H), 5.89 (s, 1H), 4.63 (s, 2H). 
13C NMR (126 MHz, DMSO) δ: 163.09, 162.28, 149.51, 145.48, 138.09, 133.07, 
130.15, 128.23, 127.54, 122.09, 119.55, 118.37, 101.76, 42.98. 
LC-MS (m/z) Calcd. for C23H18N6 [M+1]+ : 379.16, Found: 379.3, Purity: 98.5 %. 
 
4-((6-((2-hydroxyphenyl)amino)-2-phenylpyrimidin-4-yl)amino)benzonitrile (88) 
 
 
The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (102 mg, 0.33 mmol) and 2-hydroxyaniline (222 mg, 2.03 mmol) 
as described in the general procedure of method C. Yellow solid (48.8 mg, 38.6 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.60 (s, 1H), 8.36 (dd, J = 3.0, 6.6 Hz, 2H), 7.91 – 
7.87 (m, 2H), 7.78 – 7.71 (m, 3H), 7.52 – 7.47 (m, 3H), 7.36 (dd, J = 1.3, 5.0 Hz, 1H), 
7.07 (dd, J = 1.3, 3.5 Hz, 1H), 6.97 (dd, J = 3.4, 5.1 Hz, 1H), 5.90 (s, 1H), 4.78 (s, 2H). 
13C NMR (126 MHz, DMSO) δ: 162.77, 162.20, 159.71, 145.54, 143.35, 138.16, 
133.36, 133.06, 130.15, 128.24, 127.64, 126.54, 125.19, 124.88, 119.57, 118.35, 113.41, 
101.70, 85.28. 
LC-MS (m/z) Calcd. for C23H17N5O [M+1]+ : 380.14, Found: 380.1, Purity: 95.9 %. 
 
4-((6-((3-hydroxyphenyl)amino)-2-phenylpyrimidin-4-yl)amino)benzonitrile (89) 
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The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (106 mg, 0.34 mmol) and 3-hydroxyaniline (290 mg, 2.65 mmol) 
as described in the general procedure of method C. Grey solid (67.1 mg, 51.4 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.76 (s, 1H), 9.38 (s, 1H), 9.24 (s, 1H), 8.37 – 8.33 
(m, 2H), 7.94 – 7.91 (m, 2H), 7.78 – 7.75 (m, 2H), 7.56 – 7.50 (m, 3H), 7.16 – 7.12 (m, 
2H), 7.06 (ddd, J = 1.0, 2.0, 8.1 Hz, 1H), 6.46 (ddd, J = 1.0, 2.4, 8.0 Hz, 1H), 6.23 (s, 
1H). 
13C NMR (126 MHz, DMSO) δ: 162.63, 161.13, 160.13, 157.75, 145.29, 141.25, 
138.04, 133.13, 130.35, 129.41, 128.39, 127.70, 119.51, 118.57, 110.97, 109.45, 107.26, 
102.07, 86.91. 
LC-MS (m/z) Calcd. for C23H17N5O [M+1]+ : 380.14, Found: 380.1, Purity: 99.0 %. 
 
4-((6-((4-hydroxyphenyl)amino)-2-phenylpyrimidin-4-yl)amino)benzonitrile (90) 
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The title compound was synthesized from 4-((6-chloro-2-phenylpyrimidin-4-
yl)amino)benzonitrile (101 mg, 0.33 mmol) and 4-hydroxyaniline (390 mg, 3.57 mmol) 
as described in the general procedure of method C. Grey solid (22.7 mg, 18.2 %). 
1H NMR (500 MHz, DMSO-d6) δ: 9.66 (s, 1H), 9.22 (s, 1H), 8.98 (s, 1H), 8.34 – 8.30 
(m, 2H), 7.93 – 7.90 (m, 2H), 7.76 – 7.73 (m, 2H), 7.54 – 7.48 (m, 3H), 7.33 (d, J = 8.3 
Hz, 2H), 6.81 – 6.78 (m, 2H), 6.02 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 162.54, 161.87, 160.13, 153.51, 145.41, 138.14, 
133.09, 131.11, 130.22, 128.33, 127.58, 123.52, 119.54, 118.41, 115.41, 101.86, 85.41. 
LC-MS (m/z) Calcd. for C23H17N5O [M+1]+ : 380.14, Found: 380.1, Purity: 96.5 %. 
 
4,4'-((2-phenylpyrimidine-4,6-diyl)bis(azanediyl))dibenzonitrile (91) 
 
 
The title compound was the side product in synthesis of 4-((6-chloro-2-
phenylpyrimidin-4-yl)amino)benzonitrile. Yellow solid. 
1H NMR (500 MHz, DMSO-d6) δ: 9.92 (s, 2H), 8.34 (dd, J = 3.0, 6.7 Hz, 2H), 7.96 – 
7.92 (m, 4H), 7.81 – 7.77 (m, 4H), 7.55 (dd, J = 2.0, 5.0 Hz, 3H), 6.32 (s, 1H). 
13C NMR (126 MHz, DMSO) δ: 162.71, 160.33, 144.92, 137.71, 133.18, 130.64, 
128.57, 127.72, 119.42, 118.88, 102.57, 88.87. 
LC-MS (m/z) Calcd. for C24H16N6 [M+1]+ : 389.14, Found: 389.2, Purity: 98.2 %.
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9.1  List of Abbreviations 
 
ABC transporter   ATP binding cassette transporter 
ADP adenosine diphosphate 
ATP adenosine-5´-triphosphate 
APT           attached proton test 
ALD adrenoleukodystrophy 
ALS amyotrophic lateral sclerosis 
AT adenine-thymine 
BBB blood-brain barrier 
BCRP breast cancer resistance protein, ABCG2 
Calcein AM calcein acetoxymethylester 
CDCl3 Chloroform-d/deuterated chloroform 
CFTR cystic fibrosis transmembrane conductance regulator 
CysLTR1 cysteinyl leukotriene receptor 1 
d     doublet 
DCM dichloromethane 
dd doublet of doublets 
ddd doublet of doublets of doublets 
DIPEA N,N-Diisopropylethylamine 
DMF dimethylformamide 
DMSO dimethylsulfoxide 
DNA deoxyribonucleic acid 
dt doublet of triplets 
EC50 half-maximal effective concentration 
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EGFR epidermal growth factor receptor 
EL extracellular loop 
EM electron microscopy 
EM-SPA electron microscopy-single-particle analysis 
FACS fluorescence-activated cell scanning 
FTC Fumitremorgin C 
FTIR Fourier-transform infrared spectroscopy 
GlcNAc N-Acetylglucosamine 
GSH            glutathione 
HCl hydrochloric acid 
HIV human immunodeficiency virus 
HTS high throughput screening 
IC50 compound concentration leading to 50% inhibition 
Imax plateau value of maximal inhibition 
LC-MS Liquid chromatography–mass spectrometry 
m multiplet 
MDR     multidrug resistance 
MDR1 multidrug resistance protein 1 
MeOH methanol 
MRP1 Multidrug Resistance related Protein 1 
m/z mass-to-charge ratio 
n.a.   not active 
NaOH sodium hydroxide 
n.d.   not determined 
n.t. not tested 
NBD nucleotide binding domain 
NMR nuclear magnetic resonance 
NSCLC non-small cell lung cancer 
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P-gp         permeability glycoprotein, ABCB1 
ppm parts per million 
q        quartet 
QSAR quantitative structure-activity relationship 
RT room temperature 
s singlet 
SD                  standard deviation 
SLC solute carrier 
SNP single-nucleotide polymorphism 
t triplet 
TBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethylaminium 
tetrafluoroborate 
t-BuOK Potassium tert-butoxide 
td triplet of doublets 
THF Tetrahydrofuran 
TKI tyrosine kinase inhibitor 
TLC thin layer chromatography 
TM transmembrane 
TMD transmembrane domain 
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